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Abstract 
 
The first part of the dissertation involves the use of ruthenium mediated isomerization (RMI) 
followed by ring-closing metathesis (RCM) on a selection of phenols and naphthol-1-ol 
precursors – that had been subjected to allylation; followed by a heat initiated Claisen 
rearrangement; followed by re-allylation – to form a selection of benzofurans. This 
procedure, to the best of our knowledge, represents a novel method for the synthesis of 
benzofurans, with very good average yields of around 90% overall for the RMI/RCM and 
allylation steps. The lowest yield of the five synthetic steps, were for the Claisen 
rearrangements with a range of yields between 50% and 86%, indicating the potential to 
optimise the yields of these reactions, which were carried out using both conventional and 
microwave heating. The following five-membered oxygen-containing heterocycles were thus 
obtained: 4,7-dimethoxybenzofuran, 5-bromobenzofuran, 5-tert-butyl-benzofuran, 7-
phenyl-1-benzofuran and naphtho[1,2-b]furan. 
         
The second part of the dissertation involves the use of RMI and RCM on di-allylated; di-
allylated di-isomerised; and di-allylated mono-isomerized O,N- (aminophenol) and N,N- 
(benzene-1,2-diamine) protected precursors. This resulted in the formation of six-, seven- and 
eight-membered benzo-fused heterocycles respectively. Except in the case of the mono- and 
di-isomerised N,N-precursor, which failed to undergo RCM, despite several attempts. This 
failure, which is not unprecedented, is most likely due to the interaction of nitrogen‟s lone 
pairs and the adjacent saturated bonds of the precursor with the GII catalyst, resulting in de-
allylation. Of those reactions that were successful, the average yields for the RMI/RCM steps 
were in the region of 82% for the N,N-precursors and 95% for the O,N-precursors. All 
precursors readily submitted to allylation and isomerization, with an average yield of 94%. 
The following benzo-fused heterocycles were thus obtained:  six-membered: 4H-1,4-
benzoxazin-4-yl(phenyl) methanone; seven-membered: 1,5-benzoxazepin-5(4H)-
yl(phenyl)methanone; eight-membered: 2,5-dihydro-6H-1,6-benzoxazocin-6-yl(phenyl) 
methanone and  1,1'-[(3Z)-2,5-dihydro-1,6-benzodiazocine-1,6-diyl]diethanone.    
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Chapter 1:   Introduction 
 
1.1   Project overview 
 
Benzo-fused heteroaromatic structures are common motifs in many naturally-occurring 
compounds, with potentially wide-ranging pharmaceutical applications such as 
antibiotics and anti-microbial agents.
[1] 
This makes the synthesis of such components of 
interest to organic synthetic chemists. 
 
 
Of the numerous methods available for their synthesis, a modern methodology involving 
transition metal catalysts is presented in this dissertation.  Two of the key catalysts used 
in this project are the Grubbs‟ second generation (GII) ring-closing metathesis (RCM) 
catalyst and the ruthenium mediated allyl isomerization (RMI) catalyst. The use of these 
catalysts has allowed access to many synthetic products and intermediaries with 
increased ease, cost effectiveness and yield – not before achievable using previous 
synthetic methodologies.
[2] 
 
 
In addition, the tandem use of these catalysts has allowed access to a variety of five-, six-, 
seven- and eight-membered ring structures – fused to benzene sub-structures – with 
relative ease. In this dissertation ring structures containing oxygen, oxygen and nitrogen, 
and nitrogen, are presented. 
 
 
Previous work in our laboratories
[3]
 has shown that the tandem use of these catalysts have 
wide ranging scalability, in so far as the same allylated precursors can be used to achieve 
variable ring sizes, depending on at which stage and sequence of the synthesis the 
catalysts are deployed. 
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1.2   Metathesis reactions (RCM) 
 
1.2.1   Metathesis catalysts 
 
The formation of carbon-carbon double bonds is of key importance in the synthesis of 
molecular targets. The use of transition metal catalysts in this endeavour was first 
discovered in studies on the attempted addition polymerization of olefins using Ziegler-
type catalysts. These metatheses (a term first coined by Calderon in 1967) catalysts 
comprised of a transition metal halide such as MoCl5 and WCl6, mixed with an alkylating 
reagent such as Et3Al or EtAlCl2. A selection of these first generation heterogeneous 
catalysts is shown in Figure 1.
[4]
  
 
1          2          3 
Figure 1: First generation metal carbene catalysts 
 
The first „true‟ alkene metathesis catalysts were developed by Schrock and Grubbs in the 
early 90‟s (Figure 2). The Schrock catalyst 4 is still one of the most active single 
catalysts to date, but is highly sensitive to oxygen and water.
[5]
 The Grubbs‟ first 
generation catalyst 5 is less reactive, but much more tolerant to oxygen and water.
[6]
  
 
Figure 2:  Schrock 4 and Grubbs’ first generation catalyst 5 
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1.2.2   Metathesis mechanism
[7]
 
 
The mechanism by which metathesis proceeds was first proposed by Chauvin in 1970.
[7] 
According to this mechanism, shown in Scheme 1, the activated metal carbene complex 
first undergoes a [2+2] cycloaddition reaction with the olefin, forming a 
metalocyclobutane. This complex then undergoes a [2+2] cycloreversion reaction, 
releasing a molecule of ethene, whilst leaving the metal complex attached to the olefin. 
This process can then be repeated. If another olefinic substrate is present in the same 
molecule, RCM can occur (as per c in Scheme1); or the process can occur on another 
olefinic  substrate of another molecule (as per d in Scheme 1) leading to chain formation. 
 
H2C CH2
H2C
H2C [M]
[M]
H2C [M]
H2C
[M] [M]
CH2
CH2
H2C CH2 H2C
[M]
a)
a)
b)
b)
c)
d)
 
 
Scheme 1: The Chauvin mechanism 
a) [2+2] cycloaddition 
                                    b) [2+2] cycloreversion 
c) metathesis occurs within the molecule 
d) metathesis occurs with another molecule 
 
 
In all, five basic alkene-alkene metathesis reaction outcomes are possible, summarised in 
Scheme 2. 
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Scheme 2: Fundamental metathesis transformations 
i) Cross metathesis (CM) 
ii) Ring-closing metathesis (RCM) 
iii) Ring-opening metathesis (ROM) 
iv) Ring-opening metathesis polymerization (ROMP) 
v) Acyclic Diene metathesis polymerization (ADMET) 
 
Cross metathesis (CM), ring-closing metathesis (RCM) and acyclic diene metathesis 
polymerization (ADMET) reactions are all entropically driven, because the evolution of 
ethene gas as a by-product, greatly increases the disorder of the system and makes the 
reaction irreversible at this step. 
  
On the other hand, ring opening metathesis (ROM) and ring opening metathesis 
polymerization (ROMP) are both enthalpically driven because of the energy released in 
breaking the ring. No ethene gas is released in these reactions, with irreversibility 
achieved because the equilibrium lies far to the right and because the products have a 
significantly lower enthalpy on the release of ring strain – ring reformation is thus highly 
unfavourable. As with all catalysts, alkene metathesis catalysts are highly reversible in 
the initiation phase of the reaction. This can be demonstrated using the mechanism 
proposed for the Grubbs‟ first generation catalyst (GI).[8-9] The proposed initiation phase 
is shown in Scheme 3. 
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Scheme 3: Proposed initiation phase of the Grubbs’ first generation catalyst (GI) 
 
Step 1: 
The pre-catalyst A  has a stable 16 electron configuration around the central Ru atom. In 
Step 1 the bulky PCy3 ligand is lost, causing the electron distribution around the Ru atom 
to drop to an unstable 14, producing the highly reactive intermediate B. Step 1 is highly 
reversible, with the forward reaction entropically driven because of the loss of the PCy3 
ligand, and the reverse reaction favoured by the increased stability around the central 
atom. To help prevent recombination of the ligand through steric hindrance, very bulky 
ligands are used. 
 
Step 2: 
In the presence of an olefinic substrate Step 2 may occur, bringing the electron count 
around the Ru atom in intermediate C back to a stable 16. The groups R
1
 and R
2
   have the 
potential for steric and electronic hindrance and it is their identity that will determine 
whether the intermediate C will form, or fall back to intermediate B.  
 
It is the [2+2] cycloaddition phase (Scheme 4) that is the rate-determining step in the 
metathesis cascade. The amount of steric and electronic hindrance caused by the R
1
 and 
R
2
 groups will ultimately determine the speed and success of the reaction. Again, the 
reaction is driven forward entropically to intermediate E, with the release of ethene gas, 
which is then irreversible after the [2+2] cycloreversion of intermediate D. 
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Scheme 4: [2+2] Cycloaddition phase 
 The rate determining step in alkene metathesis 
 
1.2.3   Metathesis catalysts used in this project 
 
The problem of reversibility in the initiation phase of the Grubbs‟ first generation catalyst 
has largely been overcome with the advent of the Grubbs‟ second generation catalyst 
(GII) 6, shown in Figure 3.
[10-11] 
 
 
Figure 3: Grubbs’ second generation catalyst (GII). 
 
GII 6 was used exclusively in this project. It differs from GI 5 in that one of the PCy3 
ligands have been replaced by a nitrogen-containing carbene, which has both nucleophilic 
and electrophilic capabilities. This N-heterocycle carbene is kinetically inert, electron rich 
and bulky.
[9]
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The GII 6 has the following improvements over GI 5:
[12]
  
 
1) The nitrogen-containing carbene pushes electron density into the Ru centre, 
thereby lengthening – and thus weakening – the Ru-P bonds, making substrate 
bonding more facile. 
 
2) PCy3 dissociation is relatively inefficient, but due to the presence of the very 
bulky nitrogen carbene, PCy3 re-association to the Ru is much less likely – 
because the nitrogen carbene stabilizes the 14 electron intermediate, and its 
large steric bulk hinders re-association. 
 
These two factors act together to ensure the catalyst‟s coordination to the olefin is far 
more facile. 
  
The advent of the metathesis methodology has been a dramatic improvement in carbon-
carbon bond formation, as it requires a small amount of the catalyst and has the potential 
to remove several additional reaction steps that may otherwise have been necessary using 
previous methodologies. This potentially improves the cost effectiveness of the 
methodology and makes it more environmentally friendly, because the only significant 
waste product of the metathesis step is ethene gas.  
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1.3   Ruthenium mediated isomerization (RMI) 
 
1.3.1   Isomerization reaction 
 
An independent method for the displacement of saturated bonds within a molecular 
system can be important in synthesis, not only in the creation of a final product, but also 
because a saturated bond can act as a useful focal point for subsequent molecular 
moieties. As an example, a simple isomerization reaction involving olefins is expected to 
proceed according to Scheme 5, where two possible isomers can be produced.  
 
R H CH3
R H
H H
R CH3
cat
(E) (Z)  
Scheme 5: Basic isomerization outcome on an allylic substrate 
 
The action of certain transition metal metathesis compounds to facilitate such 
transformations were first noted by Maynard and Grubbs,
[13]
 when isomerization 
occurred on the expected RCM product 8a (Scheme 6), whilst being distilled in the 
presence of the decomposition products of a Ru RCM catalyst, resulting in the formation 
of 8b. It was suspected by the researchers that Ru by-products in the distillate were 
responsible for the isomerization.  
 
  
 
Scheme 6: Unexpected isomerization in the presence of Ru residues 
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Prunet and co-workers
[14]
 also found that isomerization had occurred subsequent to RCM 
in an investigation on a diene precursor 9 as part of a total synthesis towards Taxol 
(Scheme 7). In both products, ring-closure has been affected, but compound 11 has the 
double bond in an unexpected position.  
 
 
OH OH OHOTes OH OH
6% 7%
1) GI (10%)
C6H6 80 
oC
2)TBAF
9 10 11  
 
Scheme 7: Two isomeric products produced after RCM 
 
Furstner and co-workers,
[15]
 while attempting the RCM of 12 (Scheme 8) found not only 
the expected 21-membered macro cycle 13, but also a 20-membered macro cycle 14, 
indicating that isomerization had occurred prior to ring-closure. Again, only ruthenium 
RCM catalysts and their potential by-products were present. 
 
 
 
 
Scheme 8:  Isomerization occurring prior to RCM 
 
 
 
11 
 
 
1.3.2   Isomerization mechanism 
 
The first mechanistic proposals regarding Ru RCM-mediated isomerizations were made 
by Nolan, Prunet and co-workers
[15]
 based on the model study of the Taxol isomerization 
problem. The mechanism they proposed is based on a π-allyl hydride mechanism (used to 
describe olefin isomerization) as shown in Scheme 9. 
 
 
 
Scheme 9: Proposed catalytic cycle for isomerization 
(A modification of the π-allyl hydride mechanism) 
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It was found that, apart from the role that the solvent plays in reaction outcome, the 
addition of small amounts of tricyclohexylphosphane (PCy3), a ligand present on the GII 
catalyst 6, resulted in the complete suppression of isomerization.  
 
 
The mechanistic proposal is thus based on the idea that an unstable 14 electron fragment 
A resulting from the loss of the PCy3 ligand is responsible for isomerization. This was 
inferred because the excess PCy3 would prevent the formation of A thermodynamically – 
by driving the equilibrium towards the original catalyst; and also kinetically – by 
competing with any allylic substrates that would otherwise interact with A, re-stabilising 
the 16 electron count.  
 
 
Without excess PCy3, substrates with allylic groups may, depending on steric hindrance, 
more easily interact with the 14 electron fragment, resulting in the formation of a -
complex B. Then, in an agostic interaction, deprotonation of the allylic position would 
lead to an σ-alkyl/π-allyl complex C, which would react to produce the carbene complex 
D. Entropically driven dissociation of the isomerized alkene finally regenerates the 
catalytically active species A.  
 
 
1.3.3   Isomerization catalyst used in this project 
 
Numerous catalysts have been produced to facilitate isomerization. The catalyst 15 was 
used exclusively in this project and is shown in Figure 4. It is used based on the excellent 
results achieved by Krompiec and co-workers.[16]  
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Figure 4: Ruthenium isomerization catalyst used in this project 
 
 
The work by Krompiec and co-workers
[16-17] 
on N-allylamides, N-allylamines and N-allyl 
ethanamide – which gave isomerised products with high stereoselectivity when using 
catalyst 15 – may also shine light on the mechanism of the catalyst. The researchers claim 
that the observed stereoselectivity of the products (almost exclusively E-isomers) occurs 
because of the coordination of aryl groups on the substrate with the Ru atom of the 
catalyst (Figure 5); and not because of the higher thermodynamic stability of the E-
isomer, as quantum calculations using AM1 methods showed that the E- and Z-isomers 
differ in their heat of formation by only 10.52 kJ/Mol. 
 
 
Thus, if back-bonding can occur between the Ru atom and the arene ring in the course of 
the reaction – (E)-isomers will form. This analysis is consistent with the π-allyl hydride 
mechanism (Scheme 9) and helps to explain the observed high selectivity of the Ar-allyl 
isomerizations insofar as they stem from the coordination to the Ru of the catalyst and 
not because of steric effects. 
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Figure 5: AM1 quantum calculation analysis of (E)-N-phenyl-N-(1-propenyl)ethanamide (in 
the optimal conformation) showing the possibility of interaction between the Ru atom and 
the arene ring during the reaction.[17] 
 
 
1.4   Claisen rearrangements[18] 
 
This useful, heat initiated reaction is classified as a [3.3]-sigmatrophic rearrangement. In 
its most general sense it is a transformation as outlined in Scheme 10. 
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Scheme 10: Claisen rearrangement 
 
Because this process is regulated by orbital symmetry – there will be a preferred chair 
transition state for the reaction, and reactions are accelerated by charged intermediates. 
The Claisen rearrangement related to this project involved substituted allylic phenols and 
follows the general reaction mechanism outlined in Scheme 11. 
 
15 
 
 
 
 
Scheme 11: Reaction mechanism related to allylic phenols[18a] 
 
In the case of aromatic ring systems, if the both positions ortho to the oxygen are 
blocked, rearrangement can continue until a free (hydrogen) position is found, as shown 
in Scheme 12. The addition of substituent groups to the phenol can thus be used to 
regulate the final position of the allylic group. 
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Scheme 12: Showing how substituents on the ring can affect outcome[18b] 
 
1.5   Conclusion 
 
The RCM and RMI catalysts and reactions outlined above were all put to use in synthetic 
strategies, as an alternative to previous synthetic strategies found in the literature, for the 
synthesis of benzo-fused ring compounds. In doing so, the suitability of such alternate 
reactions, to those in the literature, was investigated.  
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Chapter 2:    Relevance of the research 
 
Numerous synthetic methodologies have been utilized in the formation of 5-, 6-, 7- and 8-
membered benzo-fused heterocycles. All of these structures occur in a variety of 
compounds with wide-ranging medicinal applications, as they have the ability to bind to 
multiple receptors with high affinity, and well as other applications. They have thus been 
termed „bicyclic privileged structures‟, a term first coined by Evans et al. in 1988 and is 
defined as a „single molecular framework able to provide ligands for diverse 
receptors‟.[19] There is thus an obvious interest in these structures and this chapter will 
briefly introduce relevant examples of molecules containing them and will also give a 
brief overview of previous synthetic methodologies used in their synthesis. This will 
allow for a more comparative discussion of the Wits RMI-RCM methodology. 
  
2.1   5-Membered oxygen containing benzo-fused heterocycles:  
        the benzofurans 
 
8
7
6
5
4
9
O
1
2
3
R2
R1R3
17  
Figure 6: The basic benzofuran motif 
 
The benzofuran skeleton (Figure 6) is a common motif in many naturally occurring 
bioactive compounds. A number of natural and synthetic examples are shown in Figure 
7. Compound 18
[20]
 is a selective dopamine D-2 antagonist and compound 19
[21]
 is a -
selective agonist with a potency 25 times greater than morphine.  The analogues of 
Furochromonone 20
[22]
 inhibit platelet aggregation by inhibiting cyclic AMP 
phosphodiesterase; and specifically its analogue Khellin 21
[23]
, acts as a potent coronary 
vasodilator (isolated from the seeds of Ammi visnaga). Other examples include the 
furocoumarin Heraclenol 22
[24]
 isolated from Cymopterus watsonii and the benzo[b]-
18 
 
 
furo[3,4-d]furan-1one scaffold 23
[25]
 found in many naturally occurring products, which 
have a wide range of biological effects. 
 
N
H N N
O
F
O
N N
O O
OO
O
O
O
OO
O
O
OH
HO
OO
O
O
O
O
R1
R2
R3
18
19
20 21
22 23  
Figure 7: Molecules containing the benzofuran motif 
(R1, R2 and R3 = variety of substituents) 
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2.1.1   Previous synthetic strategies towards benzofurans 
 
Outlined below, are a selection of the most prominent synthetic strategies, extracted from 
literature sources, employed toward the synthesis of the benzofuran motif 17 – that do not 
employ a RMI-RCM approach. 
 
 
2.1.1.1   Non-metathetic ring-closure reactions 
 
A review of the literature
[26]
 shows that four main synthetic strategies have been 
employed prior to 1995. Only a brief description and representative example of each, in 
its most general form, will be given. All of the benzofuran skeletons are produced by 
direct ring-closure – sometimes with the use of catalysts.  
 
2.1.1.1.1   Ring closure by the formation of the O-C(2) bond 
 
The o-iodobenzoic acid 24 was refluxed with a suitably prepared cuprous acetylide 25 
under a nitrogen atmosphere, with pyridine acting as both solvent and base. (Scheme 13.) 
This resulted in the formation of the benzofuran 26 with a 91% yield.  
 
 
 
Scheme 13: The methodology of Stephans and Castro[27] 
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2.1.1.1.2   Ring closure by the formation of the Ar-C(3) bond 
 
 
If aryloxyalkanones (R1 and R2 = benzene) 27 are treated with p-bromobenzenesulfonyl 
chloride, the corresponding vinyl ester 28 is obtained. (Scheme 14.) 
These compounds can then be cyclized to 2,3-diarylbenzofurans 29 under the action of 
BF3 (65% overall yield). 
 
 
 
 
Scheme 14: The methodology of Cappozzi and Modena[28] 
 
 
 
2.1.1.1.3   Ring closure by the formation of the C(2)-C(3) bond 
 
 
Ethyl o-carbethoxymethylenesalicylkates 30 (which can be prepared from corresponding 
halogenated arenes or etherified phenols) underwent Dieckmann condensation to produce 
the resultant substituted benzofuran 32, under the action of NaOC2H5 and NaOH as base. 
(Scheme 15.) Compound 33 was produced after reaction with 5% H2SO4. Overall yields 
are as follows: when R = H: yield = 65%, when R = Cl: yield = 27% and when R = I: 
yield = 27%. 
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Scheme 15: The methodology of Schroeder et al.[29] 
 
2.1.1.1.4   Ring closure by the formation of the Ar-O bond 
 
The enolates of 2-aryl-1-substituted ethane-1-ones 34 can undergo photo-induced 
intramolecular cyclization to form 2-substituted benzofurans 35. The general reaction 
procedure involved using a 125 W mercury lamp to irradiate a mixture of 34 and 1,4-
dicyanonaphthalene (DCN) in a molar ratio of approximately 10:1, at > 230 nm in a 
Pyrex filter. A mixture of acetonitrile and water (8:2), with sodium hydroxide added to 
bring the pH to ~ 10, was used as solvent. (Scheme 16.) 
The overall yield of this one pot synthesis were between 50 – 60% (R1 = methyl and R2 = 
4‟methoxy, 2‟5‟-dimethoxy or 3‟4‟-dimethoxy).  
 
 
 
Scheme 16: The photo-induction methodology of Pandy et al.[30] 
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2.1.1.2   Synthesis from furans and dihydrofurans
[31] 
 
4-Chloro-2-cyclobutanone 36 can undergo Pd-catalysed cross-coupling with 2-
stannylated furans 37, followed by heating, to give 4-hydroxybenzo[b]furans 38. 
(Scheme 17.) 37 was easily prepared in good yield by reacting benzofuran with n-butyl 
lithium and TMEDA in an ether solution at -78 °C, followed by quenching with n-
Bu3SnCl. 5 mol% Cl2Pd(PhCN)2 and 10 mol% tris-2-furylphosphine acted as the Stille 
cross-coupling catalyst in the first step of the reaction, which proceeded at 50 °C for 4 
hours and at 100 °C for another 4 hours. (Dioxane was used as solvent). The overall yield 
of this reaction was 94%. 
 
 
 
Scheme 17: The methodology of Liebeskind and Wang[31] 
 
 
2.1.1.3   Use of the Perkin rearrangement
[32] 
 
Under the action of a strong hydroxide and a halogen salt, a suitably substituted 3-halo-4-
allyl-Chromenone 39 (X = Cl or Br) can undergo a Coumarin benzofuran ring contraction 
to produce the benzofuran 40. (Scheme 18.) 
The reaction process has been shown to occur in two steps by Bowden and Battah: a 
relatively rapid base-catalysed ring fission to give the acrylic acid intermediate, which 
then undergoes a relatively slow cyclization process, followed by heat-initiated de-
carboxylation to form 40. Yields for this reaction are in the region of 20% (R = NHOPh) 
to 90% (R= CH3). 
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Scheme 18: The methodology of Bowden and Battah[33] 
 
 
 
2.1.1.4   Resin-based benzofuran combinatorial approaches 
 
2.1.1.4.1   The Habermann benzofuran combinatorial approach
[34]
 
 
The synthesis utilizes solid supported reagents, the first of which – a bromine pyridine 
complex (A) – acts as a bromination agent on the commercially available acetophenols 
41 to produce 42. The second – 1,5,7-triazabicyclo[4.4.0]dec-5-ene (B) – acts as a base to 
deprotonate phenols 43 resulting in its attachment to the precursor 42 in yields > 30%. 
The third – Amberlyst 15 (C) – results in a cyclodehydration of 44 forming the 
benzofuran product 45 in yields > 57%. (Scheme 19.)  
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Scheme 19: The Habermann benzofuran combinatorial approach 
 
 
2.1.1.4.2   The Fancelli benzofuran combinatorial approach
[35]
 
 
The first stage of the reaction begins with a Mitsunobu reaction between a starting 
carboxylic acid 46 and Tentagel
®
, after which the acetate group of 47 is deprotected via 
reaction with a dilute ammonia solution. The key step in the synthesis is a palladium-
catalyzed heteroannulation of 48 utilizing terminal acetylenes, which results in the 
benzofuran motif 49. This product is then cleaved from the resin using a strong base to 
yield the product 50 in yields > 60%, depending on the identity of the acetylenes used. 
(Scheme 20.)  
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Scheme 20: The Fancelli benzofuran combinatorial approach 
 
 
2.1.1.4.3   The Nicolaou benzofuran combinatorial approach
[36]
 
 
Previously synthesized chloromethylsulfide resin 51 was treated with salicylaldehydes 52 
to produce the resin supported aldehyde 53 under the action of CsCO3. 53 was then 
treated with arylmagnesium bromide 54 (as Grignard reagent) to produce 55, which was 
then selectively oxidized with IBX to produce the benzophenone 56. Sulfur ylide 
epoxidation, followed by mCPBA oxidation resulted in the sulphone 57, which was then 
treated with potassium tert-butyl alcohol to deprotonate the methylene groups adjacent to 
the sulphone, resulting in the a 5-exo-trig cyclization, forming the final 3-aryl-benzofuran 
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compound 58. Yields for this procedure were in the region of 30 – 48% depending on the 
identity of the R groups. (Scheme 21.) 
 
 
 
Scheme 21: The Nicolaou benzofuran combinatorial approach 
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2.2   6-, 7- and 8-Membered O,N-benzo-fused heterocycles 
 
Outlined below, is a brief introduction to the 6-, 7- and 8-membered O,N-benzo-fused 
heterocyclic motifs, listed according to ring size, as well as the most prominent synthetic 
strategies, extracted from literature sources, that do not employ the RMI-RCM approach 
adopted in this project. 
 
2.2.1   6-Membered O,N-benzo-fused heterocycles: the benzoxazines 
 
 
Figure 8: The basic 1,4-benzoxazine motif 
 
The 1,4-benzoxazine skeleton 59 (Figure 8) is a rare constituent in biologically active 
and naturally occurring compounds. Examples (Figure 9) include Cappamensin A 60,
[37]
 
isolated from Capparsis sikkimensis – a Taiwanese shrub with overhanging, climbing 
branches. The roots and seeds of this genus have been used in traditional medicine since 
antiquity as antirheumatic, expectorant, antispasmodic and analgesic agents. In a paper by 
Wu et al.,
[37]
 60 – as well as its methylated derivative 61 – have been found to exhibit 
significant in vitro anti-tumour activity against a wide variety of cancers. There is thus 
hope that its analogues may also exhibit anti-tumour activity. Other examples include 
compound 62, which has been studied by Rybczynski et al.
[38] 
as a potential Peroxisome 
Proliferator-Activated  Receptor (PPAR)  agonist, and (+)-PHNO 63 studied by 
Bergman et al.,
[39] 
which is a dopamine D2 agonist.  More common, however, is the 
related hydrogenated analogue 64, which can easily be achieved from 59 by way of a 
variety of hydrogenation reactions and by reaction at the saturated bond positions to 
achieve attachment of useful moieties. Examples of hydrogenated analogues include: 
compound 65,
[40]
 which possesses PPAR  and PPAR  agonist activity and could be used 
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in treating diabetes, hyperlipidemia and other diabetic complications, and compound 
66
[41]
 which possesses neuro-protectant properties.   
 
 
 
 
  
Figure 9: Molecules containing the 1,4-benzoxazine motif 
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2.2.1.1   Previous synthetic strategies for the 1,4-benzoxazines 
 
A review of the literature, supported by Buon et al.,
[42]
 shows that there are few published 
synthetic routes allowing for access to the 1,4-benzoxazine structural unit. In fact, prior to 
2000, only one such system had been reported
[43]
. Previous strategies are those of Bartch 
et al.
[44]
 for the formation of a 3-substituted 4H-1,4-benzoxazine and McKillop et al.
[45]
 
for the formation of 2,3-disubstituted derivatives. These systems have been prepared 
primarily via cycloaddition reactions which are less generally applicable and as such will 
not be discussed. Thus, only the synthetic strategy of Buon is presented (Scheme 22). 
 
2.2.1.1.1   The synthetic strategy of Buon et al.
 
 
 
 
 
Scheme 22: The synthetic strategy of Buon et al.
[42]
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2-Aminophenol 67 is reacted with di-tert-butyl dicarbonate in dry tetrahydrofuran at 
room temperature leading to the protected N-Boc phenolic compound 68 in 96% yield. 
The 2,3-dihydrobenzoxazine 69 was then obtained in 76% yield by heating 68 and 1,2-
dibromoethane under microwave conditions in pentan-3-one for one hour in the presence 
of an excess of K2CO3. The unsaturated carbamate 70 was finally obtained in 76% yield 
by using a bromination–debromination sequence involving NBS followed by treatment 
with NaI. (Scheme 22.)  
 
 
 
2.2.2   7-Membered O,N-benzo-fused heterocycles: the benzoxazepines 
     
 
Figure 10: The basic 1,5-benzoxazepine motif 
 
The 1,5-benzoxazepine skeleton 71 (Figure 10) is a far more common biologically active 
constituent than its six-membered counterpart. Just like the benzofurans, the 1,5-
benzoxazapine sub-structure has fallen into the category of a „privileged structure‟, with 
compounds containing this motif displaying the ability to bind to several diverse 
biological receptors with high affinity.
[46]  
Examples of the inclusion in bioactive 
compounds (Figure 11) include: compound 72,
[47]
 which has been tested as a novel 
potassium channel opener, and compound 73,
[48]
 a conduction anesthetic with Curare-like 
nerve ganglion blocking activity. The skeleton also appears as part of testing libraries 
developed towards the elucidation of its status as a privileged structure, such as 
compound 74.
[46]
 In addition the motif has been added to penicillin as a modifying group, 
with some success, such as compound 75,
[49]
 which has been shown to be effective 
against S. Aureus. Finally, it also forms the basis of pyrrolo-1,5-benzoxaepines, such as 
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PBOX-21 76, which inhibits GI cyclase activity in human astrocyctoma cells, and 
PBOX-6 77, which exhibits pro-apoptic ability by binding to tubulin and acting as a 
microtubule targeting agent.
[50] 
 
 
 
Figure 11:  Molecules containing the 1,5-benzoxazepine motif 
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2.2.2.1   Previous synthetic strategies for the 1,5-benzoxapines 
 
2.2.2.1.1   Sequential N-acylamide methylenation-enamide RCM
 
 
Similar to the RCM strategy employed in our laboratories, the methodology of Bennasar 
et al.
[51]
 used a 2-aminophenol precursor which underwent a double protection step: first 
using benzoyl chloride followed by acetyl chloride. (In both cases NaH was used as base 
to selectively deprotonate the amino group.) The compound was then allylated using allyl 
bromide under the action of K2CO3 to form the mono-allylated and double protected 
precursor 78. This compound was then subjected to RCM using a 30 mol% GII catalyst 
loading. Both the 6-membered 68 and 7-membered 79 ring products were produced – in a 
ratio of 3:1. (Scheme 23.) 
 
 
 
   
Scheme 23: The RCM strategy of Bennasar et al.
[51]
 
 
2.2.2.1.2 Substituted 1,5-benzoxazepines from the reduction of chromanone oximes 
 
During investigations into the reducing ability of LiAlH4, the reduction of the oximes of 
the chroman-4-ones were studied. A 3,3,7-trimethyl-3,4-dihydronaphthalen-1(2H)-one 
oxime 80 was subjected to such reduction in refluxing ether containing 300 mol% 
LiAlH4. (Scheme 24.) This resulted in two products. The first – a corresponding 4-amino 
derivative 81 (42% yield), the second – a ring opening product – a 1,5-benzoxazepine 82 
(17% yield). 
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Scheme 24: The reduction strategy of Dudykina et al.
 [48]
 
.    
 
2.2.3   8-Membered O,N-benzo-fused heterocycles: the benzoxazocines 
 
 
Figure 12: The basic 1,6-benzoxazocine motif 
 
Medium ring sizes, such as the 1,6-benzoxazocines 83, are more scarce in naturally 
occurring compounds. One of the few examples with the O and N atoms in the 1 and 6 
positions is compound 84
[52]
 – a highly selective human -3-adrenergic receptor agonist 
with high cell permeability (Figure 13). Other examples, indicating the importance 
placed on medium ringed heterocycles, include compound 85, produced by natural 
enzymatic pathways.
[53]
 More common are their 2,5-counterparts such as Nefopam 86 – a 
potent non-sedative analgesic that possesses a profile distinct from that of other anti-
inflammatory drugs,
[54]
 and the compound porritoxin 87, extracted from Alternaria porri, 
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which inhibits the growth of seedlings
[55]
. Furthermore, molecules such as 88 are being 
used as precursors in new types of transannular reactions involving selective 
transformations into useful oxazine and oxazole derivatives.
[56]
 
 
 
 
 
Figure 13: Molecules containing the 1,6-benzoxazacine motif 
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2.2.3.1   Previous synthetic strategies for the 1,6-benzoxacines 
 
The most common synthetic strategies for medium to large membered ring cycles, 
particularly those fused to benzene, involve RCM similar to the method used in this 
project and thus only a representative example will be given here. References citing these 
methods include Ibrahim et al.,
[57] 
Mamouni et al.
[58]
 and van Otterlo et al.
[59]
 
 
2.2.3.1.1   The RCM enyne metathesis strategy of Mori et al.
[60]
 
 
A suitably tosylated 1-aminophenol 89 was subjected to allylation (allyl bromide, K2CO3) 
and enylation (1-bromobut-2-yne; NaH) to produce compound 90. This was then 
subjected to RCM using a 10 mol% solution of the GI catalyst 5 in CH2Cl2. The reaction 
was left to run at room temperature for 7 hours, resulting in a 99% yield of the 8-
membered ring product 91. (Scheme 25.) 
 
 
 
 
Scheme 25: The enyne RCM strategy of Mori et al.
 [60]
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2.3  6-, 7- and 8-Membered N,N-benzo-fused heterocycles 
 
Outlined below, is a brief introduction to the 6-, 7- and 8-membered N,N-benzo-fused 
heterocyclic motifs, listed according to ring size, as well as the most prominent synthetic 
strategies, extracted from literature sources, that do not employ the RMI-RCM approach 
adopted in this project. 
 
2.3.1  6-Membered N,N-benzo-fused heterocycles: the quinoxalines 
 
 
Figure 14: The 1,4-quinoxaline motif 
 
As with its 6-membered „O,N‟ counterpart, the 1,4-quinoxaline motif  92 (Figure 14) is 
relatively rare in naturally occurring compounds and as of yet has seen little application 
in medicinal formulations. Some medicinal examples that contain the motif exist, albeit 
with variations on the level of oxidation. With reference to Figure 15, these include: the 
quinoxaline HBY (097) 93,
[61]
 a non-nucleoside reverse transcriptase inhibitor; the 
isothiazole compound 94,
[62]
 which is a powerful analgesic and compound 95,
[63]
 
(NBQX) a potent AMPA receptor antagonist. More common is its analogue 96, which 
shows one of the types of electronic conjugation that 6-membered di-nitrogen ring system 
can support due to the presence of 8  electrons,
[64]
 examples of the tautomeric forms 
 
that 
can be adopted by this system are shown in Scheme 26
[65]
. In these forms, its applications 
are far more numerous and include antituberculosis, antibacterial and anticancer 
agents.
[66]
 Examples include: olaquindox 97,
[67]
 which is a powerful antibacterial 
mutagenic agent and compound 98,
[68] 
a hypoxia-cell selective anticancer agent, fifteen 
times more potent than currently used agents.   
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Figure 15: Molecules containing the 1,4-quinoxaline motif 
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Scheme 26: Possible tautomeric forms of 8  1,4-quinoxaline 
2.3.1.1   Previous synthetic strategies for the 1,4-quinoxalines 
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2.3.1.1.1   Reduction methodologies involving quinoxalines 
 
Sheinkman et al.
[69]
 utilizes the quinoxaline 99, which is reduced in the presence of zinc 
dust to the radical anion intermediate, followed by acylation utilizing acetic anhydride, to 
form 1,1-quinoxaline-1,4-diyldiethanone 100 in a relatively poor yield of 10%. In the 
synthetic strategy of Hamer et al.
[70]
 direct reduction of 99, employing sodium in boiling 
ethanol produces tetrahydroquinoxaline 101 in a yield of 43%. (Scheme 27.) 
 
 
 
 
Scheme 27:  Reduction strategies of Sheinkman et al.[69] and Hamer et al.[70] 
 
2.3.1.1.2   Oxalate addition methodologies involving di-amines  
 
The methodology of Gomtsyan et al.
[71]
 involved the use of 3-nitrobenzene-1,2-diamine 
102 and glyoxal as a 40% solution in water, with ethanol as solvent. The reaction was 
heated to reflux for 2 hours and allowed to react at room temperature for a further 16 
hours resulting in 103 with a yield of 32%. (Scheme 28.) 
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Scheme 28:  Oxolate addition methodology of Gomtsyan et al.[71] 
 
The methodology of Tene Ghomsi et al.
[72] – A –  used a protected diamine 104 (R1 = 3-
phenyl-1H-pyrazole) which was reacted with the substituted oxalate 105 (R2,R3 = OEt), 
acting as both reactant and solvent. After concentration of the reaction mixture compound 
106 was re-crystallized from ethanol with a 90% yield. (Scheme 29: route A) 
 
The „green chemistry‟ methodology of Hazarika et al.[73] – B – used the un-protected 
diamine 104 (R1 = H) which was reacted with the substituted oxalate 105 (R2,R3 = 
alkyl/aryl) ), using InCl3 (10 mol%) as catalyst, at room temperature with water as 
solvent. This led to the formation of 107 with yields between 88% (R2,R3 = alkyl) and 
98% (R2,R3 = aryl). (Scheme 29: route B) 
 
 
 
Scheme 29: Addition strategies of Tene Ghomsi et al.[72] (A) 
and Hazarika et al.[73] (B) 
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2.3.1.1.3   Beirut methodologies involving benzofuroxans 
 
Numerous syntheses towards 6-membered di-nitrogen rings are possible utilizing 
variations of the well-known Beirut reaction.
[77]
 The required substituted benzofuroxans 
109, were readily producible from variously substituted 2-nitrobenzenamines 108, 
produced under the action of strong bases. The resultant benzofuroxans were then reacted 
with various -ketoesters 110, and triethylamine which was added dropwise at 0 °C and 
ethanol as solvent. The reaction mixtures were then left at room temperature for 1 – 3 
days. After evaporation to dryness the required quinoxaline-2-carboxylate 1,4-dioxide 
derivatives 111 were obtained, with yields for the reactions varying between 2 – 44%, 
depending on the identity of the R groups. (Scheme 30.)  
 
 
 
 
 
Scheme 30: Generalized methodologies of Jaso et al.,[74] Carta et al.[75] and Marin et al.[76] 
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2.3.2   7-Membered N,N-benzo-fused heterocycles: the benzodiazepines 
 
 
 
Figure 16: The 1,5-benzodiazepine motif 
 
 
One of the most common structural motifs in biologically active and medicinal 
compounds is the 1,5-benzodiazepine motif 112 (Figure 16). Even its simplest analogues 
(Figure 17) have long been known to have potent medicinal effects. Examples include: 
compound 113, which significantly lowers blood pressure; compound 114, a powerful 
analgesic; and compound 115, a well known tranquilizer.
[78]
 Its analogues are also known 
to exhibit antiviral activity, such as the HIV-1 reverse transcriptase inhibitor Nivirapine 
116.
[79]
 Compound 117
[80]
 has significant aldose-redutase ability and is currently being 
investigated for medicinal applications. The motif has been added to glycosides to 
investigate the behaviour of C-nucleocides, such as compound 118.
[81]
 The motif also 
occurs as part of larger compounds, such as the pyridobenzodiazepines: these include 
compound 119,
[82] 
(VNA-932) a potent, orally active, non-peptidic vasopressin V2 
receptor selective agonist; and compound 120,
[83] 
a
 
powerful inhibitor of the Hepatitis C 
virus (via NS5B polymerase inhibition).  
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Figure 17: Molecules containing the 1,5-benzodiazapine motif 
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 2.3.2.1   Previous synthetic strategies for the 1,5-benzodiazapines 
 
Generally, 1,5-benzodiazepines are synthesized by the condensation reaction of o-
phenylenediamines with α,β-unsaturated compounds,[84] β-haloketones,[85] and 
ketones.
[86]
 Among these methods, the acid catalyzed condensation of o-
phenylendiamines with ketones is one of the simplest and most applicable approaches for 
the synthesis of 1,5-benzodiazepines. A number of these methodologies will be described 
in the next section. 
 
2.3.2.1.1   The reaction of o-phenylenediamines with unsaturated carbonyls  
 
 
 
Scheme 31: Generalized methods applied by Loskutov et al.,[87] (Route A) 
and Bindra et al.[88] (Route B) 
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In the above methodologies, variously substituted di-amines 121 were reacted with 
various unsaturated carbonyls, such as ketones 122 (Route A) or di-ketones 123 (Route 
B), by refluxing for up to 15 hours in a Dean-Stark apparatus. (Scheme 31.) The key 
intermediates involved are the Michael adducts, which undergo Schiff base formation at 
either of the two carbonyl functionalities to give the 7-membered rings 124 and 125 
(depending on the nature of the carbonyl), after a second condensation. Overall yields for 
124 are in the region of 24% and for 125 the overall yields are in the region of 36%  
 
2.3.2.1.2   The one-pot three-component strategy 
 
In this novel one-pot, three-component reaction, benzene-1,2-diamine 126 was condensed 
with a variety of -keto esters 127. The reaction proceeded for 4 hours with C6F5COOH 
as acid. This resulted in the formation of an enaminoester intermediate, which then 
reacted with the aromatic aldehyde 128. (Scheme 32.) The main feature of this reaction is 
the -selective C–C bond formation of -enaminoesters – probably due to the 
thermodynamic control derived from intramolecular hydrogen bonding of the enamino 
esters. Yields for 129 after solvent optimization were in the region of 60%.    
 
 
 
 
Scheme 32: The -Ketoester methodology of Murai et al.[89] 
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2.3.2.1.3   Synthesis involving the catalytic action of zeolites 
 
The use of synthetic and natural zeolites in the methodology of Tajbakhsh et al.
[90]
 
represents true heterogeneous catalysis involving heterocyclization. Two equivalents of 
various ketones 130 were added to 2-aminophenol 126. The reaction mixture was then 
refluxed in acetone for 3 to 6 hours, over a variety of zeolites. Types of zeolites used 
included:  heulandite, HY and HZSM-5. Yields obtained for 131 were in the region of 69 
– 81%, depending on the ketone and zeolites used. (Scheme 33.)  Ketones relevant to the 
generalized reaction scheme below, included: acetone, 3-butanone, 4-methyl-2-
pentanone, acetophenone and 6-methyl-5-hepten-2-one.   
 
 
 
Scheme 33: The highly improved protocol of Tajbakhsh et al.[90] 
 
 
 
2.3.3  8-Membered N,N-benzo-fused heterocycles: the benzodiazocines 
 
 
         Figure 18: The 1,6-benzodiazocine motif 
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As with its 8-membered „O,N‟ counterpart, the 1,6-benzodiazocine motif 132 (Figure 18) 
is rare in naturally occurring compounds with known biological and medicinal effects. 
These types of bicyclic molecules are, however, potential pharmacological scaffolds with 
interesting biological activities.
[91-92]
 They have also been used as scaffolds for 
bridgehead studies
[93]
 and intramolecular flexibility studies.
[94]
 Figure 19 shows two 
examples of the 8-membered 1,6-dinitrogen ring system. Compound 133
 [95]
 (KT5720) is 
a protein kinase A, which regulates multiple signal transduction events via protein 
phoshorylation and is integral to all cellular responses involving the cyclic AMP second 
messenger system. Compound 134
[96]
 (K252a) is a potent inhibitor of protein kinase A 
(as well as kinases C and G) which acts by competing with ATP binding sites that have 
Ki values in the region of 18-25 nM. 
 
 
 
 
 
 
Figure 19: Molecules containing the 1,6-benzodiazacine motif 
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2.3.3.1   Previous synthetic strategies for the 1,6-benzodiazacines 
 
2.3.3.1.1   Reaction of protected di-amines with cis-1,4-dichloro-2-butene 
 
This strategy of Proust et al.
[93]
 (Scheme 34) involved refluxing the tosylated 1,2-
benzodiamine 135 with cis-1,4-dichloro-2-butene 136, in acetonitrile for 24 hours. The 
reactants were in 1:1 equivalence, with 5 equivalents of K2CO3 used as base to initiate the 
reaction. The yield of 137 was 75%.  
 
 
 
Scheme 34: The synthetic method used by Proust et al.[93] 
 
2.3.3.1.2 Methodologies involving RCM of allylated 1,2-benzodiamines  
 
The most common synthetic strategies for 8-membered ring cycles, particularly, those 
fused to benzene, involve RCM reactions similar to the method used in this project and 
thus only one example will be given here. References citing other RCM methods include: 
Mamouni et al.,
[58]
 Mori et al.
[60]
 and Dragutan et al.
[97]
 
 
The methodology of van Otterlo et al.,
[59]
 (Scheme 35) utilized a tosylated 1,2-
benzodiamine 135 that was subjected to double allylation with allyl bromide and K2CO3 
(as base). After refluxing in acetone for 20 hours at 60 °C, the double allylated product 
138 resulted. 138 was subjected to RCM, using a 5 mol% loading of the GII catalyst 6 in 
toluene at rt for 5 hours, leading to the formation of the 8-membered ring product  139  
with a 94% yield. 
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Scheme 35: The synthetic method used by van Otterlo et al.[59] 
 
 
 
2.4   Conclusion 
 
With the importance of the molecular scaffolds presented, as well as these previous 
synthetic strategies in mind, attention can now be drawn to the Wits RMI-RCM 
methodology presented in the next chapter of this dissertation. In doing so, it is hoped 
that the utility of the methodology can be seen in a more appropriate context. 
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Chapter 3:   Results and discussion 
 
This chapter presents the synthetic work undertaken in this dissertation and will be 
discussed in some detail. The sections are arranged according to the structural motif 
produced and will include an in-depth analysis of the synthetic methodology. 
 
3.1   The Wits RMI-RCM approach to benzofurans 
 
The following section will introduce the synthetic methodology undertaken in the 
production of the benzofuran motif. It begins with the retro-synthetic analysis of the 
problem at hand and proceeds to the actual methodology implemented towards this aim. 
The reaction results are then discussed in detail, with note taken of the various yields of 
the compounds produced, notes of synthetic interest and a discussion of the spectroscopic 
evidence confirming the identity of the compounds. 
 
3.1.1   Retro-synthetic analysis of the benzofurans 
 
The retro-synthetic methodology towards the Wits RMI-RCM approach to the 
benzofurans is represented in Scheme 36. The required target A can be envisaged to 
form, through RCM, if un-saturated bonds are in the positions shown in synthon B. To 
achieve synthon B, it was envisaged that allylic attachments in the required positions 
shown in synthon C, could be subjected to RMI. To achieve these attachments, variously 
substituted phenols D would suffice through dual allylation in the positions shown. 
Standard allylation reactions would result in attachment of the allyl group to the OH of 
the phenol. Thus it was envisaged that an allylation reaction followed by a Claisen 
rearrangement would cause the displacement of the allyl group to the adjacent carbon 
position. The OH group could then be re-allylated.  With this strategy in mind a 
standardized series of simple reactions was instituted to form the benzofuran motif. This 
strategy is shown in Scheme 37. 
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Scheme 36: The disconnection strategy adopted in Wits RMI-RCM methodology 
towards the synthesis of benzofurans 
 
 
3.1.2   General methodology implemented towards the benzofurans 
 
Towards the benzofuran synthetic goal – shown in Scheme 37 – several substituted 
phenols 140a-e (with at least one free ortho position) were subjected to a simple 
allylation reaction, utilizing allyl bromide as allylation reagent and potassium carbonate 
as base, to yield 141a-e. These compounds were then subjected to a Claisen 
rearrangement, either via conventional heating methods or under microwave radiation, to 
yield compounds 142a-e. These compounds were then re-allylated under the same 
allylation conditions used before, to yield the di-allylated compounds 143a-e. At this 
stage the Ru catalysts were introduced. Compounds 143a-e underwent RMI with catalyst 
15, utilizing an average catalyst loading of 5 mole %, to yield the di-isomerized products 
144a-e. These compounds were then subjected to RCM using the GII catalyst 6, again 
with a 5 mole % catalyst loading, resulting in the final benzofuran products 145a-e. 
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Scheme 37: The Wits RMI-RCM approach to benzofurans 
  a (R1 = OMe, R2 = H , R3 = H, R4 =OMe) 
  b (R1 = H, R2 = H, R3 = Br, R4 = H) 
c (R1 = H, R2 = H, R3 =t-butyl, R4 = H ) 
d (R1 = Bz, R2 = H, R3 = H, R4 = H ) 
e (R1 , R2 , R3 , R4 = Ar) 
  (For letter code clarification, please see Figure 20) 
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3.1.3   Substituted phenols and naphthalene-1-ol precursors 
 
A series of commercially available substituted phenols 140a-d and naphthalene-1-ol 140e 
were used as the precursors to the benzofurans (Figure 20). The choice of these 
compounds was based on the type and position of the relevant functionalities attached to 
the phenol ring – as these functionalities may be used as a means, and position, for the  
attachment of  other structural motifs at a later stage of a complete synthesis of a  larger 
structural complex. None of the compounds required purification prior to use. 
 
 
 
Figure 20: Precursors to the benzofurans 
 
3.1.4   Results and analysis of the individual reaction steps  
 
3.1.4.1   Allylation of the substituted phenols and naphthalene-1-ol 
 
A standardized allylation procedure was adopted as per the generalized mechanistic 
proposal outlined in Scheme 38 and proceeded as follows: potassium carbonate (in a 
molar excess of 2.5 equivalents) was used as a base to deprotonate the hydroxyl group of 
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the precursors, in the presence of allyl bromide (in a molar excess of 2.5 equivalents) as 
allylation reagent. All reactions were heated to 60 °C, and left to reflux in acetone for 12 
hours under an inert nitrogen atmosphere. The reaction mixtures were then filtered 
through celite, to remove the base, and the solvent was then removed under reduced 
pressure. This was followed by purification using silica gel column chromatography with 
hexane/ethyl acetate mixtures as eluent (optimized according to the retention factor of the 
individual compounds) to afford the desired compounds.  
 
 
  
Scheme 38: General mechanistic proposal of the allylation of  
phenols and naphthalene-1-ol 
 
The following allylated compounds 141a-e (Figure 21) were thus produced. 
 
 
 
Figure 21: Mono-allylated precursors 
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3.1.4.1.1   Yield and characterization data regarding the allylation procedures 
 
At this early stage of the synthetic methodology, the identities of the allylated precursors 
were confirmed primarily via HRMS and/or 
1
H NMR spectroscopy – only if they were 
previously uncharacterized compounds. This was the case with compounds 141a and 
141d. In the case of compound 141b, 141c and 141d, familiarity with the allylation 
protocol, along with TLC analysis, indicating that the reaction had run to completion, 
resulted in these known compounds being submitted directly to the next reaction step 
without further characterization.  
 
The yield data for the compounds, as well as the m/z of the parent ion (unless it was a 
known compound, in which case the relevant literature reference is given) are presented 
in Table 1.  
 
Table 1: Yields and HRMS data of the allylated compounds  
Compound Yield  
(%) 
HRMS (e/z) 
Expected Found 
141a 60 194.0943 194.0942 
141b 98 211.9837 
[98] 
141c 99 190.1358 
[99] 
141d 100 210.1045 210.1045 
141e 100 184.0888 
[100] 
 
 
As can be seen from the yields in Table 1, only 2,5-dimethoxyphenol (141a), did not 
proceed to completion, due to the possible steric interaction of the adjacent methoxy 
group. The 
1
H NMR signals for the allylic substituents on compounds 141a, 141b and 
141d, used to confirm that allylation of the OH groups had indeed taken place, are 
presented in Table 2. All signals are in the expected shift ranges. 
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Table 2: Relevant 1H NMR signals used for identification 
Compound 
1
H NMR  
 Identity Shift (ppm) Multiplicity Integration 
141a H2C= 5.26 – 5.30 
5.37 – 5.43 
m 
m 
1 
1 
 =CH– 6.01 – 6.14  m 1 
 –CH2– 4.57 – 4.59  m 2 
141b H2C= 5.27 – 5.44  m 2 
 =CH– 5.91 – 6.04  m 1 
 –CH2– 4.50 d 2 
141d H2C= 5.18  
5.31  
dd 
dd 
1 
1 
 =CH– 5.96  tdd 1 
 –CH2– 4.51  td 2 
 
 
 
3.1.4.2   Claisen reactions of the allylated precursors 
 
The allylated precursors 141a-e (Figure 21) were then subjected to two separate heating 
methods to effect the Claisen rearrangement (Scheme 39). The first method entailed 
conventional heating, with the reaction vessel submerged in either an oil bath (for 
temperatures below 90 °C), or in a Wood‟s Metal bath (for temperatures above 90 °C). 
The second method involved subjecting the allylated precursors to focused microwave 
radiation in a sealed reaction tube. Where conventional heating was used, the reaction 
progress was checked by TLC every 30 minutes.  If no significant conversion had 
occurred after 1 hour, the reaction temperature was increased by 30 °C and heating 
continued, until the reaction had either run to completion or decomposition products 
became evident. When microwave irradiation was used, the reaction progress was 
monitored via TLC every 15 minutes.  
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Scheme 39: General mechanistic description for the Claisen rearrangement 
 of the phenols and naphthalene-1-ol 
 
The following compounds 142a-e  (Figure 22) were thus produced. 
 
 
 
Figure 22: Claisen products 
 
 
3.1.4.2.1   Yield and characterization data regarding the Claisen procedures 
 
Table 3 shows the comparative yields of the relevant compounds that underwent Claisen 
rearrangement, as well as heating time, heating temperature and heating method (M = 
microwave radiation, C = conventional heating). In the case of microwave radiation the 
following parameters were used with regards to the CEM Discover microwave device: 
ramp time = 2 min; pressure = 100 psi; power = 150 W; cooling = on).   
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Table 3: Yield, reaction time and heating method for the various compounds 
Compound Time 
(min) 
Heating 
Method 
Temp. 
(°C) 
Yield 
(%) 
142a 40 C 230 49 
142b 15 M 180 –* 
142c 50 M 220 56 
142d 90 M 200 60 
142e 2 M 180 86 
      * not isolated, used directly in the next step 
 
Overall, the yields of the Claisen rearrangements were poor to moderate, with an average 
yield of just 62 %. The heating methodology employed does not, however, represent the 
optimal heating time or temperature. In each case it was clear that significant 
decomposition was indeed occurring. Thus a large opportunity is left for yield 
optimisation, with the potential for the results obtained for 142e (where the highest yield 
was 86 %) to be achieved. The molecule most unstable towards heating was 142b; this 
was most likely due to the bromine substituent on the ring, which also may have made 
the precursor compound 141b unstable and prone to decomposition. This resulted in 
142b being submitted directly to the next reaction step, without purification, as it also 
appeared to decompose on silica. 
 
On average the microwave method did not represent a significant improvement in 
reaction times, when compared with conventional heating methods. However, in the case 
of 142e, which underwent rearrangement in less than 4 minutes, accompanied by a 
sudden temperature rise signalling the end of the reaction, a high yield of 86 % was 
obtained. This may have been due to the increased electronic conjugation in the 
naphthalene ring, allowing the sigmatrophic shift to proceed more easily. This dramatic 
temperature rise was not observed in the other compounds undergoing Claisen 
rearrangement under microwave conditions. In the case of 142a, the relatively low yield 
is because the Claisen rearrangement proceeded not only to the required position A, but 
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also to positions B and C, as per the Claisen mechanism outlined in Scheme 12 in chapter 
one.  
 
Table 4 contains spectrographic data used to identify the compounds (with the exception 
of the bromine containing 142b). The primary identifying characteristics sought in the 
1
H 
NMR spectra were the existence, as well as movement of, the allylic substituent‟s signals. 
Where additional confirmation was needed, HRMS was used. All other signals were 
present in the 
1
H NMR and 
13
C NMR spectra which showed all the relevant signals 
needed to conclusively identify these compounds. 
 
Table 4: HRMS and relevant 1H NMR allylic signals used for identification 
Compound HRMS (e/z) 
1
H NMR  
Expected Found Identity Shift (ppm) Multipl. Integration 
142a 194.0943 194.0943 H2C= 4.92 – 5.07 m 2 
   =CH– 5.89 – 6.05  m 1 
   –CH2– 3.43  br d 2 
142c 190.1358 
[99] H2C= 5.14 – 5.20 m 2 
   =CH– 6.00 – 6.06 m 1 
   –CH2– 3.41  br d 2 
142d 210.1045 210.1062 H2C= 5.07 – 5.19  m 2 
   =CH– 6.06  tdd 1 
   –CH2– 3.47  br d 2 
142e 184.0888 
[100] H2C= 5.23 – 5.32 m 2 
   =CH– 6.03 – 6.17 m 1 
   –CH2– 3.58  d 2 
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3.1.4.3   Re-allylation of the Claisen products 
 
A standardized allylation procedure was again adopted as per the generalized mechanistic 
proposal outlined in Scheme 38 and proceeded as follows: potassium carbonate (in a 
molar excess of 2.5 equivalents) was used as a base to deprotonate the phenol group of 
the Claisen precursors 142a-e (Figure 22), in the presence of allyl bromide (in a molar 
excess of 2.5 equivalents) as allylation reagent. All reactions were heated to 60 °C, and 
left to reflux in acetone for 12 hours under an inert nitrogen atmosphere – with the 
exception of 142b, which was only reacted for 2 hours. The reaction mixtures were then 
filtered through celite and the solvent removed under reduced pressure, followed by 
purification using silica gel column chromatography with hexane/ethyl acetate mixtures 
as eluent (optimized according to the retention factor of the individual compounds).  
 
The following re-allylated compounds 143a-e (Figure 23) were thus produced. 
 
 
 
 
Figure 23: Re-allylated Claisen products 
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3.1.4.3.1   Yield and characterization data regarding the re-allylation procedures 
 
The yield data for the compounds as well as the m/z of the parent ion, obtained through 
HRMS, are presented in Table 5.  
 
Table 5: Yields and HRMS data of the re-allylated compounds 
Compound Yield (%) HRMS (e/z) 
Expected Found 
143a 92 234.1256 234.1258 
143b 25 250.1358  250.1360 
143c 90 230.1671 230.1648 
143d 82 210.1045 210.1045 
143e 99 224.1201 224.1204 
 
 
As can be seen from the yields in Table 5, only 143b gave a poor yield. This was a two-
step yield based on 141b, as its precursor 142b was used un-purified, due to the silica 
decomposition problem mentioned earlier. The slightly lower than expect yield for 143d, 
is most likely because this reaction was only run for 2 hours and not left overnight, as 
was done for the others. Nonetheless, the yield for such a short reaction time does 
indicate the high reactivity between the reagents, which would most likely have resulted 
in a higher yield, if it was allowed to react for longer, as was evidenced by the presence 
of a small amount of starting material on the TLC plate.   
 
Table 6 contains 
1
H NMR spectrographic data also used to identify the compounds. The 
primary identifying characteristic sought in the 
1
H NMR spectra, was the existence of 
two sets of allylic signals – in the regions of those signals found in Table 2 and Table 4. 
Apart from this, all other signals were present in the 
1
H NMR spectra. In addition, the 
13
C 
NMR spectra showed all the relevant signals needed to conclusively identify these 
compounds.  
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Table 6: Relevant 1H NMR spectroscopy signals (* = overlapping signals) 
Compound 
1
H NMR  
 Position Identity Shift (ppm) Multiplicity Integration 
143a O H2C= 5.21 dd 2 
 O =CH– 5.32 – 5.43  m 1 
 O –CH2– 4.48  td 2 
 Ar H2C= 4.91 – 5.03  m 2 
 Ar =CH– 6.09  tdd 1 
 Ar –CH2– 3.44 td 2 
143b O H2C= 5.27 and 5.40  dd and dd 2 
 O =CH– 5.85 – 6.12* m 1 
 O –CH2– 4.51  td 2 
 Ar H2C= 5.02 – 5.13 m 2 
 Ar =CH– 5.85 – 6.12*  m 1 
 Ar –CH2– 3.37 br d  2 
143c O H2C= 5.23 and 5.41 dd and dd 2 
 O =CH– 6.00 – 6.06* m 1 
 O –CH2– 4.52 td 2 
 Ar H2C= 5.00 – 5.12 m 2 
 Ar =CH– 6.00 – 6.06* m 1 
 Ar –CH2– 3.41 br d 2 
143d O H2C= 5.03 – 5.15* m 2 
 O =CH– 5.96 – 6.10 m 1 
 O –CH2– 3.91 br d 2 
 Ar H2C= 5.03 – 5.15* m 2 
 Ar =CH– 5.68 – 5.84 m 1 
 Ar –CH2– 3.49 d 2 
143e O H2C= 5.32 d 2 
 O =CH– 6.16 – 6.28 m 1 
 O –CH2– 4.51 dd 2 
 Ar H2C= 5.07 and 5.12 d and dd 2 
 Ar =CH– 5.94 – 6.13 m 1 
 Ar –CH2– 3.61 dd 2 
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3.1.4.4   Di-isomerization of the di-allylated compounds 
 
A standardized procedure was adopted in the RMI reactions on the di-allylated products 
from the previous step. The precursors 143a–e (Figure 23) were placed in a round 
bottom flask and dissolved in minimal (~2 mL) degassed toluene. The reaction solution 
was then degassed under reduced pressure and the vessel and then re-gassed with argon. 
(This was necessary because of the high sensitivity of the catalyst to oxygen.) In each 
case 5 mole % Ru isomerization catalyst 15 was then added and the vessel, which was 
again degassed and then re-gassed with argon. All reaction mixtures were then heated to 
65 °C and allowed to react for 12 to 14 hours.  
 
The following isomerized compounds 144a-e (Figure 24) were thus produced: 
 
 
 
 
 
Figure 24: Di-isomerized products  
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3.1.4.4.1   Yield and characterization data regarding the isomerization procedures 
 
The isomerized compounds were characterized using HRMS and 
1
H/
13
C NMR 
spectroscopies. As the molecular weights of the compounds were not expected to change 
after isomerization, masses of the parent ions, acquired via HRMS, were not considered 
conclusive. All of the masses of the parent ions were, nonetheless, as expected. However, 
the HRMS fragmentation patterns produced did differ, indicating that some molecular 
conversion had indeed occurred. The primary means for the identification of the products 
was left to 
1
H NMR, with the appearance of 2 methyl group signals, being considered a 
definitive sign that isomerization had indeed taken place. All other expected signals in 
both the 
1
H NMR and 
13
C NMR spectra were observed. 
 
Table 7 shows the yields found for the di-isomerized compounds 144a–e, as well as the 
characteristic methyl group signals that appeared after the compounds were isomerized.  
 
Table 7: Yield and 1H NMR characterization for the isomerized compounds   
Compound Yield (%) 
1
H NMR  
  Identity Shift (ppm) Multipl. Integration 
144a 98 O-~-CH3 1.78 dd 3 
  Ar-~-CH3 1.91 dd 3 
144b 100 O-~-CH3 1.86 – 1.92 m 3 
  Ar-~-CH3 1.55 – 1.73 m 3 
144c 86 O-~-CH3 1.69 dd 3 
  Ar-~-CH3 1.91 dd 3 
144d 98 O-~-CH3 1.85–1.93 m 3 
  Ar-~-CH3 1.57–1.62 m 3 
144e 93 O-~-CH3 1.91 – 1.97* m 3 
  Ar-~-CH3 1.91 – 1.97* m 3 
       * = overlapping signals 
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The isomerization of compound 144d – which was analyzed only with 200MHz NMR 
making splitting patterns difficult to discern – had its identity further confirmed via the 
different fragmentation patterns observed in the HRMS spectrum. The fragmentation 
peaks that differed (as well as those of its precursor) are shown in Table 8. 
 
Table 8: HRMS fragmentation patterns used for the characterization of 144d 
(Only non-corresponding peaks are shown; both M+ = 250) 
Precursor (143d) Isomerized product (144d) 
Peak (m/z) Intensity (%) Peak (m/z) Intensity (%) 
214 28 236 21 
209 28 208 26 
181 57 207 37 
175 24 191 26 
153 16 179 22 
139 16  
132 21 
77 17 
41 47 
 
 
All of the isomerization reactions proceeded with high yield (with 144c showing the 
lowest yield at 86 %). An interesting aspect of these products is that they occur as a 
mixture of E/Z-isomers, usually in an approximate ratio of 1:2 (based on the results of 
those compounds submitted to NMR). The catalyst has shown that it has high versatility, 
in terms of the substrates it can transform –  compound 144b was unstable towards 
Claisen reactions and  allylation, but underwent isomerization without difficulty. Catalyst 
removal was also easily effected in this group of compounds. It was sufficient to simply 
filter the reactant solution though a compacted celite plug and then purify the compounds 
using silica gel column chromatography. 
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3.1.4.5   RCM of the di-isomerized compounds 
 
The procedure adopted for the RCM reactions of the di-isomerized compounds 144a-e 
proceeded as follows: the di-isomerized precursors were dissolved in ~5 mL distilled 
degassed toluene and placed in a round bottom flask. The flask was then evacuated under 
vacuum and flushed with purified nitrogen gas. Grubbs‟ second generation catalyst 6 was 
then added at a standard 5 mole % relative to the precursor. The flask was then evacuated 
again and flushed with additional purified nitrogen. The reaction mixture was then left to 
stir under nitrogen over a range of times and at an average temperature of 90 °C. Catalyst 
removal was effected by filtering the reaction solution through a compacted celite plug; 
after which the solvent was removed under vacuum and the products purified using silica 
gel column chromatography. 
 
The following benzofuran products 145a-e (Figure 25) were thus obtained: 
 
 
 
                    
Figure 25: RCM products – the benzofurans 
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3.1.4.5.1   Yield and characterization data regarding the RCM procedures 
 
The yields, reaction times and temperatures of the RCM reactions are shown in Table 9, 
as well as HRMS data used in the identification of the compounds.  
 
Table 9: Yield, reaction time and temperature for the RCM products and HRMS data 
Compound Time 
(hr) 
Temp. 
(°C) 
Yield 
(%) 
HRMS (e/z) 
Expected Found 
145a 3 90 100 178.0630  178.0644 
145b 14 65 100 195.9524 195.9516 
145c 3 90 71 174.1045  174.1029 
145d 3 90 63 194.0732  194.0711 
145e 12 60 93 168.0575  168.0573 
 
 
With regard to Table 9: compound 145b was allowed to react at a temperature of 65 °C 
(instead of the usual temperature of 90 °C used for most RCM reactions in this project) as 
it was felt that the bromine substituent on the precursor may become unstable at higher 
temperatures. TLC analysis showed that the compound was slow to convert. However, 
after a reaction time of 14 hours a 100 % yield was obtained. This prompted a 
temperature of 60 °C to be used on compound 145e. This yield was less, despite the 
reaction time of 12 hours. All other reactions were done at 90 °C, which allowed the 
reactions to proceed to completion within 3 hours, but resulted in lower yields (with the 
exception of 145a) possibly due to decomposition.  As can be seen from these results, 
there appears to be an inverse relationship between reaction temperature and reaction 
time. There is thus an opportunity to optimize these experimental variables, with regard 
to the RCM reactions, to maximize the reaction yields. 
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Table 10 shows selected 
1
H NMR spectroscopic data used to conclusively identify these 
products. Only the signals for the 2 carbon substituents on the 5-membered ring are 
given. All signals shown integrate for 2 hydrogens. All other signals are, nonetheless, 
accounted for. (See Experimental Section.) 
13
C NMR spectra also showed that all 
products contained the relevant number of signals in the required shift ranges.  
 
Table 10:  Relevant 1H NMR signals from the 5-membered ring  
used to identify the benzofuran products  
Compound 
1
H NMR 
Identity Shift (ppm) Multiplicity Coupling (Hz) 
145a -O-CH-CH- 7.55 d 2.1 
 -O-CH-CH- 6.86 d 2.1 
145b -O-CH-CH- 6.72 d 2.2 
 -O-CH-CH- 7.26 d 2.2 
145c -O-CH-CH- 7.43 d 2.9 
 -O-CH-CH- 6.73 d 2.9 
145d -O-CH-CH- 7.67 d 2.2 
 -O-CH-CH- 6.83 d 2.2 
145e -O-CH-CH- 7.75 d 2.1 
 -O-CH-CH- 6.89 d 2.1 
 
As can be seen from the data in Table 10, both saturated carbons on the 5-membered ring 
show the expected doublet splitting pattern and an expected coupling constant value of 
around 2.0 Hz. The only exception, in terms of coupling constants, is compound 145c, 
which are higher than expected. This anomaly is possibly due to the interaction of the 
tert-butyl group, causing broadening of the observed signals. 
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3.1.5   Conclusion regarding the benzofuran RMI-RCM methodology  
 
Graph 1 shows the relative yields of all 5 steps of the methodology, although only 3 
readings have been given for compound B. As can be seen, there is a downward yield 
trend at the Claisen step. As discussed earlier, there is an opportunity here to optimise the 
temperature and reaction times of the Claisen reaction to maximise yields. Both allylation 
procedures proceeded with high yield (the exception being 141a, which was not reacted 
for long enough). The RMI reaction was the most high yielding overall, but could 
probably be optimised in terms of lowering the amount of catalyst used (i.e. less than 5 
mole %) to increase efficiency. The RCM reaction step, also gave generally high yields, 
but with 145c and 145d still leaving room for reaction optimization towards yield 
improvement. Overall, the synthesis of 145e was the most efficient; and the synthesis of 
145b the least efficient probably due to the instability of the bromine substituent. 
 
Chart 1: Overall yield trends in the synthesis of the benzofurans 
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3.2   The Wits RMI-RCM approach to the 6-, 7- and 8-membered  
         O,N- and N,N-benzo-fused heterocycles 
 
The following section will introduce the synthetic methodology undertaken in the 
production of the 6-, 7- and 8-membered benzo-fused heterocyclic motif. It begins with 
the retro-synthetic analysis of the problem at hand and proceeds to the actual 
methodology implemented towards this aim. Each reaction step of the methodology is 
then discussed in detail with note taken of: the various yields of the compounds 
produced, notes of synthetic interest and a discussion of the evidence confirming the 
identity of the compounds from various spectroscopies. 
 
3.2.1   Retro-synthetic analysis of 6-, 7- and 8-membered  
           benzo-fused heterocycles 
 
The retro-synthetic methodology of the Wits RMI-RCM approach to the 6-, 7- and 8-
membered benzo-fused heterocycles is represented in Scheme 40. The required targets 
A1-3 can be envisaged to form, through RCM, if un-saturated bonds are in the positions 
shown in synthons B1-3. To achieve synthon B3, it was envisaged that simple allylic 
attachments could be subjected to dual RMI. To achieve synthon B2, it was envisaged 
that one of the allylic substituents could be subjected to RMI. To achieve synthon B1, it 
was envisaged that a di-substituted benzene C would suffice, through dual allylation. 
With this strategy in mind, a standardized series of reactions – where the order of the 
allylation and deployment of the RMI catalyst were key to the methodology – was 
instituted to form the 6-, 7- and 8-membered benzo-fused heterocycles. Readily available 
2-aminophenol 146 was used as starting material for the O,N-containing benzo-fused 
heterocycles (Scheme 41); and benzene-1,2-diamine 156 was used as starting material for 
the N,N-containing benzo-fused heterocycles (Scheme 42). 
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Scheme 40: The disconnection strategy adopted in the Wits RMI-RCM synthesis of the  
6-, 7- and 8-membered benzo-fused heterocycles 
 
3.2.2   General methodologies implemented towards the O,N- and N,N-  
           benzo-fused heterocycles 
 
The next section will give an overview of the synthetic methodology adopted towards the 
6-, 7- and 8-membered benzo-fused heterocycles, synthesized in this project. The O,N-
72 
 
 
benzo-fused heterocycles (Scheme 41) are discussed first, followed by the N,N-
benzofused heterocycles (Scheme 42). 
3.2.2.1   General methodology towards the O,N-benzo-fused heterocycles 
 
2-Aminophenol 146 was subjected to a protection reaction, utilizing benzoyl chloride, to 
ensure that the amine group would only accept one allyl group in subsequent reaction 
steps. (Scheme 41.) 
   
The next step was to ensure that only allylation at the OH group occurred on the 
protected product 147. Potassium carbonate (a base with a suitably weak pKa) was used 
to ensure that the protected NH group was not deprotonated. Allyl bromide, in one to one 
equivalence, was then used as allylation reagent to form the mono-allylated product 148.   
 
At this stage, the synthesis split into three main reaction paths.  
 
First path:  
The mono-allylated product 148 was re-allylated – this time using the stronger base: 
sodium hydride – followed by the addition of allyl bromide to form the di-allylated 
product 149. The di-allylated product was subjected to RCM, using GII 6, to afford the 8-
membered ring product 150.  
 
Second path:  
The di-allylated product 149 was subjected to RMI using catalyst 15, to afford the di-
isomerized product 151. This in turn was then subjected to RCM, using GII 6, to afford 
the 6-membered ring product 152. 
 
Third path:  
The mono-allylated product 148 was subjected to RMI using catalyst 15, to afford the 
mono-isomerized product 153. It was then re-allylated using allyl bromide, with sodium 
hydride as base, to afford product 154. This in turn was then subjected to RCM, using GII 
6, to afford the 7-membered ring product 155.     
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Scheme 41: The Wits RMI-RCM approach to 6-, 7- and 8-membered O,N-heterocycles 
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3.2.2.2   General methodology towards the N,N-benzo-fused heterocycles 
 
Benzene-1,2-diamine 156 was subjected to a double protection step, utilizing acetic 
anhydride, to ensure that the amine groups would only accept one allyl group each, in 
subsequent reaction steps. (Scheme 42.) At this stage, the synthesis split into three main 
reaction paths.  
 
First path:  
To ensure that only one amine group on the protected precursor 157 was deprotonated, a 
very strict one to one molar ratio of sodium hydride (as base) was used. Allylation using 
allyl bromide – also in a strict one to one molar ratio – led to the formation of the mono-
allylated product 158. This product was then subjected to RMI using catalyst 15, to afford 
the mono-isomerized product 163. It was then re-allylated using allyl bromide, with 
sodium hydride as base, to afford product 164. This in turn was then subjected to RCM, 
using GII 6, to afford the 7-membered ring product 165. (However, after several attempts 
using different solvents, catalyst loadings, and reactions times and temperatures, results 
pertaining to the formation of the 7-membered ring were inconclusive – whilst the parent 
ion was detected using HRMS; 
1
H and 
13
C NMR spectra were problematic.) 
 
Second path: 
The protected precursor 157 was di-allylated – again using sodium hydride as base, 
followed by the addition of allyl bromide (2 equivalents) to form the di-allylated product 
159. The di-allylated product was then subjected to RCM, using GII catalyst 6, to afford 
the 8-membered ring product 160.  
 
Third path: 
The di-allylated product 149 was then also submitted to RMI using catalyst 15, to afford 
the di-isomerized product 161. This in turn was then subjected to RCM, using GII 6, in 
an attempt to afford the 6-membered ring product 162. (However, after several attempts 
using different solvents, catalyst loadings, and reactions times and temperatures, 
formation of the 6-membered ring proved unsuccessful.) 
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Scheme 42: The Wits RCM approach to 6-, 7- and 8-membered N,N-heterocycles 
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3.3   Results obtained for the individual reaction steps  
 
Each of the individual reaction steps will now be discussed in some detail. Based on the 
type of reaction used, the N,N-benzo-fused heterocycles and the O,N-benzo-fused 
heterocycles will be discussed together. Characterization and discussion of the individual 
compounds will then follow. 
  
3.3.1   Protection of the heterocyclic precursors   
 
Commercially available 2-aminophenol 146 and benzene-1,2-diamine 156 were used as 
the precursors to the benzo-fused heterocyclic compounds. 156 did require purification 
prior to use. The purification method used involved refluxing 156 in minimal toluene, in 
the presence of activated charcoal, for 30 minutes. The charcoal was then removed via 
hot filtration. Upon cooling, pure 156 precipitated out of solution and was removed via 
filtration.  
 
3.3.1.1   Protection of 2-aminophenol with benzoyl chloride  
 
The protection method for 2-aminophenol (Scheme 42) involved dissolving precursor 
146 in dry dichloromethane, after which the temperature of the reaction mixture was 
lowered to 0 °C in an ice bath. Pyridine (1 equivalent) was then added, followed by the 
addition of benzoyl chloride (1 equivalent). The choice of pyridine as base was 
important, because it was crucial not to deprotonate the hydroxyl group as this would 
have prevented allylation at a later stage; and pyridine mopped up the hydrogen chloride 
produced during the reaction. The reaction mixture was stirred under nitrogen at room 
temperature for 24 hours. It was then quenched with enough saturated solution of sodium 
hydrogen carbonate to bring the pH to 7. The organic fraction was then dried (using 
anhydrous magnesium sulphate) and the solvent then removed under reduced pressure. 
On purification (silica gel column chromatography) the identity of the protected product 
147 (100 % yield) was confirmed using 
1
H NMR spectroscopy (showing additional 
77 
 
 
signals from new arene ring) and 
13
C NMR spectroscopy (showing the presence of the 
carboxyl group). 
 
 
Scheme 42: Protection of 2-aminophenol 
 
 
 
3.3.1.2   Protection of benzene-1,2-diamine with acetic anhydride 
 
The protection method for benzene-1,2-diamine (Scheme 43) involved dissolving 156 in 
excess (10 equivalents) of pyridine (used as both base and solvent). The temperature of 
the mixture was lowered to 0 °C (in an ice bath) followed by the dropwise addition of 
acetic anhydride (3 equivalents). The reaction mixture was stirred under nitrogen at room 
temperature for 24 hours. It was then quenched with enough saturated solution of sodium 
hydrogen carbonate to bring the pH to 7. The organic fraction was dried (using anhydrous 
magnesium sulphate) and the solvent removed under reduced pressure. On purification 
(silica gel column chromatography) the identity of the protected product 157 (93 % yield) 
was confirmed using 
1
H NMR spectroscopy which showed the presence of the methyl 
groups. 
 
 
 
Scheme 43: Protection of Benzene-1.2-diamine 
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3.3.2   Sequential and dual allylation protocols 
 
The varying pKa values of the functional groups on the protected 2-aminophenol 147, 
allowed mono-allylation to be strictly controlled. This was done by varying the type of 
base used. To deprotonate the phenol group; potassium carbonate (2 equivalents) was 
used. To deprotonate the protected amine group; sodium hydride (1.2 equivalents) was 
used. In the protected benezene-1,2-diamine 157, the precise one to one stochiometric 
addition of the allyl bromide and sodium hydride was responsible for mono-allylation 
control; by de-protecting only one of the amine groups on the molecule. For dual 
allylation the same principles were used, with the hetero-atom on the substrate 
determining the type of base to be used. The general allylation-reaction mechanistic 
proposal is outlined in Scheme 43, showing a representative synthon undergoing 
allylation using the two different bases. 
 
 
 
Scheme 43: General allylation protocol 
 
Acetone was the solvent of choice for these reactions, due to its ease of preparation (as it 
only needed to be distilled prior to use). However, it is known that sodium hydride is 
sufficiently powerful to deprotonate acetone and thus dimethylformamide (DMF) is 
recommended as solvent whenever sodium hydride was required.
[101]
 However, it was 
subsequently found that if strict kinetic control conditions (-14 °C, dropwise reactant 
addition) were employed, the greater reactivity of the substrates towards sodium hydride, 
would prevent it from reacting with acetone. Thus acetone was eventually used for all 
reactions requiring sodium hydride, as long the kinetic reaction conditions were upheld. 
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The mono-allylated product‟s (148 and 158) and the di-allylated product‟s (149 and 159) 
spectrographic data (Table 13) is presented first, as the NMR signals from these 
compounds were crucial in assigning the correct signals to the mono-allylated mono-
isomerized products 154 and 164 (Table 15). This was because the latter compounds 
existed in two E,Z-isomeric forms and as a result, many of their 
1
H and 
13
C NMR signals 
overlapped.  
 
3.3.2.1    Mono- and di-allylations performed on the precursors 
 
Listed below are all the allylation reactions on the precursors, compounds 147 and 157. 
The products thus obtained include: the mono-allylated compounds 148 and 158 and the 
di-allylated compounds 149 and 159. These products, as well as their precursors are 
shown in Scheme 45. All allylation reactions were left to reflux under a nitrogen 
atmosphere overnight (~18 hours).  
 
 
 
Scheme 45: Allylation reactions performed on precursors  
 
The reaction conditions related to these compounds are listed in Table 11. These include: 
the precursor used; the base used; the stochiometric ratios of the base and allyl bromide 
to the precursor; the solvent used; the reaction temperature and product yield. With 
regards to the reaction temperature: if two values are given in the table, it means that the 
reaction began at the first temperature and was allowed to warm to the second 
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temperature. This was the case where kinetic conditions were used or where the high 
reactivity of NaH needed to be curtailed. 
 
Table 11: Yield and reaction conditions employed in the allylation reactions 
Pre-
cursor 
Base 
used 
Stochiometric 
Ratio 
Solvent 
used 
Reaction 
temp. (°C) 
Yield 
(%) 
Product 
  Base Allyl Br     
        
147 K2CO3 2 1.2 acetone 60 80 148 
148 NaH 1.2 2 DMF 0 to 25 90 149 
        
157 NaH 1 1 DMF 0 to 25 94 158 
157 NaH 1 1 acetone -14 to 25 95 158 
157 NaH 2 2.2 acetone -14 to 25 93 159 
 
As can be seen from Table 11, all the reactions enjoyed a high yield. The lowest yield 
found was for compound 148 (80 %). This was most likely due to the incomplete 
deprotonation of the phenol group on the precursor. Compound 158 was subjected to two 
synthetic procedures. The first method used DMF as solvent, the second acetone as 
solvent with full kinetic conditions. Both reactions had almost identical yields (94 %), 
indicating that NaH can indeed be used with acetone as so long as sufficient care is taken.  
 
3.3.2.1.1    Characterization of the preceding allylation products 
 
The following section will describe the spectrographic data used to confirm reaction 
outcome, with regards to the allylation reactions performed on the precursors. The 
characterization of these compounds involved the use of HRMS (Table 12); and 
1
H 
NMR (Table 13) and 
13
C NMR spectroscopy.  
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Table 12: HRMS data used to characterize the mono- and di-allylated products 
Compound HRMS (e/z) 
Expected Found 
148 253.1103 253.1121 
149 293.1416 293.1424 
158 232.1211 232.1211 
159 272.1525  272.1526 
 
As can be seen from Table 12, all masses found were as expected.  
 
Table 13: NMR data used to characterize the mono- and di-allylated products’ allylic signals 
Compound 
1
H NMR  
Identity Shift (ppm) Multipl. Integration 
148 H2C= 5.33 ; 5.43 dd ; dd 1 ; 1 
 =CH– 6.08  tdd 1 
 –CH2–O 4.64 dt 2 
149 H2C= 5.26 ; 5.36 dd ; dd 1 ; 1 
 =CH– 5.78 – 6.14 m 1 
 –CH2–O 4.44 ; 4.64 dd ; dd 1 ; 1 
 H2C= 5.08 ; 5.13 dd ; dd  1 ; 1 
 =CH– 5.78 – 6.14 m 1 
 –CH2–N 4.26 dd 2 
158 H2C= 5.09 ; 5.15 d ; d  1 ; 1 
 =CH– 5.90 ddd 1 
 –CH2–N 3.93 ; 4.50 dd ; dd 1 ; 1 
159 H2C= 5.01 ; 5.10 d ; d  2 ; 2  
 =CH– 5.75 – 5.91 m 2 
 –CH2–N 3.49 ; 4.90 dd ; dd 2 ; 2 
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As can be seen from Table 13, signals for the O-allyl substituent on the O,N-mono-
allylated compound 148, correspond with the equivalent signals in the di-allylated 
compound 149. The same applies to the N,N-compounds 158 and 159. (Keep in mind, of 
course, that the signals of the symmetrical molecule 159 need to have their integration 
values doubled.)  
 
3.3.2.2    Allylation reactions performed on the ‘isomerized’ precursors 
 
Listed below are all the allylation reactions on the „isomerized‟ precursors, compounds 
153 and 163. The products thus obtained include: compounds 154 and 164. (Scheme 46.) 
All allylation reactions were left to reflux under a nitrogen atmosphere overnight (~18 
hours). 
 
 
Scheme 46: Allylations performed on the ‘isomerized’ precursors  
 
The reaction conditions related to these compounds are listed in Table 14. (With the 
same reaction details used in Table 11.) 
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Table 14: Yield and reaction conditions employed in the allylation reactions 
Pre-
cursor 
Base 
used 
Stochiometric 
Ratio 
Solvent 
used 
Reaction 
temp. (°C) 
Yield 
(%) 
Product 
  Base Allyl Br     
153 NaH 1.2 2 DMF 0 to 25 95 154 
        
163 NaH 1.2 2.4 acetone -14 to 25 99 164 
  
As can be seen from Table 14, all the reactions enjoyed a high yield. Again, the first 
reaction used DMF as solvent; the second acetone as solvent with full kinetic conditions.  
 
3.3.2.2.1    Characterization of the preceding allylation products 
 
The following section will describe the spectrographic data used to confirm reaction 
outcome, with regards to the allylation reactions performed on the „isomerized‟ 
precursors. The characterization of these compounds involved the use of HRMS (Table 
15); and 
1
H NMR (Table 16) and 
13
C NMR spectroscopy.  
 
Table 15: HRMS data used to characterize ‘isomerized’ allylated products 
Compound HRMS (e/z) 
Expected Found 
154 293.1416 293.1424 
164 272.1525  272.1529 
 
The HRMS value for 154 is expected to be the same as that of 149; and the value of 164 
is expected to be the same as that of 159. (See Table 12.) It should be noted, however, 
that the HRMS fragmentation patterns for these molecules were different. (See 
experimental.) 
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Table 16: NMR data used to characterize the ‘isomerized’ allylated products’ allylic signals  
Compound 
1
H NMR  
Identity Shift (ppm) Multipl. Integration 
154 H3C– 1.69 dd  3 
 –CH= 4.84 – 4.94 m 1 
 =CH–O 5.86 – 6.12 m 1 
 H2C= 5.13 dd  2 
 =CH– 5.86 – 6.12 m 1 
 –CH2–N 4.37 ; 4.58 dd ; dd 1 ; 1 
164 H3C– 1.64 dd  3 
 –CH= 4.80 dq 1 
 =CH–N 7.07 – 7.34 m 1 
 H2C= 4.93 – 5.29 m  2  
 =CH– 5.75 – 5.91 m 1 
 –CH2–N 3.34 – 3.75 
4.33 – 4.69   
m 
m 
1 
1 
 
 
As can be seen from Table 16, the signal shift ranges for the N-allylic group of 
compound 154 corresponds to the N-allylic group signal shift ranges of compound 149 
(shown in Table 13); and the signal shift ranges for the N-allylic group of compound 164 
corresponds to the N-allylic group signal shift ranges of compounds 158 and 159 (shown 
in Table 13).  
 
Furthermore, the signal shift ranges for the isomerized substituent in compound 154 
corresponds to the signals shift ranges of its mono-allylated precursor 153; and the signal 
shift ranges for the isomerized substituent in compound 164 corresponds to the signals 
shift ranges of its mono-allylated precursor 163. The signals assignments for these 
compounds (153 and 163) are shown in Table 14 in the previous section. 
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3.3.3    Isomerization (RMI) protocol 
 
The procedure adopted in the RMI reactions on the mono-allylated precursor 158 and di-
allylated precursors 149 and 159 proceeded as follows: 
The precursors were placed in a round-bottom flask and dissolved in minimal distilled 
toluene (~ 2 mL). The reaction solution was then degassed under reduced pressure and 
the vessel and then re-gassed with argon. In each case 5 mole % Ru isomerization 
catalyst 15 was then added and the vessel was again degassed and then re-gassed with 
argon. All reaction mixtures were then heated to 65 °C and allowed to reflux under an 
argon atmosphere for 12 to 14 hours. 
  
In an attempt to demonstrate the utility of the microwave methodology, towards 
accelerating the isomerization reaction – precursor 148 was placed in a microwave 
reaction tube and dissolved in minimal (~1 mL) distilled degassed toluene, which was 
then sealed.  5 Mole % Ru isomerization catalyst 15 was then quickly added to the vessel, 
followed by irradiation under microwave conditions (power: 150W with cooling, ramp 
time: 2 °C per min, maximum pressure: 100 psi) in a pressure tube. Under these 
conditions the isomerization reaction proceeded to completion in just 10 minutes, when 
an optimised temperature of 90 °C was used. 
 
Catalyst removal was effected by filtering the reaction solutions through a compacted 
celite plug; after which the solvent was removed under vacuum and the products purified 
using silica gel column chromatography. Catalyst removal in the di-nitrogen compounds 
158 and 159 did, however, prove difficult. These compounds had a very low retention 
factor in most solvent systems. The most effective removal strategy appeared to be 
dissolving the crude product in a 2 to 5 % ethyl acetate/hexane mixture and slowly 
filtering it through a compacted celite plug, up to 4 times, followed by flash silica gel 
column chromatography using a 100% ethyl acetate. 
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The following isomerized products (Figure 26) were thus obtained: 
 
 
 
Figure 26: Isomerization products 
 
3.3.3.1   Yield and characterization data regarding the RMI procedures 
 
The isomerized compounds were characterized using HRMS and 
1
H/
13
C NMR 
spectroscopy. As their molecular weights (acquired through HRMS) were expected to be 
the same as their non-isomerized counterparts, this data alone was not considered 
conclusive evidence that isomerization had indeed occurred. The masses of the parent 
ions acquired were, however, as expected. The HRMS data, as well as the yields for these 
compounds are given in Table 17. It should be noted, however, that the HRMS 
fragmentation pattern data for the isomerized compounds did differ from their non-
isomerized counterparts.  
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Table 17: Yield and HRMS fragmentation data for the isomerized compounds 
Compound Yield (%) HRMS (e/z) 
Expected Found 
151 98 293.1416 293.1416 
153 92 253.1103  253.1091 
161 93 272.1524  272.1519 
163 96 232.1212  232.1214 
 
More important in the characterization of these compounds was the 
1
H NMR 
spectroscopy data. Table 18 presents the methyl signals of the isomerized allylic 
substituents obtained for these compounds. The existence of one methyl-group signal (for 
compounds 153 and 163) in the appropriate region; and two methyl-group signals (for 
compounds 151 and 162) in the appropriate region was considered a definitive sign that 
isomerization had indeed taken place. All other expected signals in both the 
1
H NMR and 
13
C NMR spectra were found. It was possible – based on 1H and 13C NMR spectroscopy 
signal integration ratios – to determine the isomeric E/Z-ratios of the compounds 
produced. 
 
 
Table 18: Characteristic methyl group signals and isomeric ratio  
of the isomerized compounds 
Compound 
1
H NMR  
Identity Shift (ppm) Multipl. Integration Ratio (E/Z) 
153 O-~-CH3 1.68 ; 1.75 dd ; dd 3 1 : 2 
151 O-~-CH3 1.66  ; 1.61 dd ; m 3 1 : 2 
 N-~-CH3 1.66  dd 3 
163 N-~-CH3 1.64 dd 3 - 
161 N-~-CH3 1.61 br dd 6 ~1 : ~1 : ~1 
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As with the other isomerization reactions in this project, these isomerization reactions 
proceeded efficiently and with high yield. The mono-isomerized compound 153 occurred 
as both E and Z isomers, whereas compound 163 occurred as only one isomer. The di-
isomerized O,N-compound 151 occurred as two isomers – the signals for which 
overlapped.  
 
The di-isomerized N,N-compound 161 occurred as three isomers: EE, EZ and ZZ. This 
made the interpretation of its 
1
H NMR spectrum extremely complex. Therefore all signals 
are given as multiplets, with compound 163 being used to assign the shift regions 
correctly. The 
1
H NMR signals for compounds 163 and 161 are thus given in some detail 
in Table 19.  The assignment of the correct identities of compound 161 were also 
confirmed via a 
13
C-
1
H correlated spectrum, which is included in Appendix B. 
 
Table 19: Mono-isomerized 163 and di-isomerized 161 1H NMR signals,  
showing their congruence 
Assignment Shift (ppm) 
163 161 
NCHCH-CH3 1.64 1.54 – 1.65 
C-(=O)-CH3 1.82 1.74 – 1.88 
C-(=O)-CH3 2.18 2.12 – 2.25 
NCH=CH-CH3 4.40 – 4.58 4.39 – 4.93 
N-CH=CHCH3 7.11 7.02 – 7.29 
ArCH‟s 7.21 7.31 –  
7.60   ArCH‟s 7.38 – 7.52 
 
From Table 19 it can be seen that the regions in the complex 
1
H NMR spectrum of 
compound 161, match up with the known regions in the much simpler spectrum of 
compound 163, thereby confirming that the correct shift assignment have been made.  
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3.3.4    RCM protocol 
 
The procedure adopted in the RCM reactions on the O,N-precursors 149, 151 and 154; 
and the N,N-precursors 159 and 161 was as follows: The precursors were placed in a 
round bottom flask and dissolved in minimal distilled toluene (~ 5 mL). The reaction 
solution was then degassed under reduced pressure and the vessel and then re-gassed with 
argon. The GII RCM catalyst 6 was then added to the vessel, which was again degassed 
and then re-gassed with argon. All reaction mixtures were then heated to between 80 and 
90 °C and allowed to reflux under an argon atmosphere for 8 to 18 hours – with reaction 
progress checked via TLC every 4 hours. All reactions proceeded to completion, except 
for compound 161 (which failed to ring close, despite several attempts at various catalyst 
loadings, temperatures and reaction times) and compound 164, which resulted in only 
trace amounts of the expected product 165. 
 
The microwave methodology was again investigated towards accelerating the RCM 
reaction, using precursors 161 and 164. Each precursor was placed in a microwave 
reaction tube and dissolved in minimal (~1 mL) distilled degassed toluene, which was 
then kept sealed.  5 Mole % RCM catalyst 6 was then added to the vessel, followed by 
irradiation under microwave conditions (power: 150W with cooling, ramp time: 2 °C per 
min, maximum pressure: 100 psi) in a pressure tube. Under these conditions the RCM 
reaction for 164 appeared to proceed to completion in just 20 minutes, when an optimised 
temperature of 90 °C was used. Compound 161, however, failed to ring-close. 
 
Catalyst removal was effected by filtering the reaction solution through a compacted 
celite plug. After which the solvent was removed under vacuum and the products purified 
using silica gel column chromatography. 
 
The relevant precursors and their RCM products and their precursors are shown in 
Scheme 47: 
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Scheme 47: RCM products obtained 
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3.3.4.1   Yield and characterization data regarding the successful RCM products 
 
The yields, optimized reaction conditions and HRMS data for the successful RCM 
reactions are shown in Table 20. All the expected HRMS masses for these compounds 
were found.  
 
Table 20: Yield, HRMS, optimized reaction times and temperature for the RCM products 
Com-
pound 
% GII 
loading 
Time 
(hr) 
Temp. 
(°C) 
Yield 
(%) 
HRMS (e/z) 
Expected Found 
152 8 8 90 96 237.0790  237.0789 
155 5 8 80 100 251.0946  251.0946 
150 5 18 90 88 265.1103  265.1118 
160 8 18 90 90 244.1212 244.1212 
165 5 20 min * 90 trace** 230.1055 230.1056 
165 8 18 90 trace**   
* = microwave reaction time 
** = largest product not the required 7-membered benzo-fused ring 
 
Regarding the data for compound 165 – when the reaction was performed under 
conventional heating conditions, the parent ion for the expected product 165 was not 
obtained and the 
1
H and 
13
C NMR spectra showed that significant amounts of starting 
material 164 were still present, and the product obtained was clearly a decomposition 
product. When the reaction was performed under microwave conditions, the expected 
parent ion of 165 was detected, but the primary product could not be conclusively 
identified using 
1
H and 
13
C NMR. (Spectra shown in Appendix A).  
  
Table 21 shows selected 
1
H NMR spectroscopic data used to conclusively identify the 
O,N-ring-closed products 152, 155 and 150. Only the hydrogen signals from the bridge 
carbons along the ring are presented. All other signals are, nonetheless, accounted for. 
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(See Experimental Section.) 
13
C NMR spectra also showed that all products contained the 
relevant number of signals in the required shift ranges. 
 
Table 21: NMR data used to characterize the O,N-RCM Products 
Compound 
1
H NMR  
Identity Shift (ppm) Multipl. Integration Coupling (Hz) 
152 –O–CH= 6.05 d 1 4.5 
 =CH–N– 6.27 br d 1 2.5 
155 –O–CH= 6.51 – 6.58 m 1 - 
 –CH=CH– 4.94 d 1 3.1 
 –CH2–N– 3.37 ; 5.36 br s ; br s 2 - 
150 –O–CH2– 3.95 – 5.48* m 2 - 
 O–CH2–CH= 5.80 dt 1 10.4 and 8.3 
 =CH–CH2–N 5.95 dt 1 10.4 and 4.0 
 –CH2–N– 3.95 – 5.48* m 2 - 
* = overlapping signals 
 
Where coupling values could be obtained in compound 152, the apparent difference in 
the values obtained for the saturated carbons in the heterocyclic ring (which should be the 
same) is most likely due to the close proximity of the highly electronegative nitrogen 
atom‟s lone-pair interacting with the hydrogen on the carbon adjacent to the nitrogen, 
which led to significant broadening of the signal. The value given for this hydrogen is 
thus only approximate. A similar effect is also noted in compound 150, where significant 
ring movement is expected, and the second coupling constant is around half the value of 
its counterpart. 
  
Table 22 shows selected 
1
H NMR spectroscopic data used to conclusively identify the 
N,N-ring-closed product 160. Only the hydrogen signals from the bridge carbons along 
the 6-membered ring are presented. All other signals are, nonetheless, accounted for. (See 
Experimental Section.) 
13
C NMR spectra also showed that the product contained the 
relevant number of signals in the required shift ranges.  
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Table 22: NMR data used to characterize the N,N-RCM Product 
Compound 
1
H NMR  
Identity Shift (ppm) Multipl. Integration Coupling (Hz) 
160 –N–CH2– 3.47–5.19 m 4 - 
 –CH2–CH= 5.82–6.11 m 2 - 
 
It was very difficult to purify compound 160 completely, as its high polarity and apparent 
tendency to adhere to silica required the use of a highly polar solvent system. The use of 
pure ethyl acetate was found to be the most effective eluent which gave a retention factor 
of 0.28 to the compound in the column. The catalyst was less polar than 160 and was 
substantially removed via gradient elution utilizing a 10% ethyl acetate/hexane mixture, 
which left the compound unmoved on the column. Re-crystallization was attempted, as a 
means of purification, but was unsuccessful.  
 
3.3.4.2   Data regarding the unsuccessful RCM products 
 
Despite several efforts, compound 161 failed to ring-close. All the reaction conditions 
employed towards the attempted ring closure of compound 161 are presented in Table 
23. The failure of di-nitrogen containing compounds, of this type, to ring-close is not, 
however, unprecedented and will be discussed in some detail in Chapter 4. 
 
Table 23: Reaction conditions employed towards the attempted RCM of 161 
% GII 
loading 
Heating 
method 
Time 
 
Temp. 
(°C) 
5 C 8 hr 90 
5 M 40 min 90 
8 C 12 hr 80 
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8 M 50 min 90 
12 C 24 hr 95 
 
 
Most disappointing, were the results regarding the attempted synthesis of compound 165. 
As stated earlier, HRMS did find the expected parent-ion and the subsequent mass 
fragmentation pattern was obtained, but this product most likely formed only in trace 
amounts. Subsequent 
1
H and 
13
C NMR analysis indicated that the major products isolated 
were not the expected 7-membered benzo-fused ring, but most likely resulted from single 
or dual de-allylation of the precursor. This result will be discussed in detail in Chapter 4. 
 
 
3.4 Conclusion regarding the O,N- and N,N-benzofused heterocycles 
 
The yields of all the individual reaction steps leading up the final RCM step of the 
methodology were very high, and proceeded without much difficulty. These yields were 
all in the region of 90–100%. Where ring-closure could be affected, the yields were 
similarly high in the region of 88–100%.  There did not appear to be any correlation 
between the size and the ring produced and the yield obtained. 
 
Numerous attempts at RCM to form the 6-membered di-nitrogen product 162, all met 
with failure. Previous attempts in these laboratories in similar di-nitrogen compounds, 
albeit with different protecting groups, have also met with failure.
[59]
 The attempted 
synthesis of the 7-membered di-nitrogen product 165 was met with some success, but 
overall it cannot be conclusively stated that the methodology was successful. 
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        CONCLUSION  
 
     FUTURE WORK 
4.1   Conclusions and future work regarding the benzofurans 
 
The most successful part of this project involved the formation of the benzofurans, 
utilizing the Wits RMI-RCM methodology – a simple, versatile method for the synthesis 
of substituted benzofurans involving the novel use of RMI on C- and O-allyl functional 
groups, followed by RCM. A large range of arene-ring substituents has been 
demonstrated to be tolerated by the methodology.  
 
The Wits RMI-RCM methodology proved to be most efficient for compounds containing 
electron rich substituents on the arene ring, such as 145a (dimethoxy) and 145b (bromo), 
as well as the naphtho-compound 145e. While the yields were lower, bulky groups para 
or ortho to the phenol group, such as 145c (tert-butyl) and 145d (benzo) did not prevent 
RCM from occurring.  The high level of tolerance to all these arene substituents, in terms 
of both their identity and position is useful, as they may be converted to other functional 
groups as part of a later complete synthesis, requiring the attachment of a benzofuran 
motif.   
 
The Claisen reactions performed in this project showed the lowest yields overall, with the 
di-allylated 4-bromophenol 143b showing extensive decomposition during the reaction. 
There is thus scope left to optimise this reaction, with the hope of finding an ideal 
reaction time and temperature, to increase the overall efficiency of the methodology. 
 
The most efficient part of the methodology involved RMI, with the Ru-catalyst 15 
proving itself to be most versatile (being reacted both with and without solvent) and with 
a seemingly universal tolerance to its substrate.  
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The utilization of microwave radiation,  not only as a method of affecting the Claisen 
rearrangement, but also for RMI and RCM reactions, has shown to improve the 
efficiency of the methodology in terms of both time and energy. 
 
 
4.2   Conclusions and future work regarding the O,N-benzo-fused  
        heterocycles 
  
The deployment of RMI to mono- and di-allylated O,N-precursors, was successful. The 
methodology showed high tolerance to both the N- and O-allyl functional groups, with 
very high yields obtained. The RCM reactions occurred readily and with high yield on 
both the O,N-di-allylated; O,N-di-isomerised; and O-mono-allylated-isomerized and N-
allylated functionalities – leading to the formation of the required 8-, 6- and 7-membered 
ring-closed products. 
 
The reaction most notable is the formation of the 6-membered ring product 152, in which 
the precursor 151 had an allylic amine group (shown in red) but nonetheless underwent 
RCM with a high yield. (Scheme 48.) This is of interest, as the N,N-precursors 161 and 
164 with this same allylic amine configuration did not undergo ring-closure, but instead 
underwent allylic cleavage, followed by possible secondary metathesis reactions. 
 
 
Scheme 48: Formation of the 6-membered O,N-product 
 
Future work regarding the formation of 6-, 7 and 8-membered benzo-fused heterocycles 
may include the use of O,N-precursors with a wide variety of substituents on the arene-
ring, to determine if the Wits RMI-RCM methodology is still applicable to such systems. 
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This is of interest because such systems would allow for the formation of more 
complicated motifs, with such functionalities acting as useful attachment points of the 
heterocyclic motif to other molecules, or they may be converted to other functional 
groups as part of a later complete synthesis, potentially towards medicinally useful 
molecules such as those discussed in Chapter 2. 
 
4.3   Conclusions and future work regarding the N,N-benzo-fused  
        heterocycles 
 
The Wits RMI-RCM methodology met with failure, with regards to the formation of 6- 
and 7-membered di-nitrogen benzo-fused heterocycles, but was successful in the 
formation of the 8-membered di-nitrogen heterocycle.  One possible explanation for this 
failure involves the allylic amine system (shown in red in Scheme 49). The presence of 
two of these systems in similar molecules (but with different protecting groups) has 
resulted in other failures to ring close.
[59]
  
 
 
Scheme 49: Non-formation of the 6- and 7-membered N,N-products 
 
As mentioned in the previous section, however, this system is present in the O,N-
precursor 151, but did not affect the reaction outcome. This result, and the presence of 
trace amounts of the 7-membered product 165, but none of the 6-membered product 162, 
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may indicate that the GII catalyst 6 is tolerant to only one such system in a molecule. It 
also leaves open the possibility that the formation of the 7-membered product is indeed 
possible, with further study involving catalyst loading, reaction time, reaction 
temperature, and solvent system needed. The 
1
H and 
13
C NMR spectra obtained for the 
expected 165, formed using the microwave reaction methodology but not the 
conventional heating methodology, reiterates the possibility that reaction conditions 
affect outcome. Several papers
[102-105]
 have discussed the Ru-initiated de-allylation of  
such allylic amine systems,  and the tolerance of certain substrates (such as 151) to this 
phenomenon and not others (such as 161  and 164) warrants further investigation. 
  
Finally, a steric argument for the failure of these precursors to ring-close may be 
proposed, in that the positions of the allylic and isomerized-allylic substituents on the 
precursor are beyond the bite-angle of the catalyst. A method of investigating this would 
involve a molecular modeling study. In such a study, a crystal structure of the relevant 
precursor is obtained and submitted to a force field methodology (e.g. MM+).  The 
following steps for such a methodology are envisaged (Chart 1): 
 
Step 1: The Single-point energy optimized model of the molecule, has its isomerized-
allylic substituent‟s atoms restrained by an external torsional force. (A common 
procedure in the HyperChem software suite.) 
 
Step 2:  The molecule is then submitted to a Geometry Optimization method such as 
Newton Raphson and/or Polak Ribiere, followed by the new determination of its Single-
point energy. 
  
Step 3: The angle of the restrained isomerized-allylic substituent is then altered by a 
small amount, and Step 2 is then repeated. 
 
Steps 2 and 3 are then repeated until the isomerized-allylic substituent has been rotated 
through 360°. At each step, the Single-point energy, along with the associated 
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conformation of the molecule, is stored. The procedure can be repeated on the other 
isomerized-allylic substituent.  
 
From the resulting data, a plot of the Single-point energy of the molecule versus torsional 
angle can be produced. The conformation of the computationally determined molecule 
with the lowest energy is expected to be the most likely conformation of the molecule in 
reality. If the isomerized-allylic substituents on this molecule are in positions that make 
them unlikely to come within the bite-angle of the GII catalyst 6, then this may be a 
reason for the failure to ring-close.  
 
Precursors with different protecting groups (such as benzoyl, tosyl, etc.) can also be 
subjected to this computational methodology, to determine if a suitable protecting group 
exists that may bring the isomerized-allylic substituents on the molecule into more 
favourable positions, with regards to the bite-angle of the catalyst. 
 
 
Chart 1: Program methodology envisaged for determining the most stable conformation  
of a precursor 
 
 
 
 
 
1 Set torsional 
restraint on 
substituent 
2 Determine single-
point energy 
 
1 Perform 
geometry 
optimization 
2 Record energy 
of molecule  
1 Change angle 
of restraint on 
substituent 
Repeat through 360o   
Plot of Energy versus Torisional 
angle is produced 
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        EXPERIMENTAL SECTION 
5.0   General experimental procedures 
 
Spectroscopy 
 
1
H spectra were recorded either on a Bruker AC-200 or a Bruker 300 spectrometer at the 
frequency indicated.  Chemical shifts ( ) are reported in parts per million (ppm) relative 
to tetramethylsilane as the internal standard. Abbreviations used: s = singlet, d = doublet, 
dd = double doublet, t = triplet, dt = double triplet, ddt = double double triplet, q = 
quartet, m = multiplet and b = broad. 
13
C spectra were recorded on a Bruker 300 spectrometer at 75 MHz. Chemical shifts ( ) 
are reported relative to the central signal of deuterated chloroform taken as 77.00 ppm.  
The probe temperature for all experiments was 300 K ±1 K. All spectra were recorded in 
deuterated chloroform in 5 mm NMR tubes. All spectra were subjected to Fourier 
transform using the Mestrec Nova software package for interpretation. 
 
Infrared spectra were recorded on either a Bruker IFS 25 Fourier transform spectrometer 
using KBr plates or on a Bruker Vector 22 Fourier Transform spectrometer on a diamond 
cell platform. The absorptions are reported on the wave number (cm
-1
) scale in the 600–
3500 cm
-1 
range. 
 
Mass spectra were recorded on a Kratos MS 9/50, VG 70E MS or a VG 70 SEQ mass 
spectrometer. The polarity was positive, ionization employed was EI, with a resolution of 
3000, a mass range of 3000 amu (8 kV) and a scan rate of 5 secs/decade. Data are quoted 
in relative abundance (m/z). 
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Solvents and separations 
 
Macherey–Nagel kieselgel 60 (particle size 0.063 – 0.200 mm) was used for conventional 
silica gel chromatography.  Flash Silica was used where indicated. The Rf values quoted 
are those obtained from thin layer chromatography on aluminium backed Macherey-
Nagel ALUGRAM Sil G/UV254 plates, pre-coated with 0.25mm silica gel. 
  
All solvents used for reactions and chromatography were distilled and purified via 
standard laboratory methods prior to use. Tetrahydrofuran and diethyl ether were distilled 
from sodium metal wire and benzophenone. Benzene and toluene were distilled from 
sodium metal lumps. Dichloromethane and DMF were stored over 4Å molecular sieves 
after low pressure distillation. Acetic anhydride was distilled from 4Å molecular sieves. 
Pyridine was distilled from potassium hydroxide. Hexane and ethyl acetate were distilled 
at atmospheric pressure. 
 
Miscellaneous  
 
All melting points were obtained on a Reichert hot-stage microscope and are uncorrected. 
 
Grubbs‟ II catalyst 6 and the Ru-isomerization catalyst 15 were stored in Schlenk tubes 
under argon and protected from light. 
 
Celite
®
 was used as filtration medium in a Hirsh apparatus for all filtrations performed. 
 
All microwave reactions were performed in a CEM Corporation Discover Focused 
Microwave Synthesis system, with the following parameters: Ramp time = 2 min; 
Pressure = 100 psi; Power = 150 W (unless otherwise indicated); and Cooling = On.   
 
All reactions were performed under an inert Nitrogen or Argon atmosphere as indicated. 
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Solvent evaporations were performed first on a rotary evaporator (± 20 mmHg, 40–50 
°C) followed by final drying under high vacuum conditions utilizing an oil pump 
manifold (± 1–2 mmHg) at room temperature.  
 
 
 
 
 
5.1   The benzofurans 
 
 
5.1.1   Mono-allylation of the precursors 
 
 
5.1.1.1   1,4-Dimethoxy-2-(prop-2-en-1-yloxy)benzene   141a 
 
Allyl bromide (5.5 g, 45 mmol, 3.9 mL) and K2CO3 (9.5 
g, 69 mmol) were added to 2,5-dimethoxyphenol 140a 
(5.0 g, 32 mmol) dissolved in dry acetone (500 mL). The 
reaction mixture was then heated at reflux (60 °C) under 
N2 overnight. The resulting crude residue was then passed 
through a silica gel column (10% EtOAc/hexane) to 
afford 1,4-dimethoxy-2-(prop-2-en-1-yloxy)benzene 141a as a light yellow oil (3.7 g, 
60%). m/z (EI): 195 (M
+
 +1, 55%), 194 (M
+
, 90), 153 (100), 125 (90), 110 (30), 79 (35), 
69 (40), 52 (40), 41 (53); HRMS: calcd for C11H14O3 194.0943, found: 194.0942; max 
(CHCl3)/cm
-1
: 1610, 1602, 1510; 
1
H NMR (300 MHz, CDCl3): (ppm) = 3.75 (3H, s, 
ArOC
14
H3), 3.82 (3H, s, ArOC
12
H3), 4.57–4.59 (2H, m, OC
8
H2CHCH3), 5.26–5.30 (1H, 
m, OCH2CHC
10
HAHB), 5.37–5.43 (1H, m OCH2CHC
10
HAHB), 6.01–6.14 (1H, m, 
OCH2C
9
HCH2), 6.40 (1H, dd, J = 8.7 Hz and 2.8 Hz, ArC
4
H), 6.52 (1H, d, J = 2.8 Hz, 
ArC
6
H), 6.79 (1H, d, J = 8.8 Hz, ArC
3
H); 
13
C NMR (75 MHz, CDCl3); (ppm) = 55.5 
(OC
14
H3), 56.6 (OC
12
H3), 69.8 (OC
8
H2CHCH3), 102.2 (ArC
6
H), 103.6 (ArC
4
H), 112.6 
(ArC
3
H), 117.8 (OCH2CHC
10
H2), 133.3 (OCH2C
9
HCH2), 143.9 (ArC
2
), 148.9 (ArC
10
), 
154.2 (ArC
5
).  
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5.1.1.2   1-Bromo-4-(prop-2-en-1-yloxy)benzene    141b 
 
Allyl bromide (8.741 g, 72.25 mmol, 6.25 mL, 2.5 
equiv.) and K2CO3 (9.986 g, 72.25 mmol, 2.5 equiv.) 
were added to 4-bromophenol 140b (5.002 g, 28.91 
mmol, 1.eqiv.) dissolved in dry acetone (100 mL). The 
reaction mixture was then stirred at 60 °C under N2 
overnight. After cooling the reaction slurry was passed through a Celite plug to remove 
the base and the resulting crude residue was then passed through a silica gel column 
(10% EtOAc/hexane) to afford 1-bromo-4-(prop-2-en-1-yloxy)benzene 141b as a yellow 
oil (6.026 g, 98%). Rf = 0.66 (10% EtOAc/hexane); 
1
H NMR (200 MHz, CDCl3): (ppm) 
= 4.50 (2H, d, J = 5.2 Hz, OC
9
H2CHCH2), 5.27 – 5.44 (2H, m, OCH2CHC
11
H2), 5.91–
6.04 (1H, m, OCH2C
10
HCH2), 6.70 (2H, dd, J = 10.0 Hz and 8.8 Hz, ArC
3
H and ArC
5
H), 
7.19–7.38 (2H, m, ArC2H and ArC6H);. {The 1H NMR spectrum confirmed that 
allylation had taken place and this known compound
[98]
 was used without further 
characterisation.} 
 
5.1.1.3   1-tert-Butyl-4-(prop-2-en-1-yloxy)benzene   141c 
 
Allyl bromide (10.07 g, 83.21 mmol, 7.20 mL, 2.5 
equiv.) and K2CO3 (11.50 g, 83.21 mmol, 2.5 equiv.) 
were added to 4-tert-butylphenol 140c (5.000 g, 33.28 
mmol, 1.equiv.) dissolved in dry acetone (100 mL). The 
reaction mixture was then stirred at 60 °C under N2 
106 
 
 
overnight. After cooling the reaction slurry was passed through a Celite plug to remove 
the base and the solvent removed under reduced pressure. The resulting crude residue 
was then subjected to silica gel column chromatography (10% EtOAc/hexane) to afford 
1-tert-butyl-4-(prop-2-en-1-yloxy)benzene 141c as a yellow oil (6.284 g, 99%). Rf = 0.84 
(10% EtOAc/hexane). {This known compound
[99]
 was submitted directly to the next 
reaction step.} 
 
5.1.1.4   2-(Prop-2-en-1-yloxy)biphenyl   141d 
 
Allyl bromide (9.11 g, 75.3 mmol, 6.37 mL) and K2CO3 
(10.2 g, 73.8 mmol) were added to biphenyl-2-ol 140d 
(5.00 g, 29.4 mmol) dissolved in dry acetone (100 mL). 
The reaction mixture was then stirred at 60 °C under N2 
overnight. After cooling the reaction slurry was passed 
through a Celite plug to remove the base and the resulting 
crude residue was then passed through a silica gel column 
(10% EtOAc/hexane) to afford 2-(prop-2-en-1-yloxy)biphenyl 141d as a yellow oil (6.18 
g, 100%). m/z (EI): 211 (M
+ 
+1, 17%), 210 (M
+
, 100), 195 (12), 191 (11), 181 (18), 168 
(14), 167 (20), 165 (29), 153 (13), 152 (21), 139 (10), 115 (21), 77 (13);  HRMS: calcd 
for C15H14O 210.1045, found: 210.1045; max (CHCl3)/cm
-1
: 1638, 1590, 1497, 1458, 
1433;  
1
H NMR (300 MHz, CDCl3): (ppm) =  4.51 (2H, td, J = 4.7 Hz, 1.6 Hz and 1.6 
Hz, OC
8
H2CHCH2), 5.18 (1H, dd, J = 10.6 Hz and 1.5 Hz, OCH2CHC
10
HAHB), 5.31 (1H, 
dd, J = 17.3 Hz and 1.7 Hz OCH2CHC
10
HAHB), 5.96 (1H, tdd, J = 17.2 Hz, 10.4 Hz, 4.8 
Hz and 4.8 Hz, ArOCH2C
9
HCH2), 6.95 (1H, d, J = 8.2 Hz, ArC
6
H), 7.02 (1H, dt, J = 7.5 
Hz, 7.5 Hz and 0.9 Hz, ArC
4
H), 7.26 (1H, dd, J = 8.0 Hz and 1.5 Hz, ArC
5
H), 7.28–7.35 
(2H, m, ArC
3
H and ArC
14
H), 7.35–7.42 (2H, m, ArC13H and ArC15H), 7.52–7.58 (2H, m, 
ArC
12
H and ArC
16
H);  
13
C NMR (75 MHz, CDCl3): (ppm) = 69.1 (OC
8
H2CHCH2), 
113.0 (ArC
6
H), 116.8 (OCH2CHC
10
H2), 121.1 (ArC
4
H), 126.8 (ArC
5
H), 127.9 (ArC
12
H 
and ArC
16
H), 128.5 (ArC
14
H), 129.6 (ArC
13
H and ArC
15
H), 130.9 (ArC
3
H), 131.1 
(ArC
2
), 133.3 (OCH2C
9
HCH2), 138.5 (ArC
11
), 155.4 (ArC
1
). 
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5.1.1.5   1-(Prop-2-en-1-yloxy)naphthalene   141e 
 
Allyl bromide (10.71 g, 88.54 mmol, 7.662 mL, 2.5 equiv.) 
and K2CO3 (12.24 g, 88.54 mmol, 2.5 equiv.) were added to 
naphthalen-1-ol 140e (5.106 g, 35.42 mmol, 1 equiv.) 
dissolved in dry acetone (100 mL). The reaction mixture was 
then stirred at 60 °C under N2 overnight. After cooling the 
reaction slurry was passed through a Celite plug to remove the base and the resulting 
crude residue was then passed through a silica gel column (10% EtOAc/hexane) to afford 
1-(prop-2-en-1-yloxy)naphthalene 141e as a yellow oil (6.525 g, 100%). Rf = 0.66 (10% 
EtOAc/hexane). {This known compound
[100]
 was submitted directly to the next reaction 
step.} 
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5.1.2   Claisen reactions on the mono-allylated precursors 
 
 
5.1.2.1   3,6-Dimethoxy-2-(prop-2-en-1-yl)phenol   142a 
 
1,4-Dimethoxy-2-(prop-2-en-1-yloxy)benzene  141a (1.0 
g, 5.2 mmol) was heated without solvent, under N2, at 
220–240 °C for 40 min. The dark brown residue was then 
subjected to purification by silica gel chromatography 
(20% EtOAc/hexane) to afford 3,6-dimethoxy-2-(prop-2-
en-1-yl)phenol 142a as a light oily semi-solid (0.49g, 
49%). m/z (EI): 195 (M
+
 +1, 45%), 194 (M
+
, 91), 179 (100), 151 (84), 147 (50), 136 (35), 
123 (24), 119 (26), 91 (46), 79 (22), 77 (26), 65 (20), 53 (30), 39 (20); HRMS: calcd for 
C11H14O3 194.0943, found: 194.0943; max (CHCl3)/cm
-1
: 3506 br, 1639, 1601, 1493, 
1464, 1440; 
1
H NMR (300 MHz, CDCl3): (ppm) = 3.43 (2H, br d, J = 5.6 Hz, 
ArC
10
H2CHCH2), 3.76 (3H, s, OC
14
H3), 3.82 (3H, s, OC
8
H3), 4.92–5.07 (2H, m, 
ArCH2CHC
12
H2), 5.76 (1H, s, OH), 5.89–6.05 (1H, m, ArCH2C
11
HCH2), 6.33 (1H, d, J = 
8.8 Hz, ArC
5
H), 6.65 (1H, d, J = 8.8 Hz, ArC
6
H); 
13
C NMR (75 MHz, CDCl3): (ppm) = 
27.4 (ArC
10
H2CHCH2), 55.8 (OC
14
H3), 56.1 (OC
8
H3), 100.9 (ArC
5
H), 108.1 (ArC
6
H), 
114.1 (ArC
3
), 114.9 (ArCH2CHC
12
H2), 136.3 (ArCH2C
11
HCH2), 141.0 (ArC
1
), 144.2 
(ArC
2
OH), 152.4 (ArC
4
). 
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5.1.2.2   4-Bromo-2-(prop-2-en-1-yl)phenol   142b 
 
1-Bromo-4-(prop-2-en-1-yloxy)benzene 141b (1.399 g, 
6.566 mmol) was irradiated in 3 mL Dichloromethane, 
under microwave conditions (power: 150W, ramp time: 
2 °C per min, temperature: 180 °C, maximum pressure 
100 psi) in a pressure tube. The irradiation was 
continued for 15 min. The resulting crude residue was then submitted directly to the next 
reaction step, after TLC revealed that significant decomposition was occurring on the 
silica as well as with heating times greater than 15 min. Rf = 0.30 (10% EtOAc/hexane). 
{A 
1
H NMR showed that a mixture product as well as decomposition products were 
evident, thus the compound was used without further characterisation.} 
 
 
5.1.2.3   4-tert-Butyl-2-(prop-2-en-1-yl)phenol   142c 
 
1-tert-Butyl-4-(prop-2-en-1-yloxy)benzene 141c 
(2.011 g, 10.57 mmol) was irradiated without solvent, 
under microwave conditions (power: 100W, ramp 
time: 2 °C per min, temperature: 220 °C, maximum 
pressure 100 psi) in a pressure tube. The irradiation 
was continued at 15 min intervals, at which time the reaction progress checked via TLC. 
After a total irradiation time of 50 min the dark brown residue was subjected to 
purification by silica gel chromatography (10%  EtOAc/hexane) to afford 4-tert-butyl-2-
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(prop-2-en-1-yl)phenol 142c as a clear yellow oil (1.131 g, 56%). Rf = 0.26 (10% 
EtOAc/hexane); 
1
H NMR (300 MHz, CDCl3): (ppm) = 1.29 (9H, s, C
11
(CH3)3),  3.41 
(2H, br d, J = 6.0 Hz, C
8
H2CHCH2), 4.85 (1H, br d, J = 16.4 Hz, OH), ), 5.14–5.20 (2H, 
m, CH2CHC
10
H2), 6.00–6.06 (1H, m, CH2C
9
HCH2), 6.75 (1H, d, J = 8.2 Hz, ArC
3
H), 
7.11–7.16 (2H, m, ArC5H and ArC6H). {The identity of this known compound[99] was 
confirmed with 
1
H NMR and submitted directly to the next reaction step.} 
    
5.1.2.4   3-(Prop-2-en-1-yl)biphenyl-2-ol   142d 
 
2-(Prop-2-en-1-yloxy)biphenyl 141d (2.0 g, 9.5 mmol) 
was irradiated without solvent, under microwave 
conditions (power: 100W, ramp time: 2 °C per min, 
temperature: 200 °C, maximum pressure 100 psi) in a 
pressure tube. The irradiation was continued at 15 min 
intervals, at which time the reaction progress checked via 
TLC. After a total irradiation time of 90 min the dark 
brown residue was subjected to purification by silica gel chromatography (10%  
EtOAc/hexane) to afford 3-(prop-2-en-1-yl)biphenyl-2-ol 142d as a clear yellow oil (1.2 
g, 60%). m/z (EI): 211 (M
+ 
+1, 12%), 210 (M
+
, 63), 195 (13), 178 (12), 176 (35), 169 
(100), 168 (23), 163 (18), 141 (38), 139 (21), 115 (37), 41 (10);  HRMS: calcd for 
C15H14O 210.1045, found: 210.1062;  max (CHCl3)/cm
-1
: 3062, 3025, 1649, 1597, 1584, 
1504, 1481, 1455, 1434;  
1
H NMR (300 MHz, CDCl3): (ppm) = 3.47 (2H, br d, J = 6.5 
Hz, ArC
8
H2CHCH2), 5.07–5.19 (2H, m, ArCH2CHC
10
H2), 5.31 (1H, s, ArOH), 6.06 (1H, 
tdd, J = 16.7 Hz, 10.0 Hz and 6.6 Hz, ArCH2C
9
HCH2), 6.93 (1H, t, J = 7.5 Hz, ArC
4
H), 
7.13 (2H, ddd, J = 7.3 Hz, 5.9 Hz and 1.3 Hz, ArC
3
H and ArC
5
H), 7.34–7.42 (1H, m, 
ArC
14
H), 7.43–7.51 (4H, m, ArC12H, ArC13H, ArC15H and ArC16H);  13C NMR (75 
MHz, CDCl3): (ppm) = 34.8 (ArC
8
H2CHCH2), 115.9 (ArCH2CHC
10
H2), 120.5 (ArC
4
H), 
127.8 (ArC
5
H), 127.9 (ArC
6
), 128.4 (ArC
12
H), 128.5 (ArC
16
H), 129.2 (ArC
13
H and 
ArC
15
H), 129.3 (ArC
14
H), 129.7 (ArC
3
H), 129.8 (ArC
2
), 136.6 (ArCH2C
9
HCH2), 137.3 
(ArC
11
), 150.4 (ArC
1
). 
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5.1.2.5   2-(Prop-2-en-1-yl)naphthalen-1-ol   142e 
 
1-(Prop-2-en-1-yloxy)naphthalene 141e (2.022 g, 10.97 
mmol) was irradiated without solvent under microwave 
conditions (power: 100W, ramp time: 2 °C per min, 
temperature: 180 °C, maximum pressure 100 psi) in a 
pressure tube. The irradiation was continued for just 2 min, 
after a sudden temperature and pressure increase was noted. TLC showed that the 
reaction had run to completion. The resulting crude residue was then was then passed 
through a silica gel column (10% EtOAc/hexane) to afford 2-(prop-2-en-1-yl)naphthalen-
1-ol 142e as a yellow oil (1.735 g, 86%). Rf = 0.47 (10% EtOAc/hexane); 
1
H NMR (200 
MHz, CDCl3): (ppm) = 3.58 (2H, d, J = 6.1 Hz, ArC
12
H2CHCH2), 5.23–5.32 (2H, m, 
ArCH2CHC
14
H2), 5.71 (1H, s, OH), 6.03–6.17 (1H, m, ArCH2C
13
HCH2), 7.25 (1H, d, J = 
8.3 Hz, ArC
3
H), 7.44–7.55 (3H, m, ArC4H, ArC7H and ArC8H), 7.81–7.85 (1H, m, 
ArC
6
H) and 8.22–8.27 (1H, m, ArC9H).  {The identity of the known compound[100] was 
confirmed by 
1
H NMR and submitted directly to the next reaction step.} 
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5.1.3   Re-allylation of the Claisen precursors 
 
5.1.3.1   1,4-Dimethoxy-2-(prop-2-en-1-yl)-3-(prop-2-en-1-yloxy)benzene   143a 
 
  Allyl bromide (0.599 g, 4.95 mmol, 0.42 mL) and 
K2CO3 (0.685 g, 4.95 mmol) were added to 1,4-
dimethoxy-2-(prop-2-en-1-yloxy)benzene 142a (0.481 g, 
2.48 mmol) dissolved in acetone (50 mL) and the reaction 
slurry was then stirred at 60 °C for 2 h. After cooling, the 
base was removed by filtration through a Celite plug and 
the solvent was removed under reduced pressure. The brown residue was then purified 
using silica gel column chromatography (10% EtOAc/hexane) to afford 1,4-dimethoxy-2-
(prop-2-en-1-yl)-3-(prop-2-en-1-yloxy)benzene 143a as a clear oil (0.532 g, 92%). m/z 
(EI): 234 (M
+
, 100%), 220 (21), 219 (39), 193 (94), 165 (44), 163 (33), 150 (26), 135 
(23), 133 (26), 130 (62), 118 (18), 100 (18), 91 (28), 79 (22), 77 (27), 69 (97), 41 (31); 
HRMS: calcd for C14H18O 234.1256, found: 234.1258; max (CHCl3)/cm
-1
: 1638, 1593, 
1487, 1465, 1439; 
1
H NMR (300 MHz, CDCl3): (ppm) = 3.44 (2H, td, J = 6.1 Hz and 
1.4 Hz, ArC
13
H2CHCH2), 3.77 (3H, s, OC
8
H3), 3.80 (3H, s, OC
17
H3), 4.48 (2H, td, J = 
5.7 Hz and 1.3 Hz, ArC
10
H2CHCH2), 4.91–5.03 (2H, m, ArCH2CHC
15
H2), 5.21 (1H, dd, 
J = 10.4 Hz and 1.6 Hz, OCH2CHC
12
HAHB), 5.20 (1H, dd, J = 17.2 Hz and 1.6 Hz, 
OCH2CHC
12
HAHB), 5.32–5.43 (1H, m, OCH2C
11
HCH2), 6.09 (1H, tdd, J = 14.7 Hz, 9.1 
Hz and, 5.0 Hz, ArCH2C
14
HCH2), 6.56 (1H, d, J = 8.9 Hz, ArC
5
H), 6.73 (1H, d, J = 8.9 
Hz. ArC
6
H); 
13
C NMR (75 MHz, CDCl3); (ppm) =  28.3 (ArC
13
H2CHCH2), 56.0 
(OC
17
H3), 56.2 (OC
8
H3), 73.8 (OC
10
H2CHCH2), 105.6 (ArC
5
H), 110.2 (ArC
6
H), 114.3 
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(ArCH2CHC
15
H2), 116.9 (OCH2CHC
12
H2), 123.2 (ArC
3
), 134.4 (OCH2C
11
HCH2), 137.0 
(ArCH2C
14
HCH2), 146.9 (ArC
2
O), 147.2 (ArC
1
), 152.2 (ArC
4
). 
 
 
 
 
 
5.1.3.2   4-Bromo-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)benzene   143b    
 
Allyl bromide (1.60 g, 13.2 mmol,  1.12 mL) and 
K2CO3 ( 1.83 g, 13.2 mmol) were added to 4-bromo-2-
(prop-2-en-1-yl)phenol 142b (1.41 g, 6.62 mmol) 
dissolved in acetone (50 mL) and the reaction slurry was 
then stirred at 60 °C for 2 h. After cooling, the base was 
removed by filtration through a Celite plug and the solvent was removed under reduced 
pressure. The brown residue was then purified using silica gel column chromatography 
(10% EtOAc/hexane) to afford 4-bromo-2-(prop-2-en-1-yl)-1-(prop-2-en-1-
yloxy)benzene 143b as a yellow oil (1.40 g, 25% quantitative). Rf = 0.66 (5% 
EtOAc/hexane);  m/z (EI): 254, (M
+
 +2, 56%), 252 (M
+
, 56), 220 (31), 210 (37), 209 
(20), 185 (18), 132 (100), 118 (19), 104 (33), 103 (17), 55 (14); HRMS: calcd for 
C12H13BrO 252.0150, found: 252.0133; max (CHCl3)/cm
-1
: 1638, 1591, 1487, 1455, 
1424, 1410; 
1
H NMR (300 MHz, CDCl3): (ppm) = 3.37 (2H, br d, J = 6.7 Hz, 
ArC
12
H2CHCH2), 4.51 (2H, td, J = 4.9 Hz, 1.4 Hz and 1.4 Hz, OC
9
H2CHCH2), 5.02–
5.13 (2H, m, ArCH2CHC
14
H2), 5.27 (1H, dd, J = 10.6 Hz and 1.5 Hz, 
OCH2CHC
11
HAHB), 5.40 (1H, dd, J = 17.3 Hz and 1.6 Hz, OCH2CHC
11
HAHB), 5.85–6.12 
(2H, m, OCH2C
10
HCH2 and ArCH2C
13
HCH2), 6.70 (1H, d, J = 9.3 Hz, ArC
3
H), 7.23–
7.28 (2H, m, ArC
2
H and ArC
6
H); 
13
C NMR (75 MHz, CDCl3): (ppm) = 34.0 
(ArC
12
H2CHCH2), 68.9 (OC
9
H2CHCH2), 112.9 (ArC
1
), 113.2 (ArC
3
H), 116.1 
(OCH2CHC
11
H2), 117.2 (ArCH2CHC
14
H2), 129.7 (ArC
6
H), 131.3 (ArC
5
), 132.4 (ArC
2
H), 
133.0 (OCH2C
10
HCH2), 135.9 (ArCH2C
13
HCH2), 155.3 (ArC
4
). 
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5.1.3.3   4-tert-Butyl-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)benzene   143c 
   
Allyl bromide (0.66 g, 5.5 mmol, 0.46 mL) and K2CO3 
(0.76 g, 5.5 mmol) were added 4-tert-butyl-2-(prop-2-
en-1-yl)phenol 142c (0.52 g, 2.7 mmol) dissolved in 
acetone (25 mL) and the reaction slurry was then 
stirred at 60 °C for 3 h. After cooling, the base was 
removed by filtration through a Celite plug and the solvent was removed under reduced 
pressure. The brown residue was then purified using silica gel column chromatography 
(10% EtOAc/hexane) to afford 4-tert-butyl-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy) 
benzene 143c as a yellow oil (0.57 g, 90%). Rf = 0.66 (5% EtOAc/hexane); m/z (EI): 230 
(M
+
, 24%), 216 (17), 215 (100), 173 (7), 159 (13), 128 (8), 115 (11), 91 (9), 41 (13); 
HRMS: calcd for C16H22O 230.1671, found: 230.1648;  
1
H NMR (300 MHz, CDCl3): 
(ppm) = 1.29 (9H, s, C
14
(CH3)3), 3.41 (2H, br d, J = 6.6 Hz, ArC
11
H2CHCH2), 4.52 (2H, 
td, J = 4.9 Hz, 1.5 Hz and 1.5 Hz, OC
8
H2CHCH2), 5.00–5.12 (2H, m, ArCH2CHC
13
H2), 
5.23 (1H, dd, J = 10.6Hz and 1.6 Hz, OCH2CHC
10
HAHB), 5.41 (1H, dd, J = 17.3 Hz and 
1.6 Hz, OCH2CHC
10
HAHB), 6.00–6.06 (2H, m, OCH2C
9
HCH2 and ArCH2C
12
HCH2), 
6.76 (1H, d, J = 9.2 Hz, ArC
3
H), 7.15–7.17 (2H, m, ArC5H and ArC6H);  
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5.1.3.4   3-(Prop-2-en-1-yl)-2-(prop-2-en-1-yloxy)biphenyl    143d 
 
   
Allyl bromide (0.794 g, 6.56 mmol,  0.555 mL) and 
K2CO3 (0.907 g, 6.56 mmol) were added to 2-(prop-2-en-
1-yloxy)biphenyl 142d (0.690 g, 3.28 mmol) dissolved in 
acetone (50 mL) and the reaction slurry was then stirred at 
60 °C for 2 h. After cooling, the base was removed by 
filtration through a Celite plug and the solvent was 
removed under reduced pressure. The brown residue was 
then purified using silica gel column chromatography (10% EtOAc/hexane) to afford 3-
(prop-2-en-1-yl)-2-(prop-2-en-1-yloxy)biphenyl 143d as a light yellow oil (0.670 g, 
82%). m/z (EI): 250 (M
+
, 55%), 235 (15), 221 (16), 214 (28), 209 (28), 194 (42), 181 
(57), 178 (25), 175 (24), 168 (100), 166 (20), 165 (65), 153 (16), 152 (26), 139 (16), 132 
(21), 115 (29), 77 (17), 41 (47);  HRMS: calcd for C18H18O 250.1358, found: 250.1360;  
max (CHCl3)/cm
-1
: 1638, 1600, 1498, 1459, 1431;  
1
H NMR (300 MHz, CDCl3): (ppm) 
= 3.49 (2H, br d, J = 6.6 Hz, ArC
11
H2CHCH2), 3.91 (2H, br d, J = 5.7 Hz, 
OC
8
H2CHCH2), 5.03–5.15 (4H, m, ArCH2CHC
13
H2 and OCH2CHC
10
H2), 5.68–5.84 (1H, 
m, ArCH2C
12
HCH2), 5.96–6.10 (1H, m, OCH2C
9
HCH2), 7.09–7.15 (1H, m, ArC
4
H), 
7.15–7.23 (2H, m, ArC5H and ArC3H), 7.27–7.36 (1H, m, ArC17H), 7.36–7.43 (2H, m, 
ArC
16
H and ArC
18
H), 7.54–7.61 (2H, m, ArC15H and ArC19H);  13C NMR (75 MHz, 
CDCl3, one quaternary carbon not observable): (ppm) = 34.4 (ArC
11
H2CHCH2), 73.7 
(OC
8
H2CHCH2), 115.8 (OCH2CHC
10
H2), 117.2 (ArCH2CHC
13
H2), 124.1 (ArC
4
H), 127.1 
(ArC
5
H), 128.2 (ArC
15
H and ArC
19
H), 129.1 (ArC
16
H and ArC
18
H), 129.2 (ArC
17
H), 
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129.4 (ArC
3
H), 133.8 (OCH2C
8
HCH2), 135.1 (ArC
6/2
), 137.4 (ArCH2C
12
HCH2), 138.9 
(ArC
14
), 154.3 (ArC
1
). 
   
 
 
 
 
 
5.1.3.5    2-(Prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)naphthalene   143e    
 
 Allyl bromide (1.168 g, 9.651 mmol, 0.835 mL, 2.5 
equiv.) and K2CO3 (1.334 g, 9.651 mmol, 2.5 equiv.) were 
added to 2-(prop-2-en-1-yl)naphthalen-1-ol  142e (0.7112 
g, 3.860 mmol, 1 equiv.) dissolved in dry acetone (50 mL) 
and the reaction slurry was then stirred at 60 °C for 12 h. 
After cooling, the base was removed by filtration through a Celite plug and the solvent 
was removed under reduced pressure. The brown residue was then purified using silica 
gel column chromatography (5% EtOAc/hexane) to afford 2-(prop-2-en-1-yl)-1-(prop-2-
en-1-yloxy)naphthalene 143e as a yellow oil (0.8564 g, 99%). Rf = 0.81 (10% 
EtOAc/hexane); m/z (EI): 224, (M
+
, 63%), 183 (100), 165 (58), 155 (70), 139 (12), 128 
(26), 102 (6), 77 (10), 41 (10); HRMS: calcd for C16H16O 224.12012, found: 224.12044; 
max (CHCl3)/cm
-1
: 3076, 3009, 2978, 2911, 2863, 1638, 1572, 1386, 1360, 1343, 1260, 
1246, 1181, 1078, 992, 918, 814, 757;  
1
H NMR (300 MHz, CDCl3  ppm = 3.61 (2H, 
dd, J = 6.4 Hz and 0.8 Hz, ArCH2C
15
HCH2), 4.51 (2H, dd, J = 5.5 Hz and 1.0 Hz, 
OCH2C
12
HCH2), 5.07 (1H, d, J = 1.4 Hz, ArCH2CHC
17
HAHB), 5.12 (1H, dd, J = 4.5 Hz 
and 1.4 Hz, ArCH2CHC
17
HAHB), 5.32 (1H, d, J = 10.4 Hz, OCH2CHC
14
HAHB), 5.51 (1H, 
d, J = 17.2 Hz, OCH2CHC
14
HAHB), 5.94–6.13 (1H, m, ArCH2C
16
HCH2), 6.13–6.28 (1H, 
m, OCH2C
13
HCH2), 7.32 (1H, d, J = 8.4 Hz, ArC
6
H), 7.52–7.39 (2H, m, ArC7H and 
ArC
8
H), 7.58 (1H, d, J = 8.5 Hz, ArC
4
H), 7.81 (1H, d, J = 7.9 Hz, ArC
3
H), 8.09 (1H, d, 
J = 8.1 Hz, ArC
9
H);  
13
C NMR (75 MHz, CDCl3): (ppm) = 34.0 (ArC
15
H2CHCH2), 75.2 
(OC
12
H2CHCH2), 115.8 (OCH2CHC
14
H2), 117.3 (ArCH2CHC
17
H2), 118.1 (ArC
2
), 122.1 
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(ArC
4
H), 124.0 (ArC
3
H), 125.4 (ArC
10
), 125.5 (ArC
9
H), 125.8 (ArC
8
H), 127.8 (ArC
7
H), 
128.2 (ArC
6
H), 128.6 (ArC
5
),  133.9 (OCH2C
13
HCH2), 137.2 (ArCH2C
15
HCH2), 152.2 
(ArC
1
O).  
 
 
 
 
 
5.1.4   Di-isomerization of the di-allylated precursors 
 
5.1.4.1   1,4-Dimethoxy-2-(prop-1-en-1-yl)-3-(prop-1-en-1-yloxy)benzene   144a 
 
1,4-Dimethoxy-2-(prop-2-en-1-yl)-3-(prop-2-en-1-yloxy) 
benzene 143a (0.31g, 1.3mmol) and [RuClH(CO)(PPh3)3] 
15 (0.063g, 0.066mmol, 5 mol%) were dissolved in 
distilled, degassed toluene (5 mL). The reaction was 
heated at 65 °C for 14 h with the completion of the 
reaction confirmed by NMR spectroscopy of a crude 
sample. The reaction solution was then purified by filtration through a short silica gel pad 
(5% EtOAc/hexane) to remove the catalyst and evaporated under reduced pressure to 1,4-
dimethoxy-2-(prop-1-en-1-yl)-3-(prop-1-en-1-yloxy)benzene 144a (a mixture of E,Z 
isomers) as a dark oil (0.30g, 98%). 
1
H NMR (200 MHz, CDCl3): (ppm) =  1.78 (3H, 
dd, J = 7.1 Hz and 1.3 Hz, ArCHCHC
15
H3), 1.91 (3H, d, J = 5.1 Hz, OCHCHC
12
H3), 
3.80 (6H, br d, J = 1.0 Hz, OC
8
H3 and OC
17
H3), 4.53–4.62 (1H, m, OCHC
11
HCH3), 
6.05–6.08 (1H, m, ArCHCHC14H3), 6.44–6.85 (4H, m, OC
10
HCHCH3, ArC
13
HCHCH3, 
ArC
5
H and ArC
6
H). {The 
1
H NMR spectrum confirmed that dual isomerization had taken 
place and the compound was used without further characterisation.} 
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5.1.4.2     4-Bromo-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene   144b 
 
4-Bromo-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy) 
benzene 143b (0.23 g, 0.91 mmol) and 
[RuClH(CO)(PPh3)3] 15 (0.043 g, 0.047 mmol, 5 mol%) 
were dissolved in distilled, degassed toluene (5 mL). 
The reaction was heated at 65 °C for 14 h with the 
completion of the reaction confirmed by NMR spectroscopy of a crude sample. The 
reaction solution was then purified by filtration through a short silica gel pad (5% 
EtOAc/hexane) to remove the catalyst and evaporated under reduced pressure to produce 
4-bromo-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene 144b (a mixture of E,Z 
isomers in a ratio of 1:2) as a dark oil (0.23 g, 100%). Rf = 0.78 (5% EtOAc/hexane); m/z 
(EI): 254 (M
+
 +2, 52%), 252 (M
+
, 54), 239 (33), 237 (35), 225 (59), 223 (60), 218 (26), 
210 (23), 198 (28), 196 (27), 173 (40), 158 (100), 145 (21), 144 (22), 132 (55), 130 (32), 
116 (21), 115 (87), 103 (30), 89 (26), 69 (20), 63 (23), 41 (20);  HRMS: calcd for 
C12H13BrO 252.0150, found: 252.0150;  
1
H NMR (200 MHz, CDCl3): (ppm) = 1.55–
1.73 (3H, m, ArCHCHC
14
H3), 1.86–1.92 (3H, m,  OCHCHC
11
H3), 4.88 (dt, J = 6.2 Hz 
and 0.6 Hz) and 5.32 (dt, J = 6.9 Hz and 5.1 Hz) [1H, OCHC
10
HCH3], 6.08–6.31 (2H, m, 
ArCHC
13
HCH3 and OC
9
HCHCH3), 6.54–6.68 (1H, m, ArC
12
HCHCH3), 6.77 (1H, dd, J 
= 5.7 Hz and 2.9 Hz, ArC
3
H), 7.22 (1H, dd, J = 6.3 Hz and 2.2 Hz, ArC
2
H), 7.52 (1H, d, 
J = 2.2 Hz, ArC
6
H). 
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5.1.4.3   4-tert-butyl-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene    144c  
 
4-tert-butyl-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy) 
benzene 143c (0.22 g, 0.96 mmol) and 
[RuClH(CO)(PPh3)3] 15 (0.046 g, 0.048 mmol, 5 
mol%) were dissolved in distilled, degassed toluene (5 
mL). The reaction was heated at 65 °C for 14 h with 
the completion of the reaction confirmed by NMR spectroscopy of a crude sample. The 
reaction solution was then purified by filtration through a short silica gel pad (5% 
EtOAc/hexane) to remove the catalyst and evaporated under reduced pressure to afford 4-
tert-butyl-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene 144c (a mixture of E,Z 
isomers) as a light oil (0.19 g, 86%). Rf = 0.78 (5% EtOAc/hexane); m/z (EI): 230 (M
+
, 
24%), 216 (17), 215 (100), 173 (7), 159 (13), 128 (8), 115 (11), 91 (9), 41 (13); HRMS: 
calcd for C16H22O 230.1671, found: 230.1648; 
1
H NMR (200 MHz, CDCl3): (ppm) = 
1.31 (9H, s, C
14
(CH3)3), 1.69 (3H, ddd, J = 9.8 Hz, 5.3 Hz and 1.6 Hz, OCHCHC
10
H3), 
1.91 (3H, dd, J = 2.6 Hz and 1.6 Hz, ArCHCHC
13
H3), 5.05 (1H, m, OCHC
9
HCH3), 6.23–
6.34 (2H, m, ArCHC
12
HCH3 and OC
8
HCHCH3), 6.76 (1H, td, J = 12.1 Hz and 1.7 Hz, 
ArC
11
HCHCH3),  6.86 (1H, d, J = 2.0 Hz, ArC
6
H), 7.17 (1H, d, J = 8.5 Hz, ArC
5
H), 7.44 
(1H, s, ArC
3
H). {The HRMS and 
1
H NMR results confirmed that isomerization had taken 
place, and the compound was used without further characterization.} 
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5.1.4.4    3-(Prop-1-en-1-yl)-2-(prop-1-en-1-yloxy)biphenyl    144d 
 
3-(Prop-2-en-1-yl)-2-(prop-2-en-1-yloxy)biphenyl 143d 
(0.24 g, 0.96 mmol) and [RuClH(CO)(PPh3)3] 15 (0.046 g, 
0.048 mmol, 5 mol%) were dissolved in distilled, degassed 
toluene (5 mL). The reaction was heated at 65 °C for 14 h 
with the completion of the reaction confirmed by NMR 
spectroscopy of a crude sample. The reaction solution was 
then purified by filtration through a short silica gel pad 
(5% EtOAc/hexane) to remove the catalyst and evaporated under reduced pressure to 
afford 3-(prop-1-en-1-yl)-2-(prop-1-en-1-yloxy)biphenyl 144d (a mixture of E,Z isomers) 
as a dark oil (0.23 g, 98%). m/z (EI): 250 (M
+
, 100%), 236 (21), 235 (98), 221 (64), 208 
(26), 207 (37), 194 (80), 191 (26), 179 (22), 178 (50), 168 (21), 166 (28), 165 (89), 152 
(46), 115 (41); HRMS: calcd for C18H18O 250.1358, found: 250.1333; 
1
H NMR (200 
MHz, CDCl3): (ppm) = 1.57–1.62 (3H, m, ArCHCHC
13
H3), 1.85–1.93 (3H. m, 
OCHCHC
10
H3), 4.27–4.66 (1H, m, OCHC
9
HCH3),  5.76–5.81 (1H, m, ArCHC
12
HCH3), 
6.25–6.29 (1H, m, OC8HCHCH3), 6.63–6.73 (1H, m, ArC
11
HCHCH3),  7.14–7.48 (8H, 
m, 8 × ArCH). {The HRMS and 
1
H NMR results confirmed that isomerization had taken 
place, and the compound was used without further characterization.} 
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5.1.4.5   2-(Prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)naphthalene   144e  
 
 2-(Prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)naphthalene 143e 
 (0.2919 g, 1.301 mmol) and [RuClH(CO)(PPh3)3] 15 (61.97 
mg, 0.06507 mmol, 5 mol%) were dissolved in distilled, 
degassed toluene (5 mL). The reaction was heated at 60 °C 
for 12 h under a N2 atmosphere. The reaction mixture was 
then filtered through a compacted Celite plug (3 ×) to 
remove the catalyst and the solvent was then removed under reduced pressure. The 
resulting crude residue was passed through a silica gel column (5% EtOAc/hexane) to 
afford 2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)naphthalene 144e (a mixture of E,Z-
isomers) as a yellow oil (0.2713 g, 93%). Rf = 0.78 (5% EtOAc/hexane); m/z (EI): 224 
(M
+,
 65%), 209 (95), 195 (100), 181 (40), 165 (68), 139 (21), 115 (31), 101 (6), 77 (7), 
63 (4), 39 (12); HRMS: calcd for C16H16O 224.1201, found: 224.1205;  
1
H NMR (200 
MHz, CDCl3): (ppm) = 1.91–1.97 (6H, m, OCHCHC
14
H3 and ArCHCHC
17
H3), 4.60–
4.86 (1H, m, OCHC
13
HCH3), 6.11–6.14 (1H, m, ArCHC
16
HCH3), 6.33–6.41 (1H, m, 
OC
12
HCHCH3), 6.77–6.88 (1H, m, ArC
15
HCHCH3), 7.39–7.52 (2H, m, ArC
3
H and 
ArC
4
H), 7.54–7.61 (2H, m, ArC7H and ArC8H), 7.77 (1H, dd, J = 4.1 Hz and 2.1 Hz, 
ArC
6
H), 8.04 (1H, d, J = 7.4 Hz, ArC
9
H). 
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5.1.5    RCM of the di-isomerized precursors 
 
5.1.5.1    4,7-Dimethoxybenzofuran    145a 
 
1,4-Dimethoxy-2-(prop-1-en-1-yl)-3-(prop-1-en-1-yloxy) 
benzene 144a (0.17 g, 0.74 mmol) and Grubbs‟ II catalyst 6 
(0.031 g, 0.037 mmol, 5 mol%) were dissolved in distilled, 
degassed toluene (5 mL). The reaction mixture was then 
stirred at 90 °C for 3 h under a N2 atmosphere. After 
cooling, the reaction mixture was filtered through a Celite 
plug to remove the catalyst and the solvent was removed under vacuum. The dark oil was 
purified by column chromatography (10% EtOAc/hexane) to afford 4,7-
dimethoxybenzofuran 145a as a low melting point solid (0.13 g, 100%). m/z (EI): 178 
(M
+
, 65%), 163 (100), 135 (8), 120 (8), 92 (6), 76 (5), 63 (6); HRMS: calcd for C10H10O3 
178.0630, found: 178.0644; max (CHCl3)/cm
-1
:  1607, 1590, 1540, 1504, 1461; 
1
H NMR 
(300 MHz, CDCl3): (ppm) = 3.89 (3H, s, OC
11
H3), 3.96 (3H, s, OC
13
H3), 6.53 (1H, d, J 
= 8.5 Hz, ArC
8
H), 6.70 (1H, d, J = 8.5 Hz, ArC
7
H), 6.86 (1H, d, J = 2.1 Hz, 
CC
3
HCHOC), 7.55 (1H, d, J = 2.1 Hz, CCHC
2
HOC);  
13
C NMR (75 MHz, CDCl3): 
(ppm) = 55.8 (OC
11
H3), 56.5 (OC
13
H3), 102.7 (CC
3
HCHO), 104.4 (ArC
8
H), 106.8 
(ArC
7
H), 119.5 (ArC
4
), 132.0 (ArC
6
), 140.4 (ArC
9
), 143.9 (OC
2
HCHC), 147.6 (ArC
5
). 
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5.1.5.2   5-Bromobenzofuran   145b 
 
4-Bromo-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy) 
benzene 144b (0.15 g, 0.59 mmol) and Grubbs‟ II catalyst 
6 (0.025 g, 0.030 mmol, 5 mol%) were dissolved in 
distilled, degassed toluene (5 mL). The reaction mixture 
was then stirred at 90 °C for 3 h under a N2 atmosphere. 
After cooling, the reaction mixture was filtered through a Celite plug to remove the 
catalyst and the solvent was removed under vacuum. The dark oil was purified by column 
chromatography (10% EtOAc/hexane) to afford 5-bromobenzofuran 145b as yellow oil 
(0.026 g, 22%). m/z (EI): 198 (M
+
 +2, 72%), 196 (M
+
, 43), 194 (30), 180 (23), 165 (19), 
149 (22), 132 (46), 115 (24), 111 (30), 109 (22), 97 (43), 89 (38), 85 (50), 83 (57), 82 
(20), 81 (35), 72 (35), 71 (60), 70 (25), 69 (62), 67 (24), 63 (33), 57 (100), 55 (81), 43 
(92), 41 (64);  HRMS: calcd for C8H5BrO 195.9524, found: 195.9516;  
1
H NMR (300 
MHz, CDCl3): (ppm) = 6.72 (1H, d, J = 2.1 Hz, CC
3
HCHOC), 7.38 (2H, br d, J  =  0.9 
Hz, ArC
6
H and ArC
7
H), 7.62 (1H, d, J = 2.2 Hz, CCHC
2
HOC), 7.73 (1H, br s, ArC
9
H);  
13
C NMR (75 MHz, CDCl3): (ppm) =  106.0 (CC
3
HCHOC), 112.8 (ArC
6
H), 115.7 
(ArC
8
Br), 123.8 (ArC
9
H), 127.1 (ArC
7
H), 129.4 (ArC
4
), 146.1 (CCHC
2
HOC), 153.7 
(ArC
5
). 
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5.1.5.3   5-tert-Butyl-benzofuran   145c 
 
4-tert-Butyl-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy) 
benzene 144c (0.10 g, 0.44 mmol) and Grubbs‟ II 
catalyst 6 (0.020 g, 0.022 mmol, 5 mol%) were 
dissolved in distilled, degassed toluene (5 mL). The 
reaction mixture was then stirred at 90 °C for 3 h under 
a N2 atmosphere. After cooling, the reaction mixture was filtered through a Celite plug to 
remove the catalyst and the solvent was removed under vacuum. The dark oil was 
purified by column chromatography (10% EtOAc/hexane) to afford 5-tert-butyl-
benzofuran 145c as a clear oil (0.055 g, 71%). m/z (EI): 174 (M
+
, 23%), 160 (12), 159 
(100), 115 (16), 91 (14), 89 (7), 77 (6), 63 (6), 63 (7), 40 (9);  HRMS: calcd for C12H14O 
174.1045, found: 174.1029; max (CHCl3)/cm
-1
: 1699, 1607, 1541;  
1
H NMR (300 MHz, 
CDCl3): (ppm) = 1.38 (9H, s, C(CH3)3), 6.73 (1H, d, J = 2.9 Hz, CC
3
HCHOC), 7.36 
(1H, dd, J = 8.7 Hz and 1.9 Hz, ArC
7
H), 7.42 (1H, d, J = 8.7 Hz, CCHC
2
HOC), 7.58–
7.60 (2H, m, ArC
6
H and ArC
9
H);  
13
C NMR (75 MHz, CDCl3): (ppm) =  31.5 
(C
10
(CH3)3), 31.9 (C
11
H3, C
12
H3, C
13
H3), 106.7 (CC
3
HCHOC), 110.6 (ArC
6
H), 116.2 
(ArC
4
), 117.3 (ArC
9
H), 122.2 (ArC
7
H), 127.1 (ArC
8
), 145.0 (CCHC
2
HOC), 145.8 
(ArC
5
). 
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5.1.5.4   7-Phenyl-1-benzofuran   145d 
 
3-(Prop-1-en-1-yl)-2-(prop-1-en-1-yloxy)biphenyl 144d (0.10 
g, 0.42 mmol) and Grubbs‟ II catalyst 6 (0.018 g, 0.021 
mmol, 5 mol%) were dissolved in distilled, degassed toluene 
(5 mL). The reaction mixture was then stirred at 90 °C for 3 h 
under a N2 atmosphere. After cooling, the reaction mixture 
was filtered through a Celite plug to remove the catalyst and 
the solvent was removed under vacuum. The dark oil was 
purified by column chromatography (10% EtOAc/hexane) to afford 7-phenylbenzofuran 
145d as yellow oil (0.051 g, 63%). m/z (EI): 195 (M
+
 +1, 17%), 194 (M
+
, 100), 165 (53), 
163 (10), 139 (12), 115 (9), 63 (7); HRMS: calcd for C14H10O 194.0732, found: 
194.0711; max (CHCl3)/cm
-1
: 1668, 1596, 1542, 1499, 1474, 1451, 1412; 
1
H NMR (300 
MHz, CDCl3): (ppm) = 6.83 (1H, d, J = 2.2 Hz, CHC
3
HCHOC), 7.33 (1H, d, J = 7.6 
Hz, ArC
8
H), 7.40 (1H, d, J = 4.3 Hz, ArC
7
H), 7.48 (3H, ddd, J = 9.7 Hz, 8.3 Hz and 0.9 
Hz, ArC
12
H, ArC
13
H and ArC
14
H), 7.58 (1H, dd, J = 7.7 Hz and 1.1 Hz, ArC
9
H), 7.67 
(1H, d, J = 2.2 Hz, CCHC
2
HOC), 7.83–7.88 (2H, m, ArC11H and ArC15H); 13C NMR (75 
MHz, CDCl3): (ppm) = 106.7 (CC
3
HCHOC), 120.3 (ArC
9
H), 123.2 (ArC
7
H), 123.8 
(ArC
8
H), 127.6 (ArC
13
H), 127.9 (ArC
4
), 128.5 (ArC
11
H and ArC
15
H), 128.6 (ArC
14
H and 
ArC
14
H), 129.2 (ArC
6
), 136.5 (ArC
10
), 144.9 (CCHC
2
HOC), 152.2 (ArC
5
). 
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5.1.5.5   Naphtho[1,2-b]furan    145e 
 
 2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)naphthalene 144e   
(0.1202 g, 0.5359 mmol) and Grubbs‟ II catalyst 6 (22.75 mg, 
0.02679 mmol, 5 mol%) were dissolved in distilled, degassed 
toluene (5 mL). The reaction mixture was then stirred at 60 °C 
for 12 h under a N2 atmosphere. After cooling, the reaction 
mixture was filtered through a Celite plug to remove the 
catalyst and the solvent was removed under vacuum. The dark oil was purified by column 
chromatography (10% EtOAc/hexane) to afford Naphtho[1,2-b]furan 145e as yellow oil 
(83.31 mg, 93%). m/z (EI): 168 (M
+
, 62%), 139 (38), 131 (47), 119 (10), 100 (12), 69 
(76);  HRMS: calcd for C12H8O 168.0575, found: 168.0573;  max (CHCl3)/cm
-1
: 3057, 
2926, 1511, 1392, 1322, 1269, 1170, 1128, 1069, 1022, 882, 809, 739, 686, 598, 561;  
1
H 
NMR (300 MHz, CDCl3): (ppm) = 6.89 (1H, d, J = 2.1 Hz, OCHC
3
H), 7.48 (1H, ddd, J 
= 8.1 Hz, 7.0 Hz and 1.2 Hz, ArC
8
H), 7.58 (1H, ddd, J = 8.2 Hz, 7.1 Hz and 1.2 Hz, 
ArC
9
H), 7.65 (2H, br s, ArC
7
H and ArC
8
H), 7.75 (1H, d, J = 2.1 Hz, OC
2
HCH), 7.92 
(1H, d, J = 8.2Hz, ArC
12
H), 8.31 (1H, d, J = 8.2 Hz, ArC
13
H);  
13
C NMR (75 MHz, 
CDCl3): (ppm) = 107.6 (CC
3
HCHO), 119.7 (ArC
13
H), 120.0 (ArC
12
H), 122.9 (ArC
6
), 
123.4 (ArC
8
H), 125.1 (ArC
9
H), 126.1 (ArC
4
), 126.3 (ArC
7
H), 128.3 (ArC
10
H), 131.4 
(ArC
11
), 144.1 (CCHC
2
HO), 150.6 (ArC
5
). 
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5.2   The O,N-benzo-fused heterocycles 
 
5.2.1   Protection of the precursor 
 
5.2.1.1   N-(2-Hydroxyphenyl)benzamide   147 
 
2-Aminophenol 146 (5.89 g, 53.9 mmol, 1 equiv.) was 
dissolved in dry CH2Cl2 (100 mL) and the temperature of the 
mixture lowered to 0 °C, followed by the sequential addition 
of pyridine (4.4 mL, 54 mmol, 1 equiv.) and benzoyl chloride 
(6.3 mL, 54 mmol, 1 equiv.). The reaction mixture was 
stirred at r. t. for 24 h under a N2 atmosphere. The reaction 
mixture was then quenched with saturated NaHCO3 solution to bring the pH to 7. The 
mixture was separated and the organic fraction dried (MgSO4) and the solvent removed 
under reduced pressure to afford N-(2-hydroxyphenyl)benzamide 147 as a white 
crystalline powder (11.5 g, 100%). Rf = 0.10 (20% EtOAc/hexane); 
1
H NMR (300 MHz, 
CDCl3): (ppm) = 1.70 (1H, s, OH),  4.81 (1H, s, NH), 6.85–7.20 (1H, m, ArC
6
H), 7.20–
7.45 (2H, m, ArC
5
H and ArC
4
H), 7.46–7.65 (2H, m, ArC13H and ArC15H), 7.65–7.82 
(1H, m, ArC
12
H), 7.84–7.99 (1H, m, ArC14H), 8.20–8.37 (1H, m, ArC16H), 8.10 (0.3H, s) 
and 8.69 (0.7H, s) [ArC
3
H]; 
13
C NMR (75 MHz, CDCl3): (ppm) = 119.4 (ArC
6
H), 120.6 
(ArC
4
H), 122.2 (ArC
5
H), 123.4 (ArC
3
H), 126.9 (ArC
12
H), 127.3 (ArC
16
H), 128.8 
(ArC
13
H), 128.8 (ArC
15
H), 130.2 (ArC
14
H), 132.4 (ArC
2
), 134.3 (ArC
11
), 148.5 (ArC
1
), 
167.0 (C=O). {The identity of this compound was confirmed with 
1
H and 
13
C NMR and 
submitted directly to the next reaction step.} 
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5.2.2   Allylation reactions 
 
5.2.2.1    N-(2-(Prop-2-en-1-yloxy)phenyl)benzamide   148 
 
Allyl bromide (3.00 g, 24.8 mmol, 2.1 mL, 1.2 equiv.) and 
K2CO3 (5.71 g, 41.3 mmol, 2 equiv.) were added to N-(2-
hydroxyphenyl)benzamide  147 (4.40 g, 20.7 mmol, 1 equiv.) 
dissolved in dry acetone (100 mL). The reaction mixture was 
then stirred at reflux (60 °C) for 24 h under a N2 atmosphere. 
After cooling, the reaction slurry was passed through a celite 
plug to remove the base and the resulting crude residue was then passed through a silica 
gel column (20% EtOAc/hexane) to afford N-(2-(prop-2-en-1-yloxy)phenyl)benzamide 
148 as a pale yellow solid (4.188 g, 80%). Rf = 0.48 (20% EtOAc/hexane), mp = 50–51 
°C; m/z (EI): 253 (M
+
 , 30%), 212 (15), 105 (100), 77 (36), 51 (8) ,41 (5); HRMS: calcd 
for C16H15NO2  253.1103, found: 253.1121; max (ATR)/cm
-1
:
 
3317, 1738, 1648, 1601, 
1518, 1482, 1452, 1375, 1324, 1294;  
1
H NMR (300 MHz, CDCl3): (ppm) = 4.64 (2H, 
dt, J = 5.2 Hz and 1.3 Hz, OC
8
H2CHCH2), 5.33 (1H, dd, J = 10.5 Hz and 1.3 Hz, 
OCH2CHC
10
HAHB), 5.43 (1H, dd, J = 17.3 Hz and 1.4 Hz, CH2CHC
10
HAHB), 6.08 (1H, 
tdd, J = 17.1 Hz, 10.6 Hz and 5.3 Hz, OCH2C
9
HCH2), 6.88–6.97 (1H, m,  ArC
6
H), 6.97–
7.10 (2H, m, ArC
5
H and ArC
4
H), 7.45–7.58 (3H, m, ArC16H, ArC17H and ArC18H), 7.89 
(2H, dd, J = 8.0 Hz and 1.5 Hz, ArC
15
H and ArC
19
H), 8.52–8.59 (1H, m, ArC3H), 8.63 
(1H, br s,  NH); 
13
C NMR (75 MHz, CDCl3): (ppm) = 69.5 (OC
8
H2CHCH2), 111.4 
(OCH2CHC
10
H2), 118.1 (ArC
6
H), 119.9 (ArC
4
H), 121.4 (ArC
3
H), 123.7 (ArC
5
H), 126.9 
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(ArC
15
H and ArC
19
H), 128.1 (ArC
2
), 128.7 (ArC
16
H and ArC
18
H), 131.7 (ArC
17
H), 132.7 
(OCH2C
9
HCH2), 135.3 (ArC
14
), 147.1 (ArC
1
), 165.1 (C=O). 
 
 
 
 
 
 
5.2.2.2    N-(Prop-2-en-1-yl)-N-[2-(prop-2-en-1-yloxy)phenyl]benzamide  149 
 
N-(2-(Prop-2-en-1-yloxy)phenyl)benzamide 148 (1.05 g, 4.13 
mmol, 1 equiv.) was dissolved in dry DMF (30 mL) and the 
temperature of the mixture lowered to 0 °C, followed by the 
sequential addition of NaH (60% in oil, 0.190 g, 4.96 mmol, 
1.2 equiv.) and allyl bromide (1.0 g, 8.3 mmol, 0.72 mL, 2 
equiv.). The reaction mixture was then stirred at r.t. for 24 h 
under a N2 atmosphere. Water (80 mL) was added to quench the reaction mixture, after 
which it was extracted with EtOAc (3 × 50 mL) and the combined fractions dried 
(MgSO4). The solvent was then removed under reduced pressure and the resulting crude 
residue passed through a silica gel column (20% EtOAc/hexane) to afford N-(prop-2-en-
1-yl)-N-[2-(prop-2-en-1-yloxy)phenyl]benzamide 149 as a pale yellow oil (1.10 g, 90%). 
Rf = 0.30 (20% EtOAc/hexane); m/z (EI): 293 (M
+
, 28%), 236 (11), 188 (10), 120 (5), 
105 (100), 77 (33) and 41 (7);  HRMS: calcd for C19H19NO2 293.1416, found: 293.1424; 
max (ATR)/cm
-1
: 1647, 1601, 1518, 1496, 1481, 1452, 1324, 1294, 1265, 1246, 1208, 
1125; 
1
H NMR (300MHz; CDCl3)  (ppm) = 4.26 (2H, dd, J = 14.4 Hz and 7.2 Hz, 
NC
12
H2CHCH2), 4.44 (1H, dd, J = 12.3 Hz and 3.4 Hz, OC
8
HAHBCHCH2), 4.64 (1H, dd, 
J = 14.5 Hz and 5.2 Hz, OC
8
HAHBCHCH2), 5.08 (1H, dd, J = 9.8 Hz and 1.0 Hz, 
NCH2CHC
14
HAHB), 5.13 (1H, dd, J = 15.0 Hz and 1.1 Hz, NCH2CHC
14
HAHB), 5.26 (1H, 
dd, J = 10.6 Hz and 1.4 Hz, OCH2CHC
10
HAHB), 5.36 (1H, dd,  J = 17.3 Hz and 1.4 Hz, 
OCH2CHC
10
HAHB), 5.78–6.14 (2H, m, OCH2C
9
HCH2 and NCH2C
13
HCH2), 6.71 (1H, d, 
J = 8.1 Hz, ArC
6
H), 6.80 (1H, t, J = 7.5 Hz and 7.5 Hz, ArC
5
H), 6.99–7.23 (5H, m, 
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ArC
4
H, ArC
19
H, ArC
21
H, ArC
3
H and ArC
20
H), 7.32 (2H, d, J = 7.2 Hz, ArC
18
H and 
ArC
22
H); 
13
C NMR (75MHz; CDCl3) C
12
H2CHCH2), 68.5 
(OC
8
H2CHCH2), 112.5 (NCH2CHCH2), 117.2 (OCH2CHCH2), 117.5 (ArC
6
H), 120.6 
(ArC
4
H), 127.1 (ArC
3
H), 128.0 (ArC
5
H), 128.4 (ArC
18
H and ArC
22
H), 129.2 (ArC
19
H 
and ArC
21
H), 129.9 (ArC
20
H), 132.0 (ArC
2
), 132.5 (OCH2C
9
HCH2), 133.4 
(NCH2C
13
HCH2), 136.3 (ArC
17
), 153.5 (ArC
1
), 171.1 (C=O). 
 
 
5.2.2.3   N-(Prop-2-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide   154 
 
N-(2-(Prop-1-en-1-yloxy)phenyl)benzamide 153 (0.297 g, 
1.17 mmol, 1 equiv.) was dissolved in dry DMF (30 mL) and 
the temperature of the mixture lowered to 0 °C, followed by 
the sequential addition of NaH (60% in oil, 54.0 mg, 1.41 
mmol, 1.2 equiv.) and allyl bromide (0.28 g, 2.35 mmol, 0.20 
mL, 2 equiv.). The reaction mixture was then stirred at r.t. for 
24 h under a N2 atmosphere. Water (80 mL) was added to quench the reaction mixture, 
which was then extracted with EtOAc (3 × 50 mL) and the combined fractions dried 
(MgSO4). The solvent was then removed under reduced pressure and the resulting crude 
residue passed through a silica gel column (20% EtOAc/hexane) to afford N-(prop-2-en-
1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide 154 as a pale yellow oil (0.327 g, 95%) 
as a mixture of E/Z isomers (ratio 65:35).  Rf = 0.17 (10% EtOAc/hexane); m/z (EI): 293 
(M
+
, 28%), 236 (38), 188 (5), 160 (28), 105 (75), 77 (44), 51 (6); HRMS: calcd for 
C19H19NO2 293.1416 found: 293.1424; max (ATR)/cm
-1
: 1639, 1496, 1384, 1255, 1213, 
1124, 1018, 907, 791, 725, 646;  
1
H NMR (300MHz; CDCl3, cis
1
 and trans
2
 isomers)  
(ppm) = 1.63
2
 and 1.69
1
 (3H, dd and dd, J = 6.9 Hz and 1.5 Hz, and J = 6.9 Hz and 1.6 
Hz, OCHCHC
10
H3), 4.20–4.60 (2H, br m, NC
12
H2CHCH2), 4.84–4.94
1
 and 5.29–5.412 
(1H, 2  m, OCHC
9
HCH3), 5.09–5.15 (2H, m, NCH2CHC
14
H2), 5.86–6.12 (2H, m, 
OC
8
HCHCH3 and NCH2C
13
HCH2), 6.80–6.92 (2H, m, 2  ArH), 7.03–7.23 (5H, m, 5  
ArH), 7.32–7.36 (2H, m, 2  ArH); 13C NMR (75MHz; CDCl3, cis{trans}) (ppm) = 9.4 
and 12.1 (OCHCHC
10
H3), 52.3 and 52.2 (NC
12
H2CHCH2), 108.6 and 109.8 
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(OCHC
9
HCH3), 115.5 and 115.6 (ArC
6
H), 117.7 and 117.6 (NCH2CHC
14
H2), 122.4 and 
122.3 (ArC
4
H), 127.3 and 127.3 (ArC
3
H), 128.1 (ArC
5
H), 128.6 and 128.5 (ArC
18
H), 
128.6 and 128.5 (ArC
22
H), 129.4 (ArC
2
), 130.0 and 129.9 (ArC
19
H), 130.0 and 129.9 
(ArC
21
H), 132.4 and 132.3 (ArC
20
H), 133.2 and 133.3 (NCH2C
13
HCH2), 136.1 (ArC
17
), 
140.0 and 140.9 (OCHC
8
HCH3), 152.6  (ArC
1
), 171.0 (C=O). 
 
 
 
5.2.3    Isomerization reactions 
 
5.2.3.1   N-[2-(Prop-1-en-1-yloxy)phenyl]benzamide 153 
 
N-[2-(Prop-2-en-1-yloxy)phenyl]benzamide 148 (0.401 g, 
1.58 mmol) and [RuClH(CO)(PPh3)3] 15 (60.3 mg, 0.0633 
mmol, 4 mol%) were reacted  under solventless conditions. 
The reaction mixture was heated at 65 °C for 24 h under an Ar 
atmosphere. The reaction solution was then diluted with a 5% 
EtOAc/hexane mixture (150 mL) and filtered through a 
compacted celite plug to remove the catalyst; the solvent was then removed under 
reduced pressure and the resulting crude residue passed through a silica gel column (10% 
EtOAc/hexane) to afford N-[2-(prop-1-en-1-yloxy)phenyl]benzamide 153 as a yellow oil 
(0.368 g, 92%) as a mixture of E/Z isomers (ratio 1:2). Rf = 0.57 (20% EtOAc/hexane); 
m/z (EI): 253 (M
+
, 34%), 196 (35), 105 (100), 77 (23), 51 (8);  HRMS: calcd for 
C16H15NO2 253.1103, found: 253.1091; max (ATR)/cm
-1
: 3433, 3019, 2401, 1672, 1604, 
1525, 1477, 1453, 1332, 1256, 1205, 1128, 1017, 928, 709, 667;  
1
H NMR (300MHz; 
CDCl3, cis
1 
and trans
2
 and isomers)  (ppm) =  1.68
2
 and 1.75
1
 (3H, dd and dd, J = 6.9 Hz 
and 1.4 Hz and J = 6.9 Hz and 1.6 Hz, OCHCHC
10
H3), 4.92–5.10
1
 and 6.33–6.432 (1H, 2 
 m, OCHC
9
HCH3), 6.34–6.40 (1H, m, OC
8
HCHCH3), 6.98–7.10 (3H, m, 3  ArH), 
7.43–7.58 (3H, m, 3  ArH), 7.89 (2H, dd, J = 6.5 Hz and 1.6 Hz, 2  ArH), 8.46–8.59 
(2H, m, ArH and NH); 
13
C NMR (75MHz; CDCl3, (ppm) = 9.3 and 12.6 
(OCHCHC
10
H3), 108.7 and 109.6 (OCHC
9
HCH3), 114.0 and 114.6 (ArC
6
H), 120.3 
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(ArC
4
H), 122.9 and 123.0 (ArC
3
H), 123.8 (ArC
5
H), 126.8 and 126.9 (ArC
15
H and 
ArC
19
H), 128.3 (ArC
2
), 128.7 and 128.6 (ArC
16
H and ArC
18
H), 131.7 (ArC
17
H), 135.0 
(ArC
14
), 140.4 and 141.5 (OC
8
HCHCH3), 146.1 and 146.0 (ArC
1
), 165.0 and 165.1 
(C=O). 
 
 
 
 
5.2.3.2   N-(Prop-1-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide 151 
 
N-(Prop-2-en-1-yl)-N- [2-(prop-2-en-1-yloxy) phenyl] 
benzamide 149 (0.329 g, 1.12 mmol) and [RuClH(CO)(PPh3)3] 
15 (53.4 mg, 0.0561 mmol, 5 mol%) were reacted without 
solvent. The reaction mixture was heated at 65 °C for 24 h 
under an Ar atmosphere. The reaction solution was then 
diluted with a 5% EtOAc/hexane mixture (150 mL) and 
filtered through a compacted celite plug to remove the catalyst. The solvent was then 
removed under reduced pressure and the resulting crude residue passed through a silica 
gel column (10% EtOAc/hexane) to afford N-(prop-1-en-1-yl)-N-(2-(prop-1-en-1-
yloxy)phenyl)benzamide 151 as a yellow oil (0.321 g, 98%) as a mixture of E/Z isomers 
(ratio 1:2).  Rf = 0.47 (20% EtOAc/hexane); m/z (EI): 293 (M
+
, 34%), 264 (68), 253 (4), 
236 (100), 220 (15), 188 (10), 176 (4), 161 (4);  HRMS: calcd for C19H19NO2 293.1416, 
found: 293.1416; max (ATR)/cm
-1
: 2920, 1650, 1588, 1495, 1447, 1386, 1355, 1319, 
1272, 1247, 1159, 1117, 1017, 944, 877; 
1
H NMR (300MHz; CDCl3)  (ppm) = 1.45–
1.87 (6H, m, OCHCHC
10
H3 and NCHCHC
16
H3), 4.55–4.76 (1H, m, NCHC
15
HCH3), 
4.79–4.99 and 5.22–5.46 (1H, 2 × m, OCHC9HCH3), 5.88–6.26 (1H, m, OC
8
HCHCH3), 
6.80–6.91 (1H, m, ArC6H), 6.92–7.02 (1H, m, NC14HCHCH3), 7.11–7.54 (8H, m, ArC
3-5
 
and ArC
18-22
H); 
13
C NMR (75MHz; CDCl3)  (ppm) =  9.4 and 12.1 (OCHCHC
10
H3), 
15.0 and 15.1 (NCHCHC
16
H3), 108.8 and 109.9 (OCHC
9
HCH3), 109.3 (NCHC
15
HCH3), 
115.8 and 116.2 (ArC
6
H), 122.6 (ArC
4
H), 127.5 (ArC
3
H and ArC
5
H), 128.0 (ArC
18
H and 
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ArC
22
H), 129.3 (ArC
2
), 129.4 (ArC
19
H and ArC
21
H), 129.7 (NC
14
HCHCH3), 130.9 
(ArC
20
H), 135.9 (ArC
17
), 140.0 and 140.1 (OC
8
HCHCH3), 152.9 (ArC
1
), 169.1 (C=O). 
 
 
 
 
 
 
 
5.2.4   RCM reactions 
 
5.2.4.1    4H-1,4-Benzoxazin-4-yl(phenyl)methanone   152 
 
N-(Prop-1-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl) 
benzamide 151 (0.362 g, 1.24 mmol) and Grubbs‟ II catalyst 6 
(83.9 mg, 0.0988 mmol, 8 mol%) were dissolved in distilled, 
degassed toluene (15 mL). The reaction mixture was then 
stirred at 90 °C for 8 h under an Ar atmosphere. After cooling, 
the reaction mixture was diluted with a 10% EtOAc/hexane 
mixture (100 mL) and filtered through a compacted celite plug 
to remove the catalyst. The solvent was then removed under reduced pressure and the 
resulting crude residue passed through a silica gel column (10% EtOAc/hexane) to afford 
4H-1,4-benzoxazin-4-yl(phenyl)methanone 152 as a yellow oil (0.281 g, 96%).   Rf = 
0.30 (10% EtOAc/hexane); m/z (EI): 237 (M
+
, 33%), 238 (6), 219 (23), 132 (18), 105 
(100), 77 (62), 51 (16); HRMS: calcd for C15H11NO2 237.0790, found: 237.0789; max 
(ATR)/cm
-1
: 1640, 1585, 1492, 1462, 1444, 1352, 1304, 1276, 1205, 1169, 1127, 1081, 
1050, 1018, 936, 906, 856, 813;
  1
H NMR (300MHz; CDCl3)  (ppm) = 6.05 (1H, d, J = 
4.5 Hz, OC
2
HCHN), 6.27 (1H, br d, J = 2.5 Hz, NC
3
HCHO), 6.84 (1H, dd, J = 8.0 Hz 
and 1.1 Hz, ArC
7
H), 6.90 (1H, dt, J = 8.1 Hz, 8.0 Hz and 1.0 Hz, ArC
9
H), 7.04 (1H, dt, J 
= 7.8 Hz, 7.8 Hz and 1.2 Hz, ArC
8
H), 7.37–7.50 (3H, m, ArC15H, ArC16H and ArC17H), 
7.56 (2H, dd, J = 7.7 Hz and 1.4 Hz, ArC
14
H and ArC
18
H), 7.65 (1H, br d, J = 1.14 Hz, 
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ArC
10
H); 
13
C NMR (75MHz; CDCl3 (ppm) = 111.6 (NC
3
HCHO), 116.6 (OC
2
HCHN), 
116.6 (ArC
7
H), 122.4 (ArC
10
H), 123.5 (ArC
9
H), 126.5 (ArC
8
H), 127.9 (ArC
14
H and 
ArC
18
H), 128.5 (ArC
15
H and ArC
17
H), 130.7 ArC
16
H), 131.7 (ArC
5
), 134.9 (ArC
13
), 
147.4 (ArC
6
), 166.7 (C=O). 
 
 
 
 
 
5.2.4.2   1,5-Benzoxazepin-5(4H)-yl(phenyl)methanone   155 
 
N-(Prop-2-en-1-yl)-N-(2-(prop-1-en-1-yloxy) phenyl) 
benzamide 154 (0.301 g, 1.10 mmol) and Grubbs‟ II catalyst 6 
(43.6 mg, 0.0513 mmol, 5 mol%) were dissolved in distilled, 
degassed toluene (15 mL). The reaction mixture was then 
stirred at 80 °C for 8h under an Ar atmosphere. After cooling, 
the reaction mixture was diluted with a 10% EtOAc/hexane 
mixture (100 mL) and filtered through a compacted celite plug 
to remove the catalyst. The solvent was then removed under reduced pressure and the 
resulting crude residue passed through a silica gel column (10% EtOAc/hexane) to afford 
1,5-benzoxazepin-5(4H)-yl(phenyl)methanone 155 as a low melting point solid (0.13 g, 
100%). Rf = 0.14 (10% EtOAc/hexane), mp = 27–28 °C;  m/z (EI): 252 (M
+
 +1, 94%), 
251 (M
+ 
, 30%), 196 (8), 154 (40), 136 (38), 131 (15), 120 (9);  HRMS: calcd for 
C16H13NO2 251.0946, found: 251.0946; max (ATR)/cm
-1
: 1657, 1593, 1537, 1469, 1414, 
1364, 1325, 1287, 1264, 1202, 1168, 1123, 1093, 1040, 1007, 940, 887, 865, 813, 785, 
724, 700, 658, 629; 
1
H NMR (300 MHz, CDCl3, one proton for NCH2 not observed* in 
spectrum due to very broad peaks caused by amide rotamers):  (ppm) = 3.76 and 5.36 
(1H*, 2  br s, NC
4
H2CHCHO), 4.94 (1H, d, J = 3.1 Hz, NCH2C
3
HCHO), 6.51–6.58 
(1H, m, NCH2CHCH
2
O), 6.70 (1H, br s, ArC
8
H), 6.80 (1H, br s, ArC
9
H), 7.10–7.31 (7H, 
m, 7  ArCH); 
13
C NMR (75 MHz, CDCl3): (ppm) = 44.5 (NC
4
H2CHCHO), 105.0 
(NCH2C
3
HCHO), 121.1 (ArC
8
H), 124.5 (ArC
11
H), 127.8 (ArC
10
H), 128.0 (ArC
9
H), 
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128.4 (ArC
15
H and ArC
19
H), 129.5 (ArC
16
H and ArC
18
H), 129.9 (ArC
17
H), 134.8 (ArC
6
), 
135.4 (ArC
14
), 142.9 (OC
2
HCHCH2O), 153.2 (ArC
7
), 169.8 (C=O). 
 
 
 
 
 
 
 
5.2.4.3   2,5-Dihydro-6H-1,6-benzoxazocin-6-yl(phenyl)methanone   150 
 
N-(Prop-2-en-1-yl)-N-[2-(prop-2-en-1-yloxy)phenyl] 
benzamide 149 (0.201 g, 0.682 mmol, 1 equiv.) and Grubbs‟ II 
catalyst 6 (29.0 mg, 0.0341 mmol, 5 mol%) were dissolved in 
distilled, degassed toluene (15 mL). The reaction mixture was 
then stirred at 90 °C for 18 h under an Ar atmosphere. After 
cooling, the reaction mixture was diluted with a 10% 
EtOAc/hexane mixture and filtered through a compacted celite 
plug (3 ×) to remove the catalyst. The solvent was then removed under reduced pressure 
and the resulting crude residue passed through a silica gel column (15% EtOAc/hexane) 
to afford 2,5-dihydro-6H-1,6-benzoxazocin-6-yl(phenyl)methanone 150 as a low melting 
point solid (0.142 g, 88%). Rf = 0.13 (20% EtOAc/hexane), mp = 29–30 °C; m/z (EI): 
265 (M
+
, 4%), 251 (30), 234 (5), 146 (6), 131 (24), 105 (100), 77 (42), 51 (9); HRMS: 
calcd for C17H15NO2 265.1103, found: 265.1118; max (ATR)/cm
-1
: 1645, 1497, 1360, 
1325, 1274, 1249, 1134, 1018, 906, 725, 647; 
1
H NMR (300 MHz, CDCl3): (ppm) = 
3.95–5.48 (4H, m, NC5H2 and OC
2
H2), 5.8 (1H, dt, J = 10.4 Hz and 8.3 Hz, OCH2C
3
H), 
5.95 (1H, dt, J = 10.3 Hz and 4.0 Hz, NCH2C
4
H), 6.79 (2H, dq, J = 8.0 Hz, 7.9 Hz and 
1.0 Hz, ArC
10
H and ArC
11
H), 6.89 (1H, br dd, J = 8.2 Hz and 0.6 Hz, ArC
9
H), 7.06–7.14 
(1H, m, ArC
12
H), 7.14–7.27 (3H, m, ArC17H, ArC19H and ArC18H), 7.38 (2H, d, J = 7.6 
Hz and 1.0 Hz, ArC
16
H and ArC
20
H); 
13
C NMR (75 MHz, CDCl3): (ppm) = 49.1 
(NC
5
H2), 65.2 (OC
2
H2), 121.3 (ArC
9
H), 122.3 (ArC
12
H), 124.7 (ArC
11
H), 27.4 (ArC
10
H), 
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127.6 (OCH2C
3
H), 128.1 (ArC
16
H and ArC
20
H), 129.4 (ArC
17
H and ArC
19
H), 130.1 
(NCH2C
4
H), 131.4 (ArC
18
H), 132.8 (ArC
7
), 135.6 (ArC
15
), 153.1 (ArC
8
), 171.2 (C=O). 
 
 
 
 
 
 
5.3   The N,N-benzo-fused heterocycles 
 
5.3.1   Protection of the precursor 
 
5.3.1.1   N,N'-Benzene-1,2-diyldiacetamide    157 
 
Benzene-1,2-diamine 156 (2.29 g, 21.2 mmol, 1 equiv.) was 
dissolved in pyridine (6.49 g, 63.6 mmol, 10.0 mL, 10.7 equiv.) 
and the temperature of the mixture lowered to 0 °C in an ice 
bath. Acetic anhydride (3.53 g, 34.5 mmol, 3.26 mL, 3 equiv.) 
was then added drop wise over 5 minutes. The reaction mixture 
was then stirred at r.t. for 24 h under a N2 atmosphere. The 
reaction mixture was then quenched with enough NaHCO3 to bring the pH to ~8. The 
reaction mixture was then extracted with ethyl acetate (3 × 50 mL) and dried (MgSO4), 
after which the solvent was removed under reduced pressure to afford N,N'-benzene-1,2-
diyldiacetamide 157 as a white crystalline powder (3.78 g, 93%). 
1
H NMR (300 MHz, 
CDCl3): (ppm) = 2.09 (6H, s, OC
13
H3 and OC
14
H3), 7.17 (2H, dd, J = 5.7 Hz and 3.7 
Hz, ArC
4
H and ArC
5
H), 7.29 (2H, dd, J = 5.6 Hz and 3.7 Hz, ArC
3
H and ArC
6
H), 8.44 
(2H, s, N
7
H and N
10
H); 
13
C NMR (75 MHz, CDCl3): (ppm) = 23.8 (OC
13
H3 and 
OC
14
H3), 125.5 (ArC
4
H and ArC
5
H), 126.1 (ArC
3
H and ArC
6
H), 130.5 (ArC
1
 and ArC
2
), 
169.9 (C
8
=O and C
11
=O). {The identity of this compound was confirmed with 
1
H and 
13
C 
NMR and submitted directly to the next step.} 
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5.3.2   Allylation reactions 
 
5.3.2.1   N-[2-(Acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide    158 
 
[Method 1] N,N'-Benzene-1,2-diyldiacetamide 157 (0.200 g, 
1.04 mmol, 1 equiv.) was dissolved in dry acetone (30 mL) 
and the temperature of the solution lowered to –14 °C (using 
an ice and salt slurry), followed by the sequential addition of 
NaH (60% in oil, 40.0 mg, 1.04 mmol,  1 equiv.) and allyl 
bromide (0.138 g, 1.15 mmol, 0.10 mL, 1.1 equiv.). The 
reaction mixture was then stirred at r.t. for 12 h under a N2 atmosphere. The reaction 
mixture was then quenched with water (100 mL) and extracted with EtOAc (3 × 50 mL) 
and the combined fractions dried (MgSO4). The solvent was then removed under reduced 
pressure and the resulting crude residue passed through a silica gel column (100% 
EtOAc) to afford N-[2-(acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide 158 as a pale 
yellow oil (0.229 g, 95%).  
 
[Method 2] N,N'-Benzene-1,2-diyldiacetamide 157 (0.274 g, 1.43 mmol, 1 equiv.) was 
dissolved in dry DMF (30 mL) and the temperature of the solution lowered to 0 °C, 
followed by the sequential addition of NaH (60% in oil, 54.7 mg, 1.43 mmol,  1 equiv.) 
and allyl bromide (0.172 g, 1.43 mmol, 0.12 mL, 1 equiv.). The reaction mixture was 
then stirred at r.t. for 12 h under a N2 atmosphere. The reaction mixture was then 
138 
 
 
quenched with water (100 mL) and extracted with EtOAc (3 × 50 mL), the combined 
fractions were then dried (MgSO4). The solvent was then removed under reduced 
pressure and the resulting crude residue passed through a silica gel column (100% 
EtOAc) to afford N-[2-(acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide 158 as a pale 
yellow oil (0.312 g, 94%).  
 
 
 
 
Rf = 0.40 (100% EtOAc); m/z (EI): 232 (M
+
, 20%), 213 (30), 189 (90), 172 (100), 147 
(75), 130 (68), 119 (100), 107 (32), 77 (15); HRMS: calcd for C13H16N2O2 232.12118, 
found: 232.12117; max (ATR)/cm
-1
: 3278, 1696, 1641, 1592, 1525, 1452, 1395, 1289, 
1231, 1112, 1080, 1038, 980, 929, 875, 759, 678; 
1
H NMR (300 MHz, CDCl3): (ppm) = 
1.83 (3H, m, OC
16
H3), 2.25 (3H, m, OC
17
H3), 3.93 (1H, dd, J = 14.2 Hz and 7.2 Hz, 
NCH2CHCHAHB), 4.50 (1H, dd, J = 14.2 Hz and 5.9 Hz, NCH2CHCHAHB), 5.12 (2H, 
dd, J = 17.6 Hz and 14.0 Hz, NC
8
H2CHCH2), 5.75–6.02 (1H, m, NCH2C
9
HCH2), 7.04–
7.20 (2H, m, ArC
3
H and N
11
H), 7.32–7.43 (1H, m, ArC4H), 8.38 (1H, br d, J = 8.0 Hz 
ArC
5
H), 8.57 (1H, br s, ArC
6
H);  
13
C NMR (75 MHz, CDCl3): (ppm) = 22.6 (OC
17
H3), 
24.4 (OC
16
H3), 50.8 (NC
8
H2CHCH2), 119.3 (NCH2CHC
10
H2), 122.6 (ArC
3
H), 124.2 
(ArC
6
H), 129.1 (ArC
4
H), 129.1 (ArC
5
H), 131.1 (NCH2C
9
HCH2), 132.1 (ArC
1
), 135.2 
(ArC
2
), 169.3 (C
14
=O), 171.0 (C
12
=O). 
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5.3.2.2   N,N'-Benzene-1,2-diylbis[N-(prop-2-en-1-yl)acetamide]    159 
 
N,N'-Benzene-1,2-diyldiacetamide 157 (0.478 g, 2.49 mmol, 
1 equiv.) was dissolved in dry acetone (15 mL) and the 
temperature of the mixture lowered to –14 °C (using an ice 
and salt slurry), followed by the sequential addition of NaH 
(60% in oil, 0.191 g, 4.97 mmol, 2 equiv.) and Allyl 
bromide (0.662 g, 5.47 mmol, 0.47 mL, 2.2 equiv.). The 
reaction mixture was then stirred at r.t. for 24 h under a N2 atmosphere. The reaction 
mixture was then quenched with water (100 mL) and extracted with EtOAc (3 × 50 mL) 
and the combined fractions dried (MgSO4). The solvent was then removed under reduced 
pressure and the resulting crude residue passed through a silica gel column (100% 
EtOAc) to afford N,N'-benzene-1,2-diylbis[N-(prop-2-en-1-yl)acetamide] 159 as a white 
solid (0.626 g, 93%). mp 25–26 °C; Rf = 0.27 (100% EtOAc); m/z (EI):  272 (M
+
, 2%), 
230 (22), 213 (100), 187 (46), 172 (20), 159 (48), 145 (32), 119 (34), 92 (8), 77 (9); 
HRMS: calcd for C16H20N2O2 272.1525, found: 272.1526; max (ATR)/cm
-1
: 2916, 1645, 
1594, 1499, 1441, 1378, 1333, 1298, 1281, 1250, 1228, 1205, 1114, 1081, 1018, 982, 
939;  
1
H NMR (300 MHz, CDCl3): (ppm) = 2.04 (6H, s, OC
19
H3 and OC
20
H3), 3.78 (1H, 
dd, J = 15.0 Hz and 7.6 Hz, NCH2CHC
10/14
HAHB), 5.20 (1H, dd, J = 15.0 Hz and 5.1 Hz, 
NCH2CHC
10/14
H2), 5.26–5.44 (2H, m, NC
8/12
H2CHCH2), 6.02–6.23 (m, 1H, 
NCH2C
9/13
HCH2), 7.47 (2H, dd, J = 5.8 Hz and 3.6 Hz, ArC
3
H and ArC
6
H), 7.71 (2H, 
dd, J = 5.8 Hz and 3.6 Hz, ArC
5
H and ArC
4
H); 
13
C NMR (75 MHz, CDCl3): (ppm) = 
140 
 
 
22.7 (OC
19
H3 and OC
20
H3), 49.9 (NC
8
H2CHCH2 and NC
12
H2CHCH2), 118.1 
(NCH2CHC
10
H2 and NCH2CHC
14
H2), 129.0 (ArC
3
H and ArC
6
H), 131.9 (ArC
4
H and 
ArC
5
H), 132.5 (NCH2C
9
HCH2 and NCH2C
13
HCH2), 138.7 (ArC
1
 and ArC
2
), 169.8 
(C
19
=O and C
20
=O). 
 
 
 
 
 
5.3.2.3 N-{2-[Acetyl(prop-1-en-1-yl)amino]phenyl}-N-(prop-2-en-1-yl)acetamide 164 
 
N-[2-(Acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide 163 
(0.100 g, 0.431 mmol, 1 equiv.) was dissolved in dry acetone 
(10 mL) and the temperature of the mixture lowered to –14 
°C (using an ice and salt slurry), followed by the sequential 
addition of NaH (60% in oil, 19.8 mg, 0.517 mmol, 1.2 
equiv.) and allyl bromide (0.125 g, 1.03 mmol, 0.10 mL, 2.4 
equiv.). The reaction mixture was then stirred at r.t. for 24 h under a N2 atmosphere. The 
reaction mixture was then quenched with water (100 mL) and extracted with EtOAc (3 × 
50 mL) and the combined fractions dried (MgSO4). The solvent was then removed under 
reduced pressure and the resulting residue passed through a silica gel column (100% 
EtOAc) to afford N-{2-[acetyl(prop-1-en-1-yl)amino]phenyl}-N-(prop-2-en-1-yl) 
acetamide 161 as a pale yellow oil (0.116 g, 99%). Rf = 0.57 (100% EtOAc); m/z (EI): 
272 (M
+
, 4%), 257 (2), 229 (56), 213 (100), 187 (52), 159 (35), 146 (42), 130 (25), 119 
(54), 92 (9), 77 (5);  HRMS: calcd for C16H20N2O2 272.1525, found: 272.1529; max 
(ATR)/cm
-1
: 2924, 1644, 1596, 1496, 1447, 1382, 1304, 1257, 1214, 1160, 1124, 1086, 
1018, 925, 792, 734, 698, 640;  
1
H NMR (300 MHz, CDCl3): (ppm) = 1.54–1.70 (3H, 
m, NCHCHC
18
H3), 1.75–2.33 (6H, m, OC
19/20
H3), 3.36–4.30 (1H, m,  NCH2CHCHAHB), 
4.31–4.70 (1H, m, NCH2CHCHAHB), 4.70–4.94 (1H, m,  NCHC
17
HCH3), 4.93–5.29 (2H, 
m, NC
8
H2CHCH2), 5.63–6.03 (1H, m, NCH2C
9
HCH2), 7.09–7.34 (2H, m,  
NC
16
HCHCH3 and ArC
5
H), 7.34–7.58 (3H, m, 3 × ArCH);  13C NMR (75 MHz, CDCl3,): 
141 
 
 
(ppm) =  14.8 (NCHCHC
18
H3), 22.2 (OC
19
H3), 22.3 (OC
20
H3), 50.3 (NC
8
H2CHCH2), 
112.7 (NCHC
17
HCH3), 117.4 (NCH2CHC
10
H2), 128.2 (ArC
3
H), 128.6 (ArC
6
H), 128.9 
(ArC
4
H), 129.2 (ArC
5
H), 131.1  (ArC
1
), 131.8 (ArC
2
), 132.6 (NC
16
HCHCH3), 136.8 
(NCH2C
9
HCH2), 169.0 (C
12
=O), 169.8 (C
14
=O). 
 
 
 
 
 
5.3.3    Isomerization reactions 
 
5.3.3.1   N,N'-Benzene-1,2-diylbis[N-(prop-1-en-1-yl)acetamide]    161 
 
[Method 1] N,N'-Benzene-1,2-diylbis[N-(prop-2-en-1-yl) 
acetamide]  159 (0.351 g, 1.29 mmol, 1 equiv.) and 
[RuClH(CO)(PPh3)3] 15 (61.4 mg, 0.0664 mmol, 5 mol%) 
were reacted directly. The reaction mixture was stirred at 80 
°C for 20 h under an Ar atmosphere. The reaction solution 
was then diluted with 10% EtOAc/hexane mixture (50 mL) 
and passed through a compacted Celite plug (4 ×) to remove the catalyst and the solvent 
then removed under reduced pressure. The resulting crude residue was passed through a 
silica gel column (100% EtOAc) to afford N,N'-benzene-1,2-diylbis[N-(prop-1-en-1-
yl)acetamide] 161 (a complex mixture of 3 isomers) as a pale yellow oil (0.325 g, 93%).   
 
[Method 2]  N,N'-Benzene-1,2-diylbis[N-(prop-2-en-1-yl)acetamide]  159 (0.101 g, 0.371 
mmol, 1 equiv.) and [RuClH(CO)(PPh3)3] 15 (17.7 mg, 0.0184 mmol, 5 mol%) were 
dissolved in degassed toluene (1 mL) and irradiated under microwave conditions (power: 
200W with cooling, ramp time: 2 °C per min, temperature: 80 °C, maximum pressure 100 
psi) in a pressure tube for 22 min. The reaction solution was then diluted with EtOAc (50 
mL) and passed through a compacted Celite plug (4 ×) to remove the catalyst. The 
solvent then removed under reduced pressure and the resulting crude residue passed 
through a Flash silica gel column (15% EtOAc/hexane) to afford N,N'-benzene-1,2-
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diylbis[N-(prop-1-en-1-yl)acetamide] 161 (a complex mixture of 3 isomers) as a pale 
yellow oil (96.5 mg, 96%).   
 
Rf = 0.67 (10% EtOAc/Hexane);  m/z (EI): 274 (M
+
 +2, 4%), 273 (M
+
 +1, 18%), 272 
(M
+
, 100%), 271 (6), 270 (1), 268 (1);  HRMS: calcd for C16H20N2O2 272.1524, found: 
272.1519; max (ATR)/cm
-1
: 2921, 1656, 1597, 1495, 1453, 1369, 1347, 1314, 1294, 
1273, 1133, 1095, 1036, 948, 919, 729, 646; 
1
H NMR (300 MHz, CDCl3,)  (ppm) = 
1.54–1.65 (6H, m, NCHCHC15/19H3), 1.74–1.88 (3H, m, OC
16
H3), 2.12–2.25  (3H, m, 
OC
20
H3), 4.39–4.93 (2H, m, NCHC
14/18
HCH3), 7.02–7.29 (2H, m, NCHC
14/18
HCH3), 
7.31–7.60  (4H, m, 4 × ArCH); 13C NMR (75 MHz, CDCl3, major{minor}): (ppm) = 
14.7 {14.8, 14.9} (NCHCHC
15/19
H3), 22.5 {22.7, 22.8} (OC
16/20
H3), 111.0 {113.3, 115.9} 
(NCHC
14/18
HCH3), 126.8 {128.4, 128.5} (ArC
3/6
H), 128.8 {129.1, 129.5} {(ArC
4/5
H), 
131.0 {131.8, 131.9} (NC
13/17
HCHCH3), 136.9 {137.5, 137.7} (ArC
1/2
), 168.5 {169.1, 
169.2} (C
8/11
=O). 
 
5.3.3.2   N-[2-(Acetylamino)phenyl]-N-(prop-1-en-1-yl)acetamide    163 
 
N-[2-(Acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide 158 
(0.150 g, 0.646 mmol, 1 equiv.) and [RuClH(CO)(PPh3)3] 15 
(30.8 mg, 0.0323 mmol, 5 mol%) were dissolved in degassed 
toluene (1 mL) and irradiated under microwave conditions 
(power: 150W with cooling, ramp time: 2 °C per min, 
temperature: 90 °C, maximum pressure: 100 psi) in a pressure 
tube for 10 min. The reaction solution was then diluted with a 5% EtOAc/hexane mixture 
(30 mL) and filtered through a compacted Celite plug (4 × 50 mL) to remove the catalyst. 
The solvent was then removed under reduced pressure and the resulting crude residue 
passed through a silica gel column (100% EtOAc) to afford N-[2-(acetylamino) phenyl]-
N-(prop-1-en-1-yl)acetamide 163 (a single isomer) as a pale yellow oil (0.144 g, 96%). Rf 
= 0.60 (100% EtOAc);  m/z (EI): 232 (M
+
, 5%), 213 (4), 190 (18), 172 (100), 147 (24), 
132 (28), 119 (74), 77 (5), 65 (8);  HRMS: calcd for C13H16N2O2 232.1212, found: 
232.1214;   max (ATR)/cm
-1
: 3428 (br), 2925, 1701, 1658, 1528, 1450, 1367, 1297, 1229, 
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1095, 723;  
1
H NMR (300 MHz, CDCl3): (ppm) = 1.64 (3H, dd, J = 6.7 Hz and 1.5 Hz, 
NCHCHC
15
H3), 1.82 (3H, s, OC
17
H3), 2.18 (3H, s, OC
16
H3), 4.49 (1H, qd, J =  13.6 Hz, 
6.6 Hz,  6.6 Hz, and  6.6 Hz, NCHC
14
HCH3), 7.11 (br d, 1H, J = 7.8 Hz, NC
13
HCHCH3), 
7.21 (dt, 1H, J = 7.6 Hz, 7.5 Hz and 1.2 Hz, ArC
4
H), 7. 38–7.52 (3H, m, ArC5H, ArC6H 
and N
10
H), 8.42 (1H, br d, J = 7.8 Hz, ArC
3
H); 
13
C NMR (75 MHz, CDCl3): (ppm) = 
15.0 (NCHCHC
15
H3), 22.9 (OC
16
H3), 24.8 (OC
17
H3), 109.2 (NCHC
14
HCH3), 122.5 
(ArC
6
H), 125.1 (ArC
5
H), 126.4 (ArC
4
H), 128.4 (ArC
3
H), 129.9 (NC
13
HCHCH3), 132.0 
(ArC
2
), 135.1 (ArC
1
), 168.7 (C
8
=O), 169.0 (C
11
=O). 
5.3.4   RCM Reactions 
 
5.3.4.1   Attempted synthesis of 
              1,1'-(1H-1,5-Benzodiazepine-1,5(2H)-diyl)diethanone   165 
 
[Method 1] N-{2-[Acetyl(prop-1-en-1-yl)amino]phenyl}-N-
(prop-2-en-1-yl) acetamide 164 (50.0 mg, 0.140 mmol. 1 equiv.) 
and Grubbs‟ II catalyst 6 (7.8 mg, 0.0092 mmol, 5 mol%) were 
dissolved in distilled, degassed toluene (1 mL) and irradiated 
under microwave conditions (power: 150W with cooling, ramp 
time: 2 °C per min, temperature: 90 °C, maximum pressure 100 
psi) in a pressure tube for 20 min. After cooling, the reaction 
solution was then diluted with a 10% EtOAc/hexane mixture and filtered through a 
compacted Celite plug (4 ×) to remove the catalyst. The solvent was then removed under 
reduced pressure and the resulting crude residue passed through a silica gel column 
(100% EtOAc) to afford an unknown product as a dark oil (33.0 mg, 78%) and trace 
amounts of  1,1'-(1H-1,5-Benzodiazepine-1,5(2H)-diyl)diethanone 165 detected using 
HRMS.  m/z (EI): 230 (M
+
, 55%), 213 (4), 188 (65), 161 (12), 145 (100), 130 (32), 119 
(74), 92 (8), 65 (8);  HRMS: calcd for C13H14N2O2 230.10553, found: 230.10563.    
 
 
[Method 2] N-{2-[Acetyl(prop-1-en-1-yl)amino]phenyl}-N-(prop-2-en-1-yl) acetamide 
164 (0.166 g, 0.610 mmol) and Grubbs‟ II catalyst 6 (41.4 mg, 0.0488 mmol, 8 mol%) 
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were dissolved in distilled, degassed toluene (10 mL). The reaction mixture was then 
stirred at 90 °C for 18 h under an Ar atmosphere. The reaction mixture was then 
evaporated under reduced pressure and the resultant crude product was purified by silica 
gel column chromatography utilizing gradient elution: 10% EtOAc/hexane mixture, to 
remove the catalyst, followed by 100% EtOAc to afford to afford an unknown product   
as a dark oil (20 mg, 15%).  
 
 
5.3.4.1   1,1'-[(3Z)-2,5-Dihydro-1,6-benzodiazocine-1,6-diyl]diethanone    160 
 
N,N'-benzene-1,2-diylbis[N-(prop-2-en-1-yl)acetamide]  159 
(0.141 g, 0.518 mmol) and Grubbs‟ II catalyst 6 (35.2 mg, 
0.0414 mmol, 8 mol%) were dissolved in distilled, degassed 
toluene (15 mL). The reaction mixture was then stirred at 90 °C 
for 18 h under an Ar atmosphere. The reaction mixture was then 
evaporated under reduced pressure and the resultant crude 
product was purified by silica gel column chromatography 
utilizing gradient elution: 10% EtOAc/hexane mixture, to remove the catalyst, followed 
by 100% EtOAc to afford 1,1'-[(3Z)-2,5-dihydro-1,6-benzodiazocine-1,6-diyl]diethanone 
160 as a dark oil (0.101 g, 80%). Rf  = 0.28 (100% EtOAc); m/z (EI): 244 (M+, 34%), 
230 (8), 202 (100), 184 (82), 159 (93), 143 (64), 119 (84), 93 (6), 92 (16), 77 (18), 65 (9);  
HRMS: calcd for C14H16N2O2 244.1212, found: 244.1212; max (ATR)/cm
-1
: 2931, 1712, 
1662, 1599, 1500, 1362, 1304, 1283, 1223, 1094, 1039, 905, 848, 772, 737, 707; 
1
H 
NMR (300 MHz, CDCl3): (ppm) = 1.82–2.00 (6H, m OC
17/18
H3), 3.47–5.19 (4H, m, 
NC
2
H2CHCHC
5
H2N), 5.82–6.11 (2H, m, NCH2C
3
HC
4
HCH2N), 7.25 (2H, br d, J = 2.7 
Hz, ArC
10/11
H), 7.40 (2H, br d, J = 3.3 Hz, ArC
9/12
H); 
13
C NMR (75 MHz, CDCl3): 
(ppm) = 22.4 (OC
17/18
H3), 45.2 (NC
2
H2CHCHC
5
H2N), 128.7 (ArC
10/11
H), 129.1 
(ArC
9/12
H), 130.1 (NC
2
H2CHCHC
5
H2N), 139.1 (C
7/8
), 169.2 (C
13/15
=O). 
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1
H and 
13
C NMR spectra 
for the benzofurans 
and selected precursors 
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4,7-Dimethoxybenzofuran                                                            154a            
 
 
 
 
 
 
 
155 
 
 
 
1,4-Dimethoxy-2-(prop-2-en-1-yl)-3-(prop-2-en-1-yloxy)benzene    143a 
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5-Bromobenzofuran                                                               145b    
 
 
 
157 
 
 
 
 
 
4-Bromo-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)benzene           143b    
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5-tert-Butyl-benzofuran            145c 
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4-tert-Butyl-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)benzene        143c 
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4-tert-butyl-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene           144c  
 
 
 
 
7-Phenyl-1-benzofuran                                                            145d  
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5.1.3.4   3-(Prop-2-en-1-yl)-2-(prop-2-en-1-yloxy)biphenyl                 143d 
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Naphtho[1,2-b]furan                                                                      145e  
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2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)naphthalene                 143e    
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1
H and 
13
C NMR spectra 
for the 6-, 7- and 8-membered 
O,N-benzo-fused heterocycles 
and precursors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4H-1,4-benzoxazin-4-yl(phenyl)methanone                           152  
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1,5-benzoxazepin-5(4H)-yl(phenyl)methanone                         155   
 
167 
 
 
 
 
 
 
 
 
2,5-dihydro-6H-1,6-benzoxazocin-6-yl(phenyl)methanone        150  
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N-(prop-1-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide  151  
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N-(2-(prop-1-en-1-yloxy)phenyl)benzamide                           153  
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N-(prop-2-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide  154 
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N-(prop-2-en-1-yl)-N-[2-(prop-2-en-1-yloxy)phenyl]benzamide  149 
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N-(2-(prop-2-en-1-yloxy)phenyl)benzamide                         148  
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1
H and 
13
C NMR spectra 
for the 6-, 7- and 8-membered 
N,N-benzo-fused heterocycles 
and precursors 
 
 
 
 
 
 
 
 
 
 
 
 
 
N-[2-(acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide           160 
 
175 
 
 
 
 
 
 
Unknown product spectra for the attempted formation of  
1,1'-(1H-1,5-benzodiazepine-1,5-(2H)-diyl)diethanone        165 
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N-[2-(acetylamino)phenyl]-N-(prop-1-en-1-yl)acetamide          163  
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N,N'-benzene-1,2-diylbis[N-(prop-1-en-1-yl)acetamide]               161 
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N-{2-[acetyl(prop-1-en-1-yl)amino]phenyl}-N-(prop-2-en-1-yl)acetamide     161 
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C-H correlated spectrum of 161 
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N,N'-benzene-1,2-diylbis[N-(prop-2-en-1-yl)acetamide]             159 
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N-[2-(acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide         158  
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APPENDIX B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   SELECTED MS SPECTRA 
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5.1.5.1    4,7-Dimethoxybenzofuran    145a 
 
 
 
5.1.3.1   1,4-Dimethoxy-2-(prop-2-en-1-yl)-3-(prop-2-en-1-yloxy)benzene   143a 
 
 
185 
 
 
 
5.1.5.2   5-Bromobenzofuran   145b 
 
 
 
5.1.4.2     4-Bromo-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene   144b 
 
186 
 
 
5.1.3.2   4-Bromo-2-(prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)benzene   143b    
 
 
 
5.1.5.3   5-tert-Butyl-benzofuran   145c 
 
 
187 
 
 
5.1.4.3   4-tert-butyl-2-(prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)benzene    144c  
 
 
 
5.1.5.4   7-Phenyl-1-benzofuran   145d 
 
 
188 
 
 
5.1.4.4    3-(Prop-1-en-1-yl)-2-(prop-1-en-1-yloxy)biphenyl    144d 
 
 
 
5.1.3.4   3-(Prop-2-en-1-yl)-2-(prop-2-en-1-yloxy)biphenyl    143d 
 
 
 
189 
 
 
5.1.5.5   Naphtho[1,2-b]furan    145e 
 
 
 
5.1.4.5   2-(Prop-1-en-1-yl)-1-(prop-1-en-1-yloxy)naphthalene   144e 
 
 
190 
 
 
5.1.3.5    2-(Prop-2-en-1-yl)-1-(prop-2-en-1-yloxy)naphthalene   143e    
 
 
O,N-Benzo-fused heterocycles and precursors 
 
5.2.4.2   1,5-Benzoxazepin-5(4H)-yl(phenyl)methanone    155    
 
191 
 
 
 
 
 
5.2.4.1    4H-1,4-Benzoxazin-4-yl(phenyl)methanone   152 
 
 
 
 
SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 44#5:09 - 45#5:16. Entries=26. Base M/z=105.03532. 100% Int.=0.04441. EI. POS. No Lock. 
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5.2.4.3   2,5-Dihydro-6H-1,6-benzoxazocin-6-yl(phenyl)methanone   150 
 
 
 
5.2.2.1    N-(2-(Prop-2-en-1-yloxy)phenyl)benzamide   148 
 
 
 
SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 21#1:44 - 24#1:59. Sub=9#0:44 - 11#0:54. Entries=163. Base M/z=105.03537. 100% Int.=6.44932. EI. POS. 
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5.2.3.1   N-[2-(Prop-1-en-1-yloxy)phenyl]benzamide 153 
 
 
 
5.2.2.2    N-(Prop-2-en-1-yl)-N-[2-(prop-2-en-1-yloxy)phenyl]benzamide  149 
 
 
SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 29#2:58 - 31#3:10. Sub=5#0:29 - 6#0:36. Entries=98. Base M/z=105.03346. 100% Int.=1.52811. EI. POS. 
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SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 14#1:25. Sub=5#0:29 - 7#0:42. Entries=294. Base M/z=105.0315. 100% Int.=4.75136. EI. POS. 
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5.2.3.2   N-(Prop-1-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide 151 
 
 
5.2.2.3   N-(Prop-2-en-1-yl)-N-(2-(prop-1-en-1-yloxy)phenyl)benzamide   154 
 
 
 
SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 33#2:44. Sub=12#0:59 - 18#1:29. Entries=426. Base M/z=105.04323. 100% Int.=7.92832. EI. POS. 
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SCAN GRAPH. Flagging=High Resolution M/z. Highlighting=Base Peak. 
Scan 9#1:34. Sub=1#0:10 - 3#0:31. Entries=163. Base M/z=236.10955. 100% Int.=0.94208. EI. POS. 
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N,N-Benzo-fused heterocycles and precursors 
 
5.3.2.1   N-[2-(Acetylamino)phenyl]-N-(prop-2-en-1-yl)acetamide    158 
 
 
 
 
 
 
 
 
 
 
 
 
LMAD001 #12 RT: 0.23 AV: 1 NL: 3.46E6
T: + c EI Full ms [ 49.50-500.50]
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m/z
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232.27
77.08
267.20 341.33288.34 415.42370.46 461.04 489.92
LMAD001_HREI_1-c1 #23 RT: 2.88 AV: 1 NL: 1.84E5
T: + c EI Full ms [ 217.50-245.50]
216 218 220 222 224 226 228 230 232 234 236 238 240 242 244 246
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C 14 H 17 O 1 N 2
-1.47577 ppm
235.98820
218.09986
C 12 H 14 O 2 N 2
-23.48049 ppm 223.98631
219.98812 243.99095240.98905224.99266 236.98920
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5.3.3.2   N-[2-(Acetylamino)phenyl]-N-(prop-1-en-1-yl)acetamide    163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LMAD002 #110 RT: 2.27 AV: 1 NL: 7.99E6
T: + c EI Full ms [ 49.50-500.50]
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LMAD002_HREI_1-c1 #37 RT: 2.13 AV: 1 NL: 1.77E5
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219.98644 243.99310240.98603224.99764 236.99544
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5.3.2.3 N-{2-[Acetyl(prop-1-en-1-yl)amino]phenyl}-N-(prop-2-en-1-yl)acetamide 161 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LMAD003 #121 RT: 2.51 AV: 1 NL: 2.82E7
T: + c EI Full ms [ 49.50-500.50]
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LMAD003_HREI_1-c1 #95 RT: 2.53 AV: 1 NL: 2.49E5
T: + c EI Full ms [ 253.50-283.50]
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C 15 H 17 O 2 N 2
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C 16 H 20 O 2 N 2
3.37932 ppm
266.98561
255.14793
C 16 H 19 O 1 N 2
-4.93637 ppm
277.07861
C 18 H 15 O 2 N 1
-112.31553 ppm
281.98751278.98518261.98310 273.98624267.98604264.98945
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5.3.2.2   N,N'-Benzene-1,2-diylbis[N-(prop-2-en-1-yl)acetamide]    159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LMAD004 #120 RT: 2.47 AV: 1 NL: 3.37E7
T: + c EI Full ms [ 49.50-500.50]
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77.08 92.05
272.27
293.38 322.62 347.73 365.43 393.45 430.11 459.31 475.61
LMAD004_HREI_1-c1 #14 RT: 1.75 AV: 1 NL: 1.13E5
T: + c EI Full ms [ 253.50-283.50]
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C 14 H 15 O 5 N 1
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C 16 H 20 O 2 N 2
2.34315 ppm
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C 13 H 15 O 1 N 5
9.14267 ppm
278.08406
266.98779
254.14222
C 16 H 18 O 1 N 2
3.35629 ppm
281.05208273.98101261.98466 267.98946264.28446
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5.3.4.1   1,1'-(1H-1,5-Benzodiazepine-1,5(2H)-diyl)diethanone   165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LMAD005 #84 RT: 1.73 AV: 1 NL: 2.15E6
T: + c EI Full ms [ 49.50-500.50]
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277.39244.05 355.28295.46 401.58 429.54 491.26461.40
LMAD005_HREI_1-c1 #88 RT: 3.31 AV: 1 NL: 3.58E5
T: + c EI Full ms [ 217.50-245.50]
216 218 220 222 224 226 228 230 232 234 236 238 240 242 244 246
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
230.10563
C 13 H 14 O 2 N 2
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18.57193 ppm
235.98645219.21207 243.98740239.27358
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5.3.4.1   1,1'-[(3Z)-2,5-Dihydro-1,6-benzodiazocine-1,6-diyl]diethanone    160 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
LMAD006 #127 RT: 2.62 AV: 1 NL: 1.81E7
T: + c EI Full ms [ 49.50-500.50]
50 100 150 200 250 300 350 400 450 500
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77.08 92.05
65.04 93.08 230.24
213.33 277.38 322.57 400.49365.46 429.23 456.39 477.08
LMAD006_HREI_1-c1 #49 RT: 3.04 AV: 1 NL: 5.68E5
T: + c EI Full ms [ 229.50-256.50]
228 230 232 234 236 238 240 242 244 246 248 250 252 254 256 258
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